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Abstract 
 
Albuminuria is a risk factor for kidney disease progression and cardiovascular 
events. There are strong links between high blood pressure (BP), diabetes and 
increased albuminuria. Studies suggest that loss of the normal night time dip in BP 
(non-dipping) may alter albuminuria and could be a treatment target to slow kidney 
damage and reduce cardiovascular risk. Damage to a lining of the blood vessels 
called the glycocalyx is thought to be involved in the development of albuminuria 
and could further understanding of albuminuria pathophysiology. 
    This thesis aims to further understanding of these closely linked conditions by 
exploring the relationship between 24-hour blood pressure patterns, albuminuria 
and glycocalyx integrity in newly diagnosed hypertensive patients and in type 2 
diabetes (T2DM). The primary aim is to determine whether loss of the normal night 
time blood pressure dip contributes to urine albumin excretion using an albumin 
assay which enables quantification of urine albumin in all participants.  
     Twenty-four hour BP, sublingual glycocalyx integrity and urinary albumin data 
were derived from two studies. Data were acquired prospectively from 34 
participants with T2DM within the observational BEAT-DKD study and a 
retrospective analysis was undertaken on data collected from 54 treatment naïve 
patients with grade II hypertension within the 18 week interventional DASHER trial 
(2015-16).  
     The treatment protocol significantly reduced albumin excretion rate (AER) 
(p=0.0311). There were no observed relationships with night time blood pressure 
dipping and AER in the hypertensive or T2DM cohort. In the hypertensive cohort, 
systolic, diastolic and mean arterial BP were associated with AER. In the diabetic 
cohort there were no correlations with AER and average systolic BP (Rs: 0.2072, 
p=0.2397) and pulse pressure (Rs: 0.2398, p=0.1719), but strong correlations with 
night time BP variability in those with moderately increased albuminuria (AER >20 
µg/min) (Rs: 0.6553, p=0.0032). Glycocalyx integrity showed no relationship with 
albuminuria or 24-hour blood pressure. 
     In conclusion, loss of normal night time BP dipping showed no relationship with 
albuminuria. Sublingual glycocalyx integrity showed no relevance to albuminuria or 
blood pressure. Systolic, diastolic, mean arterial pressure and pulse pressure show 
the strongest relationship with albuminuria but BP variability may be informative of 
albuminuria risk in diabetes. 
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MIA – Moderately increased albuminuria 
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NO – Nitric oxide 
OGTT - Oral glucose tolerance test 
PBR – Perfused boundary region 
PCT – Proximal Convoluted Tubule 
PGI2 – Prostacyclin 
PP – Pulse pressure 
PPP- Pulse Pressure Product 
PSNS – Parasympathetic nervous system 
RAAS – Renin angiotensin aldosterone system 
RBC – Red blood cell 
ROS – Reactive oxygen species 
SBP – Systolic blood pressure 
SIA – Severely increased albuminuria 
SNS – Sympathetic nervous system 
T2DM – Type 2 diabetes mellitus 
UAE – Urine albumin excretion 
VEGF – Vascular endothelial growth factor 
WHO – World health organisation 
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is a common risk factor for the development of 
diabetic kidney disease (DKD) and often goes hand in hand with hypertension. 
Diabetes and hypertension are the two main causes of chronic kidney disease 
(CKD) worldwide 1. CKD may progress to end-stage renal disease (ESRD) 
requiring kidney transplant or renal replacement therapy such as dialysis. The 
need for renal replacement therapy substantially shortens survival and reduces 
quality of life.  
Not only is CKD a huge burden on the patient but also on the healthcare 
system. The NHS spent an estimated £1.454 billion directly and indirectly on 
CKD in 2009 alone. Over half of this (£780 million) was spent on renal 
replacement therapy for those who had reached ESRD 2.  
DKD currently accounts for around 30% of ESRD cases in the UK 3. However, 
the prevalence of T2DM has more than doubled in the last 20 years to 3.7 
million cases and is predicted to increase to 5 million cases by 2025 4. This is 
likely as a result of the increasing obesity levels, poor diet and inactive lifestyle 
of modern society. If these environmental factors are not tackled, the 
prevalence of DKD and ESRD are likely to rise alongside T2DM.  
It is therefore vital that we increase our understanding of the development of 
DKD in order to find ways of slowing or preventing progression to ESRD, 
reducing the patient and healthcare burden. 
This thesis will focus on the complex relationship between blood pressure (BP), 
diabetes and kidney damage. It is known that albuminuria is an independent 
indicator of poor prognosis in CKD 5. Concurrent hypertension is a negative 
prognostic factor for CKD and has a close relationship with levels of 
albuminuria6. Diabetic patients may also have a tendency to lose the normal 24-
hour blood pressure patterns. This introduction will give background information 
on each of these concepts and provide context for the proposed research. 
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1.1 Thesis Overview and Structure 
1.1.1 Overview 
This study will hypothesise that there is a relationship between albuminuria and 
pathological 24-hour blood pressure patterns in T2DM patients. The study will 
examine the relationship between pathological 24-hour blood pressure patterns, 
particularly non-dipping, and albuminuria into the normal albuminuric range in 
type 2 diabetes and hypertensive patients. The study will also assess whether 
the protective glycocalyx layer of the endothelium is affected by these blood 
pressure patterns or related to albuminuria. This examination will further 
understanding of the relevance of 24-hour blood pressure patterns in the 
development of diabetic kidney disease.  
1.1.2 Structure 
Chapter 1: Introduction – This chapter provides background information on 
the complex relationship between diabetes, kidney disease, hypertension and 
albuminuria. The introduction will then analyse current literature around the 
relationship of 24-hour blood pressure patterns to albuminuria to provide 
justification for the proposed research. 
Chapter 2: Methods – This chapter will describe the methods common to the 
two studies within this thesis. 
Chapter 3: The DASHER Study – This section will analyse 24-hour blood 
pressure, urine albumin excretion and glycocalyx integrity data taken from the 
DASHER study of hypertensive patients and discuss the findings. 
Chapter 4: The BEAT-DKD Study – This section will analyse 24-hour blood 
pressure, urinary albumin excretion and glycocalyx data taken from the BEAT-
DKD study of type 2 diabetic patients and discuss the findings. 
Chapter 5: Overall discussion and conclusion. 
 
 
22 
 
1.2 Type 2 Diabetes Mellitus 
 
Diabetes literally translates as ‘passing too much urine’ and mellitus as ‘sweet’. 
It is now known that this is a symptom of an underlying condition which causes 
chronic hyperglycaemia as a result of reduced insulin sensitivity and or 
production. 
The World Health Organisation (WHO) recommends that diabetes be 
diagnosed by symptoms of diabetes (polyuria, polydipsia) alongside: 
- A random venous plasma glucose concentration ≥11.1mmol/L 
OR 
- A fasting plasma glucose concentration ≥7mmol/L (whole blood 
≥6.1mmol/L) 
OR 
- A two hour plasma glucose concentration ≥11.1 mmol/L two hours after 
75g of anhydrous glucose – Oral glucose tolerance test (OGTT). 
OR 
- A Haemoglobin A1c (HbA1c) ≥ 48mmol/mol (6.5%). 
If no symptoms are present then two separate diabetic range glucose readings 
are needed from separate days, or a repeat of the HbA1c. If the second HbA1c 
is below 48mmol/mol then the person is classed as high risk of diabetes7, 8. 
Although there are rare monogenic forms of diabetes, there are two main forms; 
Type 1 diabetes (failure to produce insulin) and Type 2 diabetes (reduced 
insulin sensitivity and consequent reduced production of insulin). This paper will 
focus on Type 2 diabetes. 
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1.2.1 Epidemiology 
 
T2DM constitutes over 85% of cases of diabetes and is increasing in 
prevalence due to its close association with obesity, inactivity and age. The 
lifetime risk for developing T2DM in the U.S. population is 40% 9.  
There are many risk factors for developing T2DM but the most significant 
include obesity, increasing age, physical inactivity, high glycaemic index diet 
and family history 10.  
 
1.2.2 Pathophysiology 
 
In T2DM insulin resistance precedes hyperinsulinaemia and then reduced 
production of insulin. Although individuals may have a genetic predisposition to 
developing T2DM, levels of obesity show a direct correlation to insulin 
resistance 11.  
It is thought that insulin resistance may be due to excess adipokines, released 
from excess adipose tissue in those that are overweight.  One significant site of 
insulin resistance is the liver. In normal physiology, the liver responds to 
decreased blood glucose and insulin levels by breaking down glycogen in to 
glucose (glycogenolysis) hence increasing blood glucose. When liver cells 
become resistant to insulin, glucose is secreted in spite of hyperglycaemia, 
raising blood glucose even further. Resistance of peripheral muscle cells to 
insulin leads to reduced glucose clearance into muscle cells 11.  
In response to high glucose levels in the urine, the sodium-glucose 
cotransporter-2 within the kidney is upregulated which leads to increased 
glucose reabsorption into the blood from the kidney 12.  
Hyperglycaemia has been shown to have a toxic effect on insulin producing     
β-cells in the pancreas 11. This leads to a vicious cycle of increasing dysfunction 
of insulin production as chronic hyperglycaemia ensues. This accounts for the 
cases where people with type 2 diabetes eventually require treatment with 
insulin.  
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1.2.3 Mechanism of diabetic vascular complications 
 
People with diabetes experience many complications as a result of 
hyperglycaemia, hyperinsulinaemia and haemodynamic factors. These can be 
divided into microvascular and macrovascular complications, although their 
pathophysiologic mechanisms may be closely related. 
Macrovascular complications include coronary artery disease, peripheral 
vascular disease and stroke. These complications arise as a result of 
development of atheroma within arterial walls. Diabetes is a direct contributor to 
atheroma formation alongside risk factors such as obesity, hypertension and 
hyperlipidaemia which are often present in diabetic individuals 13.  
Microvascular complications include nephropathy, retinopathy and neuropathy. 
These occur due to damage to the small blood vessels which are vital to the 
structure of these organs. 
These complications arise from a complex series of mechanisms which are not 
fully understood. 
An important factor in the mechanism behind these complications is the 
formation of advanced glycation end-products (AGEs) 14. AGEs are produced 
when plasma proteins or lipids are glycated as a result of hyperglycaemia and 
are thought to be important within the pathogenesis of diabetic 
microvasculopathies 14-16. When AGEs bind to cell membrane receptors they 
can increase the production of pro-inflammatory molecules and reactive oxygen 
species (ROS) 17. AGEs may modify low-density lipoproteins leading to 
accelerated atherosclerosis 18. Importantly, when AGEs are bound to cell 
membranes they increase endothelial permeability to macromolecules. This is 
thought to be a key factor in the development of diabetic kidney disease which 
occurs in 5-20% of T2DM patients19. 
AGEs alongside oxidative stress caused by ROS may decrease endothelial 
derived nitric oxide (NO) 18. NO leads to vasodilation, immune response 
modulation, prevention of platelet aggregation and leukocyte adhesion 20. 
Therefore reduced availability of NO may be an important contributor to 
vascular complications in diabetes 20, 21.  
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1.3 Diabetic Kidney Disease 
Diabetic kidney disease (DKD) is a microvascular complication of diabetes 
caused primarily by chronic hyperglycaemia and is the most common cause of 
chronic kidney disease in the world 1.  
There are four main histological changes to the glomerulus in DKD 22: 
- Podocyte injury 
- Glomerular basement membrane thickening 
- Expansion of the mesangium 
- Glomerulosclerosis 
Many of these changes may originate from the previously described oxidative 
stress as a result of hyperglycaemia in diabetes. This theory is supported by 
evidence showing that blockade of AGE receptors improves structural and 
functional signs of DKD 23.  
Increased glomerular permeability resulting in abnormal albuminuria is one of 
the earliest clinical signs of DKD 22. This is accompanied by progressive 
expansion of the basement membrane and mesangium through accumulation of 
extra cellular matrix components 24, 25. The expansion of the mesangium leads 
to stiffening and narrowing of the glomerular arterioles/capillaries and eventually 
scarring of the kidneys (glomerulosclerosis) 22. Albuminuria and the glomerular 
basement membrane (GBM) will now be discussed in more detail, in the context 
of type 2 diabetes. 
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Figure 1 - The nephron. 
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1.3.1 Albuminuria 
 
Albumin is a globular protein found in the blood with multiple functions including 
regulation of the oncotic pressure of blood.  
Albumin, alongside other molecules in the blood, is selectively filtered through 
the glomerulus. In a healthy individual, almost no albumin should be filtered into 
the urine due to the filtration barriers of the glomerulus. Pathological 
albuminuria was, until recently, defined as microalbuminuria or 
macroalbuminuria but is now defined as ‘moderately increased albuminuria 
(MIA)’ and ‘severely increased albuminuria (SIA)’.  
Normal albuminuria is <30mg/day, MIA is 30-300mg/day, SIA is >300mg/day.  
The concentration of albumin in the urine can vary depending on how dilute the 
urine is. Therefore, urine albumin excretion must be measured using an albumin 
to creatinine ratio (ACR) of a random urine sample or by a timed urine 
collection. ACR gives an approximation of albumin excretion in relation to 
creatinine excretion which is fairly consistently and exclusively filtered by the 
kidneys. Timed urine collections allow an albumin excretion rate (AER) to be 
calculated.   
Albuminuria is a hallmark of DKD and is present in around 20-25% of T2DM 
patients 26. The presence of albuminuria is accepted to be a poor prognostic 
indicator as it seems to directly exacerbate kidney damage (discussed in more 
detail in 1.3.4). Albuminuria has also been found to be an independent risk 
factor for cardiovascular mortality even in the normal albuminuria range 27, 28. 
Doubling the urine albumin concentration gives a relative risk of 1.29 (with a 
95% confidence interval between 1.18-1.40) for cardiovascular mortality and a 
relative risk of 1.12 (95% confidence interval 1.04 to 1.21) for non-
cardiovascular mortality27. This indicates a robust and significant relationship 
between increased albuminuria and mortality with particular relevance to 
cardiovascular risk. It is not understood why albuminuria is associated with 
cardiovascular events. It could be that albuminuria is a sensitive marker of 
kidney function decline or of endothelial dysfunction, both of which contribute to 
cardiovascular morbidity.  
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As CKD patients with albuminuria showed a faster rate of decline in glomerular 
filtration rate (GFR) than those without 29, KDIGO guidelines recommend that 
albuminuria is considered independently of GFR when monitoring kidney 
function 5. Even in a patient with normal GFR, a moderately or severely 
increased albuminuria indicates a high risk state.   
Studies have shown that GFR may decline two to three times faster in those 
with increased albuminuria than the general population 30, 31.  
There are likely to be several factors which contribute to the development of 
albuminuria in T2DM. These include structural changes to the glomerular 
filtration barrier (GFB), increased blood pressure and intra-glomerular pressure 
26. 
 
 
Figure 2 KDIGO 2012 Glomerular filtration rate guidelines (Colour indicates risk 
stratification: green shows low risk, yellow moderate risk, orange high risk and 
red is very high risk) 5. 
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1.3.2 The Glomerular filtration barrier 
 
1.3.2.1 The Glomerulus and Bowman’s capsule  
 
The glomerulus is constituted of an afferent arteriole which gives rise to multiple 
loops of capillaries which then re-join to form the efferent arteriole. As blood 
travels through the glomerular capillaries some of its constituents pass across a 
filtration barrier into a space called the Bowman’s capsule where they become 
the urinary filtrate. The filtration barrier is made up of three distinct layers and 
restricts movement of solutes based on size, charge and sterical     
configuration 32. Each layer of the membrane is negatively charged which repels 
other negatively charged molecules like albumin but favours the passage of 
small positively charged ions such as sodium and potassium. Recently, 
research has suggested that a lining of the endothelium called the glycocalyx 
plays a more significant role in filtration than charge selectivity 33. 
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Figure 3 The Glomerulus (above) and the layers of the glomerular filtration 
barrier (below). 
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1.3.2.2 Fenestrated endothelium of the glomerular capillaries 
 
Glomerular capillaries are unique due to their many large fenestrations which 
allow the vast majority of solutes in the blood (up to 0.1µm) to pass through the 
capillary endothelium to the glomerular basement membrane 34. The entire 
epithelium is lined with glycocalyx which extends into the fenestrations 
themselves 35. 
 
1.3.2.3 The Glycocalyx 
 
The glycocalyx is a gel-like structure which lines the lumen of all capillaries, 
including the glomerulus. 
It is made up, primarily, of glycoproteins and proteoglycans 36, 37. Proteoglycans 
are macromolecules with a protein core and various glycosaminoglycan (GAG) 
side chains. The main GAG side chain in the glycocalyx is heparan sulphate 
(50-90%) which is also present in the GBM 37. Hyaluronic acid is another GAG 
present in the glycocalyx which binds to water to give the glycocalyx its gel-like 
consistency 38.  
The main functions of the glycocalyx within the glomerulus include:  
- Adhesion of molecules to glycoproteins leading to vital mechanisms such 
as coagulation and fibrinolysis. 
- The binding of enzymes which remove ROS and reduce oxidative stress. 
- Protection of the endothelium from shear stress of plasma flow. 
- Stimulation of NO production. 
- Molecular sieve 37. 
In protecting the vascular epithelium from the shear stress of plasma flow, the 
glycocalyx itself is degraded and so its thickness constantly fluctuates as it is 
reformed 37.  
It is thought that the negative charge of molecules, including heparan sulphate, 
within the glycocalyx contribute to its ability to stop the passage of albumin 
through the glomerulus. It is also suggested that albumin has areas of positive 
charge along its structure which allow it to bind strongly to the glycocalyx 37.  
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Dysfunction of the glycocalyx is considered as a strong link between 
cardiovascular risk and renal risk, particularly in those with diabetes 36. 
Hyperglycaemia may cause damage to the glycocalyx through degradation by 
ROS 39. As a result, in diabetic patients, the endothelial response to shear 
stress may be diminished and so flow induced vasodilation may in turn become 
impaired 40.  
One of the most important factors in development of albuminuria could be 
damage to the glycocalyx 26, 36, 41, 42. The glycocalyx could therefore be the 
common pathway linking albuminuria with cardiovascular mortality. It is known 
that the endothelial glycocalyx can be damaged by acute hyperglycaemia and 
ROS 26. Endothelial activation resulting from diabetes or hypertension can also 
lead to the release of enzymes which break down parts of the glycocalyx such 
as hyaluronic acid and heparan 36. In relation to this, plasma levels of hyaluronic 
acid negatively correlate with renal function and could be used as a marker of 
glycocalyx breakdown 43.  
In relation to its function, damage to the glycocalyx provides a convincing 
mechanism behind the link between DKD, albuminuria, hypertension and 
cardiovascular morbidity.  
 
Figure 4 an electron micrograph of the endothelial glycocalyx layer of a rat 44.   
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1.3.2.4 The Glomerular basement membrane 
 
The glomerular basement membrane (GBM) is a mesh-like structure formed 
from four macromolecules; laminin, type IV collagen, nidogen and the specific 
heparan sulphate proteoglycan agrin 32, 33. It was thought that agrin and the 
other negatively charged constituents of the GBM played a major role in 
repelling negatively charged molecules, such as albumin, from being filtered 
through the membrane 32. However, several studies showed that removal of 
agrin and other molecules from the GBM resulted in a large decrease in 
negative charge of the GBM but no significant change in albumin filtration 45-47. 
This has led to the theory that charge is less important in filtration than 
previously believed and that the glycocalyx could play a more significant role. In 
diabetic kidney disease the GBM becomes thickened through deposition of 
extracellular matrix. It is thought this deposition is linked with podocyte injury 25. 
 
1.3.2.5 The Podocytes and slit diaphragm 
 
Overlying the basement membrane are many cells called podocytes. Podocytes 
take their name from their foot like processes. The foot processes of each of 
these cells interdigitate. A very thin membrane forms across the minute gaps 
between these interdigitations called the slit diaphragm. Little is known about 
the structure of the slit diaphragm but it is hypothesised to be formed from rods 
of nephrin into a zip-like structure 32. The slit diaphragm only allows passage of 
molecules smaller than 0.007µm into the Bowman’s capsule which means that 
albumin (diameter 0.007µm) is rarely filtered in healthy individuals 34. Widening 
of the podocyte slit diaphragms could be an early sign of  DKD and loss of 
nephrin within the slit diaphragm may be an important factor in albuminuria 
development 48. It is thought that in the very early stages of persistent 
hyperglycaemia, podocytes are stimulated to produce GBM matrix molecules. 
The resultant thickening of the GBM is thought to be one of the earliest stages 
of DKD 25. 
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1.3.3 Glomerular hyperfiltration 
 
In the early stages of DKD, many patients develop a hyperfiltration through high 
pressure in the glomerulus. The hydrostatic pressure within the glomerulus can 
be affected by fluctuations in the systemic blood pressure. On average, both 
kidneys filter 120ml of fluid per minute through the glomeruli, in young healthy 
individuals 34. This filtration rate relies on the hydrostatic pressure within the 
glomerular capillaries. Up to 45% of people with T2DM will demonstrate 
hyperfiltration with a GFR averaging 117-133mL/min) 49. The rise in GFR may 
contribute to glomerular hypertrophy and glomerular basement membrane 
thickening and albuminuria. There are several mechanisms involved in 
regulating glomerular pressure such as myogenic autoregulation, 
tubuloglomerular feedback and the action of angiotensin which is discussed in 
more detail in 1.4.3.4. These mechanisms may be affected by high blood 
pressure and diabetes.  
When glomerular arterioles are over stretched by higher blood pressures their 
smooth muscle contracts to reduce blood flow through the glomerulus 34. This is 
called myogenic autoregulation and helps to maintain a stable level of tissue 
perfusion at varying levels of blood pressure. This mechanism is present 
throughout the body but is particularly important within cerebral blood vessels 
and the glomerulus. Myogenic autoregulation may be reduced in diabetic 
patients and therefore may contribute to abnormal glomerular filtration 50.  
Tubuloglomerular feedback is the mechanism by which the macula densa cells 
detect changes in the concentration of sodium within the kidney tubule and 
consequently inhibit dilation of the glomerular arterioles. A rise in blood 
pressure increases GFR causing filtrate to flow through the nephron at a faster 
rate. As a result, the proximal convoluted tubule and loop of Henle have less 
time to reabsorb solutes such as sodium. Therefore, a higher concentration of 
sodium reaches the macula densa cells by the distal convoluted tubule. The 
macula densa cells detect this increase in concentration and inhibit the release 
of NO from the juxtaglomerular cells. This inhibits the dilation of the afferent 
arteriole by NO, reducing blood flow to the glomerulus 34. One theory for 
hyperfiltration in T2DM, other than impaired autoregulation, is that 
hyperglycaemia and hyperinsulinaemia stimulate sodium reabsorption in  the 
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proximal convoluted tubule (PCT) so less sodium reaches the macula densa 
and results in dilation of the afferent arteriole 22. 
 
1.3.4 Tubular Damage through albumin reabsorption 
 
Reabsorption of albumin occurs mainly in the first half of the PCT. The exact 
process is unknown however, there is strong evidence to suggest that albumin 
in endocytosed by way of two receptors called megalin and cubilin 32, 51, 52. 
Albumin binds to cubilin at the brush border of the PCT. This binding is 
catalysed by megalin which also is thought to stimulate the internalisation of 
albumin into endosomes and fusion with hydrolysing lysosomes 52. It is thought 
that there must also be alternative methods for reabsorption of albumin as in 
cubilin knockout mice urine albumin only increases around six-fold and does not 
enter the nephrotic range 29, 52. 
In pathological states where more albumin is filtered through the glomerulus, it 
is thought that the normal reabsorption mechanism becomes saturated. This 
means excess albumin and other proteins pass into the urine. It is also thought 
that the continuous reabsorption of albumin and proteins in the PCT may lead to 
damage of the PCT epithelial cells leading to an inflammatory and fibrotic 
response in the tubular interstitium. This can lead to a progressive impairment 
of the reabsorption process and tubular damage 32. 
When the capacity of the megalin mediated pathway leading to lysosomal 
digestion of proteins is exceeded this leads to the activation of alternative 
methods of protein digestion. These alternative methods may lead to improper 
digestion of albumin and important molecules 51.  
Another study has shown that patients with type 1 and type 2 diabetes may 
shed megalin and cubilin into their urine. This could be a contributing factor 
towards albuminuria in diabetics 53. 54. 
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1.4 Hypertension and Type 2 Diabetes 
 
Some individuals have pathologically high blood pressure (hypertension). 
Hypertension can also cause kidney damage and is linked with albuminuria. 
Most cases of hypertension are classed as ‘essential hypertension’ meaning the 
cause is undetermined although, we know of risk factors that can increase the 
chance of developing hypertension one of which is diabetes itself. Other risk 
factors include: 
1) Increasing age  
2) Gender (males generally at higher risk below the age of 65) 
3) Family history 
4) Ethnicity 
5) Being overweight 
6) Inactivity 
7) Excess salt intake 
8) Stress 55 
 
1.4.1 Epidemiology and complications of hypertension 
 
Hypertension is increasingly prevalent likely due to increasing corresponding 
risk factors such as diabetes, obesity and poor diet. It is estimated that around 1 
billion people are hypertensive worldwide 56. The American Diabetes 
Association reported that between 2000 and 2012, 71% of adults with diabetes 
were hypertensive or were receiving treatment for hypertension 57. 
Hypertension can lead to many different complications. These include 
ischaemic heart disease, peripheral artery disease and also kidney disease. 
High pressure within the circulation leads to strain and increased oxygen 
demand of the heart muscle. The high pressure can also damage the blood 
vessels themselves. Over activation of smooth muscle can lead to thickening of 
the intima and media layers of the blood vessels and therefore narrowing of the 
lumen and further increase in pressure 58. Damage to vessel wall endothelium 
from high blood pressure may also accelerate inflammation and the formation of 
atherosclerosis within the vessel wall 59, 60. Atherosclerosis leads to coronary 
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and peripheral artery disease and predisposes individuals to myocardial 
infarction and cerebrovascular events. 
Both thickening of the vessel wall and development of atherosclerosis stiffens 
the arteries, decreasing vessel compliance and exacerbating hypertension. This 
stiffening can be demonstrated by a wide pulse pressure (a large difference 
between the systolic and diastolic values). 
 
1.4.2 Albuminuria in hypertension 
 
Hypertension is the second largest cause of CKD after diabetes 1. Together, 
diabetes and hypertension account for around two thirds of CKD cases 61. 
Hypertension causes progressive hardening of the kidney’s microvasculature 
(nephrosclerosis). It is also well established that there is a strong relationship 
between hypertension and albuminuria. A study found that moderately 
increased albuminuria was present in 40% of non-CKD hypertensive patients 62. 
This may be due to hypertension itself leading to hyperfiltration of albumin or 
damage to the vascular endothelium as a result of high pressures. 
 
1.4.3 Pathophysiology of blood pressure in hypertension and 
diabetes 
 
There is much research into underlying causes of the association between 
essential hypertension and diabetes. However, the mechanisms are likely to be 
a complex interplay of many different factors. Common themes include salt 
handling, overstimulation of the sympathetic nervous system (SNS), increased 
peripheral resistance, endothelial dysfunction, renal dysfunction and disruption 
of circulating factors in obesity and diabetes. All of these themes are highly 
prevalent in the T2DM population which is likely why hypertension is so 
prevalent in this patient group. 
The following sections will discuss these themes and normal blood pressure 
regulatory mechanisms which may be impaired in diabetes and hypertension. 
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1.4.3.1 Intrinsic vasoactive substances 
 
The vascular endothelium releases a number of factors that control local blood 
flow, locally. These factors include metabolites produced by tissue respiration 
and endothelial secretions. 
1.4.3.1.1 Metabolites 
 
Metabolites produced through tissue respiration such as carbon dioxide, 
potassium, hydrogen, lactic acid and adenosine have a vasodilatory effect on 
blood vessels. The effect of these metabolites can be demonstrated during 
active hyperaemia. For example, during exercise, tissues undergo active 
hyperaemia as increased metabolic activity leads to an increased generation of 
metabolites. These metabolites cause vasodilation leading to hyperaemia 63.  
Reactive hyperaemia can occur when a vessel is occluded. The process is not 
as well understood as active hyperaemia however, it is thought that occlusions 
lasting several minutes cause an accumulation of vasodilatory metabolites 
leading to an episode of reactive hyperaemia once the occlusion is released 64. 
The hyperaemia slowly declines as blood flow removes the metabolites and 
restores oxygen requirements. Shorter episodes of occlusion may result in 
hyperaemia through the myogenic auto-regulatory mechanism or inadequate 
oxygen to sustain smooth muscle contraction 63. Active hyperaemia and 
reactive peak flow can be reduced in diabetic patients with microvascular 
damage 65, 66. 
1.4.3.1.2 Endothelial secretions 
 
The endothelium produces many paracrine vasoactive substances for example, 
NO, Prostacyclin (PGI2) and endothelin 63, 67.  
NO is an important vasodilator. NO is produced when the glycocalyx responds 
to the shear stress of blood flow through the capillaries. The glycocalyx causes 
increased expression of endothelial NO synthase enzyme which leads to the 
production of NO 68, 69. Circulating insulin is also a stimulus for the release of 
NO and high blood glucose is known to decrease production of NO 70. Damage 
to the endothelial glycocalyx, as witnessed in diabetes, may lead to a reduction 
in this vasodilatory mechanism. 
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PGI2 has a similar vasodilatory role to NO. They are both stimulated by thrombin 
and also both contribute to the prevention of clot formation. If there is damage 
to the endothelium, decreased production of these factors can influence 
vasoconstriction and promotion of clot formation 63. 
 
1.4.3.2 The Autonomic Nervous System 
 
The autonomic nervous system (ANS) is an important regulator of blood 
pressure. Similarly to peripheral neuropathy, diabetes can lead to cardiac 
autonomic neuropathy (CAN) 71, 72. As a result, the autonomic control of blood 
pressure is jeopardised and may contribute to hypertension amongst diabetic 
patients 71. 
The ANS is responsible for acute regulation of blood pressure and globally 
controls many aspects of the cardiovascular system. The ANS can be activated 
by external stressors and the ‘fight or flight’ response but ANS blood pressure 
control is primarily activated through baroreceptors 34.  
Baroreceptors are located within the carotid sinus and the aortic arch, 
responding to stretch within the arterial wall. When there is a decrease in 
stretch from baseline (lower blood pressure), baroreceptors send fewer signals 
to the hypothalamus via the sensory branch of the vagus nerve 34. The 
hypothalamus registers the drop and sends messages to the adrenal medulla 
which releases noradrenaline.   
Noradrenaline increases heart rate and contractility through β1 adrenergic 
receptors. β1 receptors are also present in the juxtaglomerular cells and so β1 
agonism leads to increased renin secretion and activation of the blood pressure 
raising renin-angiotensin-aldosterone system (RAAS) 67. Noradrenaline also 
activates α1 adrenergic receptors which lead to vasoconstriction which 
increases systemic vascular resistance, and in turn, blood pressure 67.  
When baroreceptors detect an increase in stretch, more signals are sent, by the 
vagus to the hypothalamus. The hypothalamus activates stimulation of the 
parasympathetic vagal nerve fibres which release acetylcholine. Acetylcholine 
acts on muscarinic receptors. Muscarinic-2 receptors decrease atrial 
contractility and also decrease heart rate through suppression of the sinoatrial 
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node. Muscarinic-3 receptors increase nitric oxide release, causing vasodilation, 
reducing blood pressure. CAN may reduce the activation of this 
parasympathetic pathway leading to a sympathetic dominance, upregulating the 
RAAS and vasoconstriction 71, 72. 
1.4.3.3 The Renin-angiotensin-aldosterone-system 
 
Renin is an enzyme which is released from the juxtaglomerular cells in the 
kidney in response to low blood pressure or glomerular pressure. There are 
three principle promotors of renin release. 
Firstly, the juxtaglomerular cells release renin when baroreceptors within the 
glomerular afferent arteriole sense a decrease in stretch. Secondly, renin is 
released in response to renal sympathetic nerve stimulation.   
Thirdly, renin is released when the macula densa cells respond to the 
concentration of sodium within the distal convoluted tubule (DCT) urinary 
filtrate. When GFR increases due to a rise in blood pressure, filtrate flows 
through the nephron at a faster rate. As a result, the PCT and loop of Henle 
have less time to reabsorb solutes such as sodium. Therefore, a higher 
concentration of sodium reaches the macula densa cells by the distal 
convoluted tubule. The macula densa relay this message to the juxtaglomerular 
cells which inhibit release of renin into the blood stream 67. 
When the opposite happens due to lower blood pressure, renin is inhibited to a 
lesser extent. The RAAS system is then activated and acts to increase blood 
pressure. The release of renin catalyses the formation of angiotensin II from 
angiotensinogen. Angiotensin II is a vasoconstrictor acting mainly via 
angiotensin 1 receptors 73. Angiotensin constricts the arterioles of the 
glomerulus, but constricts the efferent arteriole to a greater extent which 
increases hydrostatic pressure inside the glomerulus and maintains GFR. This 
is the principle by which angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) decrease albumin excretion.  
Angiotensin II also stimulates the release of the mineralocorticoid aldosterone 
from the adrenal glands which causes the principle cells within the DCT and 
collecting duct in the nephron to reabsorb more sodium, secreting potassium 
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into the tubule. Water then follows the sodium into the blood resulting in an 
increase in blood volume and pressure.  
As well as the described classical RAAS pathway there are also tissue specific 
RAAS sites including local intrarenal RAAS activity 74. Local intrarenal RAAS 
activity occurs when renin is secreted within the proximal tubules; this secretion 
is increased within DKD 75. This could be a factor contributing to hypertension in 
this patient group. It is thought that hyperglycaemia itself increases angiotensin 
II production in the kidney, leading to constriction of the efferent arteriole and 
increased glomerular pressure 76.  
1.4.3.4 Salt intake 
 
One factor which is believed to be key in the mechanism of development of 
hypertension is dietary salt intake. It is recommended by the world health 
organisation that adults should consume less than 5 grams of salt per day. The 
World Health Organisation believes that reduction in salt intake to this level 
could prevent 2.5 million deaths a year through reduced cardiovascular risk 77.  
Many studies have noted a positive correlation between increased salt intake 
and high blood pressure 78, 79. It is not well understood why salt reduction would 
lead to a decrease in blood pressure. Low salt levels would normally act to 
increase activation of the RAAS and increase blood pressure. It is speculated 
that the effect may be due to the excessive salt intake within the modern day 
diet and inability of the kidney to excrete these large amounts of salt 78. In 
response to the resultant salt loading, the extracellular space is expanded 
through passive movement of water leading to increased blood pressure 80. 
However, without evidence of a specific mechanism it is difficult to confirm a 
causal relationship between salt intake and blood pressure. It could be that the 
rise in blood pressure may be due to other concurrent dietary habits that lead to 
high salt intake, such as obesity. One study showed no significant change in 
blood pressure as a result of high salt intake in obese patients compared to lean 
individuals 81. Although all of the patients had an increase in plasma volume, 
they responded with a decrease in systemic vascular resistance and so BP was 
unchanged. This suggests that although salt intake may affect blood volume 
other pathological mechanisms must be present in order to lead to 
hypertension. 
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The Cochrane collaboration performed a meta-analysis of the impact of low 
versus high salt diet and blood pressure. The meta-analysis found that in 
normotensive people, reducing salt intake reduced blood pressure by less than 
1%. In these normotensive patients there was also a significant increase in 
renin, angiotensin and noradrenaline production which may explain why blood 
pressure remained almost stable within this group. In hypertensive patients salt 
reduction led to a 3.5% decrease in blood pressure but a similar rise in renin, 
aldosterone and noradrenaline to the normotensive group 80. These results 
suggest that reduction of salt intake may not be as vital to the pathophysiology 
of hypertension as once thought. In addition, these results included white 
participants only, the evidence for other ethnicities has not been rigorously 
meta-analysed.   
Overall these findings seem to suggest that altering salt intake can influence 
BP. However, it seems unlikely to be a sole causative factor in the development 
of hypertension. Reduction of salt intake may only lead to a significant reduction 
in BP where it is already an initial contributing causative factor and excretion 
mechanisms are impaired. 
1.4.3.5 Obesity related hypertension 
 
The mechanism of high blood pressure seen in obese patients is also likely to 
be multifactorial. When excess body fat is produced, additional blood vessels 
are also produced to supply this tissue. As a result, total blood volume must 
increase to fill the circulation and systemic vascular resistance decreases. This 
increases the workload of the myocardium. In addition to this, inflammation and 
circulating lipids as a result of obesity predisposes the development of 
atherosclerosis which narrows vessel lumen and can increase systemic 
vascular resistance.  
One of the leading theories for the mechanism which links obesity and 
hypertension is that of the hormone leptin. Leptin is the ‘hunger hormone’ which 
is released from adipose tissue to suppress the appetite 34. Leptin usually 
induces endothelial dependent vasodilation and anti-coagulation through 
catalysis of NO production 82. Leptin also stimulates the SNS which increases 
blood pressure. However, hyperleptinaemia can result from excessive amounts 
of adipose tissue 82. Obese individuals seem to develop selective leptin 
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resistance as a result of this chronic hyperleptinaemia in which there is an 
impaired anorectic effect and leptin dependent NO production is reduced but 
the SNS is still stimulated 82.  
Other theories suggest that SNS activity maybe upregulated in obesity as a 
result of impaired baroreceptor function, circulating free fatty acids (increased α-
adrenergic activity), increased levels of angiotensin II or insulin 83. Increased 
levels of angiotensinogen could be due to adipose tissue related release of 
angiotensinogen 83, 84. Excess aldosterone is released as a result of adipose 
tissue released factors such as angiotensinogen. In healthy individuals, these 
adipose tissue factors usually exhibit a negative feedback response to higher 
levels of salt. However, obese patients appear to lack this negative feedback so 
excess aldosterone is released alongside excess salt intake. Together this 
leads to elevated blood pressure as well as kidney damage and cardiovascular 
disease 84.  
Obesity related hypertension may also be a result of histological changes to the 
kidneys, primarily of increased pressure on the medulla from intrinsic or visceral 
fat 83. It is thought that the increased pressure may reduce flow rate resulting in 
more time for sodium reabsorption within the tubule. Therefore less sodium 
reaches the DCT and the macula densa stimulate the RAAS, increasing blood 
pressure 83. 
1.4.3.6 Insulin resistance and hyperglycaemia 
 
Hyperglycaemia and insulin resistance particularly in diabetes may directly lead 
to hypertension. Insulin contributes to induction of NO production and so lack of 
insulin can result in loss of the vasodilatory and other previously discussed 
effects of endothelial nitric oxide 85. Insulin also acts on the kidney to increase 
sodium reabsorption and raise blood pressure 86. In addition, the low grade 
inflammation produced as a result of oxidative stress in hyperglycaemia 
contributes to endothelial dysfunction, stiffening of arteries and hence 
hypertension 87. 
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1.5 24-hour Blood Pressure Patterns 
 
In addition to the previously discussed mechanisms of BP regulation, BP also 
has its own 24-hour pattern or circadian rhythm. This involves a drop in blood 
pressure during sleep and a surge in the morning on awakening. Others also 
report a second evening peak around 7pm 88. It has been shown that a normal 
nocturnal dip is a 10-20% drop from an individual’s daily baseline 89. Those who 
drop more than 20% are considered extreme dippers and are also at increased 
risk of cardiovascular events unless the dip is caused by anti-hypertensive 
treatment 89. It is thought that the morning surge is due to autonomic 
sympathetic activation on arousal. In a young healthy adult the morning surge 
should be around 20-25mmHg from the average nocturnal systolic blood 
pressure (SBP) however, in elderly patients with stiff arteries the rise can be 
around 40-60mmHg 88. The morning surge in BP is thought to be responsible 
for the increased number of cardiovascular events, such as stroke and heart 
attack, which occur during the morning than other hours of the day. 
 
Figure 6 A graph of a healthy individual’s systolic, diastolic blood pressure and pulse rate 
against time (24-hour clock). 
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1.5.1 Nocturnal Dipping 
 
1.5.1.1 Prevalence of non-dipping in the diabetic population 
 
Some individuals, particularly people with diabetes and hypertensive patients, 
display a loss of the nocturnal dip (non-dippers) or even a night time rise 
(risers). Both of these groups also show an increased risk of cardiovascular 
events 90-92. An increase in 10mmHg of average nocturnal SBP may increase 
mortality by as much as 21% 93. One study of 50 T2DM patients and 50 non-
diabetic patients found that 74% of T2DM patients were non-dippers compared 
to 16% of non-diabetics 94. It may be that some of the increased cardiovascular 
morbidity in people with diabetes is a result of loss of normal circadian BP 
rhythms. If this is correct, circadian BP rhythms could be an important treatment 
target in people with diabetes.  
 
1.5.1.2 Pathophysiology of non-dipping 
It is not well understood why people with diabetes show a loss of normal 24-
hour BP patterns. A study in 1999 found loss of dipping in 73% of their 
hypertensive T2DM cohort 95. This study found that non-dipping was associated 
with postprandial hyperglycaemia but not with fasting hyperglycaemia or HbA1c. 
They also found that non-dipping was related to duration of diabetes; non-
dippers had diabetes on average for 4 years longer than dippers. This study 
hypothesised that postprandial hyperglycaemia leads to peaks of oxidative 
stress which lead to the production of ROS and endothelial damage 95. This 
microvascular damage could perhaps lead to autonomic neuropathy (AN). 
Over a decade later, a study was published examining the relationship of 
autonomic dysfunction to non-dipping 96. They found that half of the T2DM 
cohort had AN and that those with AN had a significantly reduced nocturnal BP 
dip than those without (p<0.01). This study suggested that AN is an important 
factor in loss of the nocturnal BP dip and that AN may lead to a reduction of 
nocturnal vagal activity hence sympathetic prevalence.  
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The RAAS is also controlled by the sympathetic nervous system. It is thought 
that the RAAS could play a significant role in BP circadian rhythm as levels of 
renin, aldosterone and angiotensin II have been noted to be at their highest in 
the morning, falling throughout the day 97. It is thought that intrarenal RAAS 
shows a circadian rhythm 98. Some intrarenal RAAS may be due to 
angiotensinogen release from the liver which filters through the glomerulus. 
More angiotensinogen is filtered in response to increased glomerular 
permeability and hypertension. This may be another link in the relationship 
between kidney damage, hypertension and how they often progress in 
parallel98. 
Abnormal sympathetic activity could be an explanation for why people with 
hypertension also often exhibit loss of nocturnal dipping. A recent meta-analysis  
concluded that non-dipping in hypertension is a predictor of all cardiovascular 
outcomes, independent of average SBP 89. However, some suggest that non-
dipping is a sign of more advanced hypertension 99. Perhaps non-dipping is 
independent of average SBP, but related to how established the underlying 
pathophysiological processes are. 
Another factor that could contribute to loss of nocturnal dip is sleep apnoea. 
Sleep apnoea is a condition which is highly prevalent in the T2DM population 
likely due to common risk factors such as obesity 100. Apnoeic episodes during 
the sleep period are thought to increase overall nocturnal blood pressure 88. BP 
falls with the onset of the apnoea but then rises with termination of the episode. 
The influence of sleep apnoea on night time blood pressure in T2DM may be 
overlooked as sleep apnoea is often undiagnosed. It seems as though sleep 
apnoea could play a causative role towards loss of nocturnal dip but again, it 
may simply be a correlation due to similar risk factors. 
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1.5.2 Evidence for the effect of 24-hour Blood Pressure Patterns 
on Albuminuria 
 
1.5.2.1 Non-Dipping 
Several studies have specifically evaluated the relationship of nocturnal dipping 
among diabetic and hypertensive patients and albuminuria. There is an 
overarching theme that loss of nocturnal dipping correlates with increasing 
albuminuria. However, the specific parameters and strength of this relationship 
differ between studies. It is not clear whether nocturnal dipping patterns provide 
more valuable or additional information beyond average 24-hour SBP. The 
following sections will review the current literature on the effect of non-dipping 
blood pressure patterns on albuminuria. 
1.5.2.1.1 Nocturnal Systolic BP and albuminuria 
In 1997 a small study compared 24-hour blood pressure and albumin excretion 
rate (AER) in 20 T2DM patients with normal albuminuria and MIA 101. They 
found that nocturnal SBP was significantly higher in the MIA group than the 
normal albuminuria group and that only nocturnal SBP showed a significant 
relationship with urine albumin excretion (p=0.05). The study found that the 
night time dip was reduced the most within the MIA group but this difference 
was not statistically significant, perhaps influenced by the small sample size.  
A retrospective study of 16546 patients found that there were higher proportions 
of non-dippers and risers in patients with MIA and SIA than those with normal 
albuminuria. Thirty-eight percent of normal albuminuria patients, 43.3% of MIA 
patients and 43.8% of SIA patients were non-dippers. This study focussed on 
average nocturnal SBP levels rather than non-dipping and may involve 
selection bias as all patients were taken from an ambulatory blood pressure 
monitoring registry. The study found that high nocturnal SBP significantly 
correlated with increased albuminuria (p=0.001) 102. However, the significance 
of the specifically nocturnal BP and albuminuria relationship may be as a result 
of the first morning void urine measurement. The urine measurement therefore, 
may correlate more strongly with night time blood pressure values. This study 
also combined people with and without diabetes within their analysis of blood 
pressure dipping and so may not be representative of the T2DM population. 
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Both of these studies commented primarily on average night time SBP rather 
than the patient’s individual day to night BP ratio. Therefore, these studies are 
not particularly helpful in considering the importance of loss of dipping but they 
do provide evidence that SBP has a significant correlation with albuminuria. 
They seem to suggest that nocturnal SBP has a more significant relationship 
with albuminuria than daytime SBP. This relationship may be due to time of 
urine collection as night time urine may correlate more strongly with night time 
blood pressure values. Night time blood pressure measurements may also be 
more informative due to the lack of external stressors which are often present 
during the day and can affect BP variability. 
1.5.2.1.2 Non-dipping and albuminuria in type 2 diabetics 
One study followed 112 people with diabetes for 9.5 years. Individuals who 
went on to develop advanced nephropathy and albuminuria had significantly 
higher average 24-hour SBP and pulse pressure (PP) values. This study 
interestingly found that diastolic day to night BP ratio was an independent 
predictor of nephropathy progression (p=0.02) but that systolic day to night ratio 
was not (p=0.14) 103.  Strengths of this study were that patients were randomly 
selected and there was a long follow up period. It is worth noting, the night time 
BP was determined using a ‘set night time period’ rather than the patient’s own 
sleep and wake times. This could mean the study’s night time blood pressure 
values were not representative of the individuals actual sleep pattern and 
circadian rhythm. The study also used albumin creatinine ratio (ACR) rather 
than albumin excretion rate (AER) which is the gold standard measurement for 
albumin. 
Other research supports the relationship between loss of nocturnal dip and 
increasing albuminuria and suggests that loss of circadian BP may be an 
indicator of poor prognosis 104, 105. However, one of these studies only included 
male participants 104 and so is not relevant to the whole population. The second 
study found that high night-time SBP and loss of night time dipping both 
correlated with albuminuria but did not comment on the relationship between 
non-dipping and SBP, so it was not ascertained whether non-dipping 
independently contributed to albuminuria in this group 105. 
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Leitão et al performed a cross-sectional study of 270 T2DM patients to 
determine whether day to night ratio of BP was more or less strongly related to 
albuminuria than average 24-hour SBP 106. The study used 24-hour urine 
collections and an immunoturbidimetric albumin assay alongside 24-hour 
ambulatory blood pressure monitoring. They found that both average SBP and 
day to night ratios significantly correlated with albuminuria. However, 
albuminuria had a more consistent and stronger correlation with average 24-
hour SBP (r=0.418, p<0.001) than with day to night BP ratios (r=0.159, 
p=0.011). The significance of day to night BP ratios with albuminuria was not 
maintained after adjustment for age, diabetes duration and HbA1c. This could 
suggest that the observed relationship is a reflection of the severity of diabetes. 
This study had some limitations; the cohort was 77% white and so may not be 
entirely representative of any ethnicity, the patients had an average diabetes 
duration of 10 years and HbA1c of 8.2%. This may mean the patients had fairly 
advanced diabetes with overlap of microvascular complications. It would be 
beneficial to compare this group to a control group. All of the non-parametric 
data was log transformed before performing parametric statistical tests rather 
than using the raw data and non-parametric tests. 
Another study of 663 patients with T2DM showed that non-dippers (n=230) had 
a significant correlation with albuminuria and also aortic pulse wave velocity 
showing that dipping may correlate with arterial stiffness 107. This supports the 
theory that a common pathway of endothelial dysfunction may lead to abnormal 
24-hour BP patterns and albuminuria. The main significant differences between 
these groups were increased ACR (5.0 ±17.1 vs 2.0 ±9.7, p=0.004) and 
reduced GFR (88.6 ±20.7 vs 100.2 ±25.7, p=0.001) in the non-dipping group 
compared to the normal dipper group. BMI (30.7 ±4.7 vs 29.9 ±4.6, p=0.036) 
and office SBP (139.0 ±16.4 vs 136.0 ±16.2, p=0.024) were increased in the 
non-dipping group but diabetes duration, HbA1c and age did not differ between 
groups. When this study removed participant data where 24-hour BP results 
were less than 60% successful, the relationship between non-dipping and ACR 
became borderline significant (p=0.051). The study also made no comment on 
the relationship between average SBP and ACR. The paper had no mention of 
exclusion criteria and did not mention any other diabetic complication patients 
may have had. This study used ACR instead of the gold standard AER.  
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1.5.2.1.3 Non-dipping and albuminuria in hypertension 
As non-dipping is prevalent in hypertension as well as diabetes, it is important 
to understand the overlap between the two conditions in relation to albuminuria. 
Different studies have evaluated the relationship between albuminuria and 24-
hour BP patterns in diabetes and hypertension in several different ways.  
One study examined 141 newly diagnosed hypertensive patients without 
nephropathy or diabetes. This study found that patients with MIA had higher 
blood pressure values across the board than those with normal albuminuria. 
They also found that day to night ratio of diastolic blood pressure (DBP) was 
inversely associated with urine albumin excretion (UAE) independent of age 
and sex 108. This study used a set night time period which, as previously 
mentioned, may not give an accurate representation of an individual’s circadian 
BP rhythm. However, these results could suggest that day to night blood 
pressure ratio is relevant to albuminuria in the non-diabetic population.  24-hour 
AER was used in this study.   
Another study compared non-dipping in non-diabetic hypertensive people 
(n=41) and people with T2DM and hypertension (n=72)  across all ranges of 
albuminuria 109. Average systolic BP was higher in the diabetic MIA and SIA 
groups. In the T2DM group, non-dipping was observed in 80%, 74%, 43% of the 
SIA, MIA and normal albuminuria groups respectively. Thirty-seven percent of 
the non-diabetic hypertensives were non-dippers. This suggests that although 
there is a relationship between hypertension and loss of circadian BP, this link 
may be stronger in the presence of diabetes. These results also suggest that 
there is a relationship between non-dipping and albuminuria. It remains to be 
determined whether this relationship is causative or whether these signs could 
be two products of a common causative pathway. It is worth noting that the 
participants were hospitalised for the purposes of the study and so BP may not 
be reflective of the values they experience in normal daily life. The study also 
used a set night time period rather than the patient’s own sleep and wake times. 
Inaba et al looked into day to night BP ratio specifically in normotensive people 
with diabetes 110. Twenty-seven people with T2DM were compared to 10 age 
and body mass index (BMI) matched controls. The day to night ratio in patients 
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with MIA was significantly higher than healthy controls. There was also a 
correlation between AER and day to night BP ratio. DBP showed a slightly 
stronger correlation than SBP (r=0.589, p<0.05 and r=0.534, p<0.05 
respectively). This suggests that diabetes has a relationship with non-dipping 
patterns independent of hypertension status. Interestingly, although there was 
no difference in HbA1c or fasting plasma glucose between groups the patients 
with MIA had longer duration of diabetes. The linear examination of variables 
was a strength of this study. Many of the other described studies may lose data 
by separating patients into discrete non-dipper/dipper, normal 
albuminuria/MIA/SIA groups. Linearly comparing day to night BP ratio and AER 
gives insight into the progressive relationship between the two variables. 
However, this study was small and examined already hospitalised in-patients 
which gives selection bias and could lead to misleading results as these 
patients were likely acutely unwell. 
These results suggest that the potential relationship between non-dipping and 
albuminuria is not specific to the diabetic group but may be stronger in diabetes. 
Further study is needed to further clarify the relationships between these 
groups. 
1.5.2.1.4 Non- dipping and albuminuria progression 
Many studies do not evaluate the relationship between albuminuria and non-
dipping in terms of progression of disease but simply take a snapshot of 
albuminuria and 24-hour BP. However, in one study, 957 T2DM patients were 
followed up for 3 years 111. Although a higher proportion of non-dippers 
progressed to MIA than dippers, this study found that non-dipping patterns were 
not an independent predictor of albuminuria progression. However, night time 
rising was an independent predictor of albuminuria progression but ambulatory 
pulse pressure (PP) was the most informative predictor of albumin progression. 
Interestingly, there were a higher proportion of non-dippers in those with a PP 
over 65mmHg. However, this authors acknowledged itself that their 
dichotomous classification of BP patterns may have resulted in loss of 
information. 
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1.5.2.2 Other circadian blood pressure parameters and albuminuria 
1.5.2.2.1 Pulse pressure 
Increased PP is also associated with microalbuminuria in people with 
diabetes112. Knudsen et al evaluated the relationship between pulse pressure 
alongside circadian BP in T2DM 113. This showed a significant relationship 
between average 24-hour BP and increasing albuminuria and also a significant 
relationship between loss of the nocturnal dip and increasing albuminuria. 
However, the study also showed that PP correlated with increasing albuminuria 
and that nocturnal PP was significantly higher in the SIA group. This could 
suggest that circadian variation in PP is also a contributor to albuminuria in 
diabetic patients. 
1.5.2.2.2 Non-dipping heart rate  
As well as non-dipping patterns in BP, heart rate (HR) should drop overnight. It 
seems that people with diabetes are also at risk of non-dipping heart rate as a 
result of AN. A study of 179 T2DM patients found that non-dipping heart rate 
was also significantly related to increasing albuminuria 114. This suggests that 
AN may be an important factor in the mechanism behind a relationship between 
circadian BP rhythms and albuminuria.  
1.5.2.2.3 Morning surge 
Other studies have considered the relevance of other 24-hour BP patterns such 
as the morning surge in blood pressure (MBPS). One study followed 377 
individuals recently diagnosed with T2DM for an average of 6.5 years 115. They 
calculated the extent of the MBPS and evaluated its relationship with 
albuminuria throughout follow up. This found that an increase in MBPS over 
time is significantly associated with progression of albuminuria in normotensive 
T2DM patients. A patient whose MBPS increases by 25mmHg is at least 6 
times more likely to go on to develop MIA 115. Other studies support this finding 
that incremental increases in MBPS are associated with progression of kidney 
disease 116. 
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1.5.2.2.4 Afternoon peak 
One group considered the relevance of a blood pressure peak in the afternoon 
(2pm-8pm) 117. The study found that in those patients with a higher than 
average afternoon peak there was a higher prevalence of diabetic retinopathy 
and significant correlation with urine albumin excretion but this disappeared 
after adjustment for covariates including age, gender, HbA1c, duration of 
diabetes and 24-hour systolic BP. The afternoon peak perhaps needs further 
evaluation to determine whether it is a relevant measure in terms of progression 
of albumin. 
Overall the evidence suggests that there is a relationship between abnormal 24-
hour blood pressure patterns and progression of albuminuria in people with 
diabetes, irrespective of hypertension status. Particularly the rising or non-
dipping BP, non-dipping HR and MBPS patterns. Non-dipping of PP may also 
be an informative measure. However, there is some discrepancy between 
whether diastolic dipping or systolic dipping has a stronger correlation with 
albuminuria. The mechanism linking dipping status and urine albumin excretion 
is still unknown and is likely complex. However, it seems that AN may play a 
significant role.  
 
1.5.2.3 Circadian rhythms as a treatment target 
If a relationship between loss of circadian rhythms and albuminuria exists, 
circadian BP rhythms could be an important treatment target for diabetic 
patients. Some studies have attempted to target these patterns. One study of 
40 diabetic patients received 40mg of Olmesartan either on waking or at 
bedtime 118. Nocturnal SBP and average 24-hour BP were significantly lowered 
in the bedtime dose group compared to the morning dose. The bedtime dose 
significantly increased the number of nocturnal dippers however, no significant 
differences were observed in albuminuria. 
Another study showed similar results, bedtime administration of anti-
hypertensives led to a significant decrease in nocturnal SBP but no significant 
difference in albumin excretion 119.   
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However, another study of 200 hypertensive patients randomised timings of 
medication administration and showed that bedtime administration of the 
angiotensin receptor blocker (ARB) valsartan led to a 41% reduction in 24-hour 
AER 120. This was a significant reduction in albuminuria and highly correlated 
with a correction of nocturnal dipping independent of average 24-hour BP. 
Although there is some discrepancy between evidence of whether albuminuria 
can be targeted by bedtime administration of anti-hypertensives. This study had 
some important strengths including; large sample size, blood pressure was 
measured for 48 hours rather than 24 and all physical activity was monitored by 
an actigraph. However, the study excluded diabetic patients so the data may 
not be directly translated to the diabetic population and also described their 
method of urine albumin quantification as ‘the routine automatic hospital 
techniques’. This is likely to be an assay which cannot measure albumin 
throughout the entire normal albuminuric range.  
There is less evidence for how bedtime administration of anti-hypertensives 
may affect other BP patterns like MBPS. One study found that bedtime 
doxazosin seemed to diminish the MBPS and the reduction correlated with a 
reduction in urine albumin 121.  
 
1.5.2.4 Urine collection and analysis 
A common theme running through this literature review was the difference in 
choice of method of urine albumin collection and measurement, ACRs are 
prone to the variation of individual’s creatinine excretion and may sometimes 
give an inaccurate result 122. It is worth noting that, while AER is considered the 
gold standard collection method, timed collections are also prone to collection 
errors by the patient 123, 124. Many of these studies either do not describe their 
urine albumin assay in detail or used the immunoturbidimetric method of 
albumin quantification which often cannot measure albumin values within the 
normal albuminuric range.  
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1.5.2.5 Conclusion 
 
Overall there is evidence to suggest that non-dipping blood pressure patterns 
are more prevalent in diabetic patients with albuminuria than those without. 
However, the cause for this relationship is undetermined. As it is well 
established that higher average SBP leads to increased albuminuria and so it 
could be deduced that the lack of fall in BP adds to the overall 24-hour SBP 
level, hence increasing albuminuria. It could also be suggested that both 
albuminuria and non-dipping may result from a common pathway such as 
endothelial damage due to hypertension or hyperglycaemia. This is supported 
by the findings that non-dipping seems to be more prevalent in those with a 
longer duration of diabetes. No study analyses non-dipping and albuminuria in 
early diabetes or precisely into the normal albuminuric range, which is largely 
undetectable by conventional assays.  
The loss of nocturnal dipping also occurs in people with hypertension in the 
absence of diabetes. However, there is less evidence for whether non-dipping 
affects albuminuria in this cohort. 
If non-dipping does influence albuminuria, it is not clear whether it provides 
additional information to average SBP, pulse pressure or other circadian 
rhythms which have been shown to influence albuminuria levels.  
Methods of urine collection and measurement differ between studies and it is 
still unclear which method is the optimum for quantification of urine albumin. 
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1.6 Thesis Aims and Objectives 
 
1.6.1 Aims 
 
 
• To further understanding of the relationships between 24-hour blood 
pressure patterns, primarily day to night blood pressure ratios, and 
urinary albumin excretion in untreated hypertension, treated hypertension 
and type 2 diabetes. 
 
 
• Examine the effect of using different urine collection methods and 
albumin assays on the analysis of relationships between blood pressure 
and urine albumin excretion. 
 
 
• Investigate whether integrity of the glycocalyx shows a relationship with 
albuminuria and BP patterns across hypertensive and type 2 diabetic 
populations. This may help to understand whether endothelial glycocalyx 
damage plays a role in development of pathological 24-hour BP patterns 
and albuminuria. 
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1.6.2 Objectives 
 
1)  I will perform a post-hoc analysis of the DASHER study, an 18 week 
interventional study in patients with grade II hypertension who were treatment 
naïve. DASHER used a strict protocolised treatment regime to maximise 
patients adherence to treatment and minimise side effects, treatment was 
changed every two weeks if the patient had not reached target blood pressure 
or they were experiencing side effects.  I will explore the relationships between 
24-hour blood pressure, albuminuria and glycocalyx integrity in these treatment 
naïve patients with hypertension before and after 18 weeks of blood pressure 
treatment. I will use both a commonly used albumin assay and highly sensitive 
albumin assay which will enable analysis of the entire normal albuminuric 
range. Analysis will be performed on both random spot urine samples and timed 
overnight urine samples. 
 
2) I will prospectively study 34 type 2 diabetic participants from the BEAT-DKD 
study exploring the relationships between 24-hour blood pressure, albuminuria 
into the normal range and glycocalyx integrity in type 2 diabetic patients. I will 
use a commonly used albumin assay and highly sensitive albumin assay to 
enable analysis of the normal albuminuric range. Analysis will be performed on 
timed overnight urine samples and first morning void spot samples. 
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2. Chapter 2: Methods 
 
2.1 Twenty-four-hour ambulatory blood pressure 
 
2.1.1 Measurement 
 
24-hour blood pressure was measured using an automated, oscillometric TM-
2430 ambulatory blood pressure monitor (A&D, Draycott, Gloucestershire, UK).  
2.1.1.1 Monitor set up 
 
The monitor was set to record blood pressure every 15 minutes from 07:00 to 
22:00, then every 30 minutes from 22:00 to 07:00. The patient wore the cuff for 
24-hours. These timings were used as it is recommended that at least 30 
measurements are taken during the awake period and 6 measurements are 
taken during sleep. This is due to the higher level of blood pressure variation 
during the day and less at night. Thus, more readings produce a better 
reflection of the daytime average blood pressure. In many 24-hour monitoring 
periods, patients may either not tolerate and remove the cuff or have episodes 
where the monitor cannot take a reading through error. As a result more 
frequent measurements maximises the chance of an adequate number of 
readings should these events take place. It has also been found that the more 
frequent measurements are not more disturbing to the patient than less frequent 
measurements 125.  
2.1.1.2 Fitting the monitor 
 
The cuff was placed on the patient’s non-dominant arm unless there were any 
contraindications or objections (patient objection due to sleeping habits, 
musculoskeletal problem, wounds etc.). This occurred in 3 patients in the 
BEAT-DKD study. The correct size cuff was positioned correctly (see figure 7) 
as per the standard operating procedure, and connected to the monitor. A trial 
blood pressure measurement was taken to ensure patient comfort and that the 
monitor was working properly. The monitor was then set to the automatic 
programme.  
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The patient was asked to relax the arm down by their side and keep movement 
to a minimum during the readings if possible. The patient was also asked not to 
perform any strenuous exercise or get the blood pressure monitor wet. The 
patient was shown how to terminate the recordings should they not wish to 
continue with the 24-hour monitoring.  
The monitor number, measured arm and time of recording was noted in the 
patient’s clinical record form. The next day the cuff was removed; patient sleep 
and wake times were recorded. Data were retrieved using the A&D software 
and saved to the study drive. The cuff and monitor was then cleaned, ready for 
the next use. 
 
Figure 7 Positioning of the 24-hour BP monitor and cuff. 
2.1.2 Validation and Quality control 
 
The A&D TM-2430 Ambulatory blood pressure monitor has been validated by 
the British and Irish Hypertension Society across all age ranges, body mass 
indexes and sexes. It has also been shown to be accurate for those with high 
blood pressures 126, 127. 
Quality control is carried out annually on all monitors used within this study by 
the Royal Devon and Exeter Hospital Medical Electronics Management. The 
most recent quality control check was carried out in April 2019. 
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2.1.3 Analysis 
 
Data were retrieved and analysed by the A&D TM2430-13 (Doctor Pro) 
software. The software calculates various measurements from the full 24-hour 
period, the awake period and the sleep period (calculated from the patient’s 
individual sleep and wake times). These include the mean and standard 
deviation of: systolic BP, diastolic BP, mean arterial pressure and pulse. If 
patients did not provide sleep and wake times then day and night values are 
missing and were not included in analysis. 
The BP profile was further analysed resulting in several other measurements 
which are detailed below:  
• Pulse pressure - calculated from each day period by subtracting the 
mean diastolic BP from the mean systolic BP.  
• Morning surge (mmHg) - calculated using the sleep-trough morning 
surge method: (average systolic BP over the first 2 hours of waking) – 
(average of the three lowest systolic BP values during sleep)128. 
• Double product (DP) - calculated using the average systolic BP 
multiplied by the heart rate. 
• Pulse pressure product (PPP) - calculated using the average pulse 
pressure multiplied by the heart rate.  
• Night time dipping - calculated using the day/night ratios of BP 
parameters. Normal night time dipping of systolic BP is defined in the 
literature as a 10-20% drop compared to daytime average BP. All other 
BP parameters normal range will be determined based on their 
relationship to systolic BP day to night ratios 89.  
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2.2 GlycoCheck 
 
2.2.1 Overview 
 
The glycocalyx was measured using GlycoCheck (BV Microvascular health 
solutions software system, Maastricht, The Netherlands) and a side-stream 
dark-field camera (KK Technology, Honiton, England). The software generates 
a measurement of glycocalyx integrity called the perfused boundary region 
(PBR). The PBR is the difference between the width of the main blood cell 
column in a vessel and the outer edge of RBC deviation from the main column. 
This area is thought to include the most luminal part of the glycocalyx therefore, 
the higher the PBR, the lesser the glycocalyx integrity. 
GlycoCheck uses a side stream dark field camera which uses a ring of green 
light emitting diodes surrounding a central lens. The green light is preferentially 
absorbed by red blood cells (RBCs) and so produces an image of RBC transit 
through vessels. 
 
 
 
 
Figure 8 Left: an example of a sublingual side stream dark field image as taken 
with GlycoCheck. Right: GlycoCheck computer and side stream dark field 
camera. 
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2.2.2 Automated analysis 
 
GlycoCheck automatically records video segments when adequacy is obtained. 
Video adequacy is based on tissue motion, illumination intensity and focus. 
Recording continues until 3000 10µm vessel segments have been identified. 
Once recording is complete, GlycoCheck software automatically begins 
analysing each of the 3000 vascular segments. For each segment, 840 radial 
intensity profiles are obtained. From these profiles the median RBC column 
width (Median P50) and the outer edge of the RBC perfused region are 
calculated. The PBR is then calculated by the difference between the outer 
edge of RBC perfused region and the Median P50, divided by two. Each 
recording is then categorised by its individual MedianP50 giving different 
recordings for different vessel widths between 5 and 25 microns. One single 
PBR reading for 5-25 microns is also generated 129. 
 
 
 
Figure 9 demonstrating PBR and Median P50. RBCW (red blood cell column 
width) 129. 
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2.2.3 Measurement 
 
For the GlycoCheck measurement, patients were lying at 30 degrees in a 
supine position. Measurements were taken by a trained individual. A new 
disposable lens cap was used for each patient. The investigator sat behind the 
participant and the camera was positioned sublingually, perpendicular to the 
floor of the mouth, left or right of the frenulum. Excess pressure on the vessels 
was avoided and camera focus adjusted until the adequacy bar moved into the 
green. GlycoCheck automatically begins recording once adequacy is obtained. 
Areas of particularly looped capillaries were avoided. Three recordings were 
taken on each visit unless not possible due to participant compliance or time 
restraints. The software automatically generates a report and saves a copy to 
the hard drive. 
 
 
Figure 10 demonstrating the positioning of patient and GlycoCheck user during 
measurement. 
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2.2.4 Reproducibility 
 
2.2.4.1 External reproducibility 
Reproducibility carried out by the GlycoCheck company (BV Microvascular 
health solutions software system, Maastricht, The Netherlands) found that in 
healthy adult males between the ages of 20 and 29 years, PBR 5-25 varied 
between 0.9 and 2.2. Variability between visits was around ± 0.1-0.2 in the 
same individual. Other studies which evaluated GlycoCheck software found that 
healthy controls (average age 44.1 years) had an average PBR of 3.3 (±0.4) 
which was significantly different to dialysis patients who had an average PBR of 
3.6 (±0.5) 130. 
A later study found healthy controls (average age 44.8 years) had an average 
PBR 5-25 of 1.82 (±0.16) and that ESRD patients had a significantly higher 
PBR 5-25 of 2.05. Those patients who were transplanted had a PBR that was 
not statistically significant from the healthy controls 131. 
Both of these studies were conducted by the owners or manufacturers of 
GlycoCheck so requires independent verification. They state that the lower PBR 
of healthy controls in the more recent study is due to the newer method of 
calculating PBR with 3000 vessel segments 131. They believe this is therefore 
more reliable. 
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2.2.4.2 Internal reproducibility 
Reproducibility of the GlycoCheck technique was carried out on 2 participants at 
5 separate visits. Three measurements were taken at each visit. Measurements 
were taken at the same time of day and participants were asked to abstain from 
caffeine and fast from food for 3 hours prior to the measurements. 
Visit. 
Measurem
ent 
PBR 5-25 PBR high 
flow 
PBR 5-9 PBR 10-19 PBR 20-25 Median 
P50 
   
1.1 1.66 1.1 0.92 1.74 2.15 9.21 
1.2 1.4 1.18 0.93 1.63 1.41 8.96 
1.3 2.09 1.45 1.04 2.37 2.5 9.58 
2.1 1.71 1.8 1.01 1.97 1.88 8.34 
2.2 2.53 1.63 1.09 2.67 3.51 9.65 
2.3 1.82 1.69 1.04 2.17 1.92 7.59 
3.1 2.02 1.46 1.22 2.03 2.67 10.39 
3.2 1.86 1.48 1.02 1.99 2.34 12.45 
3.3 1.97 1.86 0.97 2.25 2.34 10.16 
4.1 1.98 1.31 1.15 2.23 2.28 9.14 
4.2 1.78 1.65 0.93 2.03 2.08 9.52 
4.3 1.73 1.71 1.13 2.13 1.56 11.06 
5.1 1.96 1.61 1.07 2.03 2.58 10.49 
5.2 1.64 1.35 1.05 1.95 1.6 10.86 
5.3 2.09 1.34 1.03 2.14 2.9 10.53 
Min 1.4 1.1 0.92 1.63 1.41 7.59 
Max 2.53 1.86 1.22 2.67 3.51 12.45 
Mean 1 
(±SD) 
1.88 
(±0.26) 
1.51 
(±0.22) 
1.04 
(±0.08) 
2.09 
(±0.25) 
2.25 
(±0.55) 
9.86 
(±1.19) 
95% CI 1.74-2.03  0.99-1.08 1.95-2.23   
Visit to Visit variability     
Mean 2 
(±SD) 
1.88 
(±0.12) 
1.51 
(±0.17) 
1.04 
(±0.04) 
2.09 
(±0.13) 
2.25 
(±0.23) 
9.86 
(±1.00) 
Coefficient 
of 
variation 
6.17 11.77 4.25 6.23 10.35 10.19 
Table 1 Patient 1 GlycoCheck reproducibility results. Visit.measurement 
numbers ie. 1.1 correlated to visit number one and measurement number taken. 
Mean 1 is the average of all readings from all visits. Mean 2 is the mean of each 
visits average PBR. Standard deviation and coefficient of variation of Mean 2 
shows visit to visit variability of PBR. 
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Visit. 
Measurem
ent  
PBR 5-25 PBR high 
flow 
PBR 5-9 PBR 10-19 PBR 20-25 Median 
P50 
 
      
1.1 1.93 1.83 1.11 2.11 2.31 8.35 
1.2 2.09 0.94 1 2.23 2.75 10.18 
1.3 1.85 1.43 1 2.1 2.14 11.43 
2.1 1.98 1.24 1.04 2.32 2.19 10.05 
2.2 1.78 1.34 0.96 2.08 1.94 9.19 
2.3 1.95 1.2 1.03 2.07 2.5 8.81 
3.1 1.93 1.1 1.14 2.48 1.68 8.97 
3.2 1.7 1.45 0.97 1.9 1.97 8.59 
3.3 2.22 2.42 1.12 2.41 2.81 10.03 
4.1 2.16 1.15 1.13 2.46 2.51 9.4 
4.2 2.14 1.34 1.08 2.21 2.9 9.85 
4.3 2.04 1.59 1.09 2.28 2.41 9.14 
5.1 1.97 1.03 1.16 2.19 2.33 7.46 
5.2 2.46 1.45 1.31 2.6 3.17 7.55 
5.3 2.26 0.68 1.26 2.33 2.98 9.26 
Min 1.7 0.68 0.96 1.9 1.68 7.46 
Max 2.46 2.42 1.31 2.6 3.17 11.43 
Mean 1 
(±SD) 
2.03 
(±0.20) 
1.35 
(±0.41) 
1.09 
(±0.10) 
2.25 
(±0.19) 
2.44 
(±0.42) 
9.22 
(±1.03) 
95% CI 1.92-2.13  1.04-1.15 2.15-2.35   
Visit to visit variability 
Mean 2 
(±SD) 
2.03 
(±0.14) 
1.35 
(±0.22) 
1.09 
(±0.09) 
2.25 
(±0.10) 
2.44 
(±0.28) 
9.22 
(±0.70) 
Coefficient 
of 
variation 
6.73 16.31 8.30 4.40 11.49 7.56 
Table 2 Patient 2 GlycoCheck reproducibility results. Visit. Measurement 
numbers ie. 1.1 correlated to visit number one and measurement number one 
taken. Mean 1 is the average of all readings from all visits. Mean 2 is the mean 
of each visits average PBR. Standard deviation and coefficient of variation of 
Mean 2 shows visit to visit variability of PBR. 
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Figure 11 The spread of data from patient one and patient two over the 5 visits. 
Each patient was healthy and aged 23-25. 
 
For this study the overall PBR 5-25 measurement will be used. Individual focus 
will also be given to the PBR 5-9 and PBR 10-19 as these measurements are of 
smaller vessels, which more accurately reflect the size of the capillaries within 
the glomerulus. 
It is yet to be determined what may be a clinically significant change in PBR, 
however it has been suggested that PBR is a reliable method of measuring the 
glycocalyx through its relationship with serum marks of glycocalyx shedding 130 
131. As a result, for this study, PBR will be used as a marker of glycocalyx 
integrity to ascertain whether there is a relationship between the glycocalyx, 
blood pressure and albuminuria.  
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2.3 Urine Albumin Quantification 
 
2.3.1 Collection 
 
For all urine collections, participants were asked to avoid any strenuous activity 
or sexual activity 24-hours prior to the collection. Females were also advised 
not to collect urine during their menstrual period as this can lead to false 
readings. 
2.3.1.1 Overnight urine 
 
The participant was asked to pass urine into the toilet before they go to bed and 
record the time. After this point any urine passed was collected into a 2.5 litre 
bottle. The first morning urine was also collected into the bottle and the time 
recorded. The collection is then complete. The bottle was kept in a cool place 
until the appointment that day. Women may use a sterile bowl to decant urine 
into the bottle.  
2.3.1.2 Spot samples 
 
Spot samples were either first or second morning voids or random spot test on 
arrival to the research centre.  
For first and second morning void participants were given two urine containers. 
The participant was asked to fill each container to 50ml if possible and note the 
time of the void. The containers were then stored in a cool place until the 
appointment that day. 
For the random spot test patients were asked to pass urine into a container 
within the patient toilet cubicle and hand back to the research nurse during their 
appointment.  
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2.3.2 Analysis 
 
2.3.2.1 Cobas Immunoturbidimetry 
 
Urines were initially analysed using the Cobas immunoturbidimetric assay 
(Roche Diagnostics, Rotkreuz, Switzerland) which is a common clinical 
laboratory method for quantifying urine albumin. Turbidimetry uses antibodies to 
bind to albumin which results in precipitation of immune complexes. The more 
precipitation of albumin immune complexes, the more turbid the sample 
becomes. The albumin concentration is then calculated from the amount of light 
able to pass through the sample. Cobas immunoturbidimetry of albumin has a 
lower limit of detection of 3μg/ml and so cannot be used to quantify albuminuria 
throughout the normal range 132. The Cobas company test repeatability using 
human samples and controls (n=21) and show a coefficient of variation between 
0.5-1.9%. 
2.3.2.2 Fitzgerald ELISA 
 
Overnight and spot urine samples were re-tested using the Fitzgerald 
MicroAlbumin ELISA kit (Fitzgerald industries international, North Acton, MA, 
USA), which is a highly sensitive immunoassay designed to detect levels of 
albumin into the normal albuminuric range. 
The assay kit contains microwells to which purified human albumin is bound. 
Urine samples are pipetted into the wells along with anti-human-albumin-
peroxidase conjugate. Urine albumin will compete with the bound albumin for 
the anti-human-albumin-peroxidase conjugate, the more urine albumin present 
the fewer complexes will form with the bound albumin. The microwells are then 
washed with sodium azide leaving behind only the bound complexes. Addition 
of an acid results in the bound complexes turning yellow. The intensity of the 
yellow colour is measured photometrically at 450nm. The amount of colour is 
therefore inversely proportional to the concentration of albumin.  
The Fitzgerald company state the assay has an analytical range between 0.15 
to 400mg/L with a lower limit of detection of 0.5mg/L. Repeatability show inter-
assay variation between 2.9-5.2% and intra-assay variation between 3.3-5.3%. 
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A different, independent validation of the assay found a lower limit of detection 
of 0.39mg/L with a limit of quantitation of 0.78mg/L. and when repeatability was 
analysed found a coefficient of variation between 6.44-18.42% 132.  
 
2.4 Sudoscan measurement 
 
Sudoscan (Impeto Medical, San Diego, CA, USA) is a non-invasive test that 
was used to measure sudomotor function of the hands and feet as an indicator 
of small nerve neuropathy within the BEAT-DKD group. Sudomotor function is 
measured through electrochemical skin conductance. Hands and feet are 
placed on metal plates (electrodes) which emit a low voltage current which 
extracts chloride from sweat glands. The glands which produce this sweat are 
supplied by small nerve fibres which are prone to damage even at the early 
stages of diabetes and so a reduced sweat response correlates to small nerve 
damage.  
The electrochemical skin conductance is measured in microseimens. A result of 
less than 60 microseimens represents reduced sudomotor function. Sudoscan 
has a sensitivity of 0.75, specificity of 0.98 and <0.05 error 133. 
 
2.5 HbA1c  
 
HbA1C was analysed on the TOSOH G8 automated HPLC analyser (Tosoh 
Bioscience, Inc. South San Francisco, CA, USA) by ion-exchange 
chromatography. This method has a coefficient of variation below 2%. 
 
2.6 Fasting glucose 
 
Fasting glucose was analysed on the 702 photometric module of the Cobas 
8000 automated platform (Roche Diagnostics, Rotkreuz, Switzerland). This 
method has a coefficient of variation below 2%. 
 
72 
 
2.7 BMI 
 
BMI was calculated by dividing the individual’s weight in kilograms by the 
square of their height in metres and displayed to one decimal place: 
Weight (kg) ÷ Height2 (m)= BMI. 
 
2.8 Body fat percentage 
 
Body fat percentage was measured using a Tanita BF-350 body composition 
analyser (Tanita corporation of America, Inc., Arlington Heights, IL, USA).  The 
body composition analyser uses four metal plates on which the individual 
stands with bare feet. A low frequency electrical current is passed through the 
feet. The signal passes more quickly through the water in hydrated muscle than 
body fat. This resistance is known as impedance. The analyser determines the 
percentage body fat by how quickly the electrical signal passes through the 
body and back to the analyser. 
 
2.9 Statistical analysis 
 
Data were analysed using STATA 15. The distribution of all variables was 
assessed using histograms and q-q plots. Where data were non-normally 
distributed data were summarized using median and interquartile ranges. 
Correlation was initially assessed using two way scatter plots. Pearson 
correlation was used to correlate parametric variables and Spearman’s rank 
was used to correlate non-parametric variables.   
Paired and un-paired Student’s t tests were used to compare matched and 
unmatched parametric variables from week 1 and week 18 whereas Wilcoxon 
signed-rank test was used to compare matched non-parametric variables. Mann 
Whitney U test was used to compare unmatched non-parametric variables. 
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3. Chapter 3: The DASHER Study 
 
 
 
3.1 The DASHER Study Overview 
 
Data for this analysis were taken from the DASHER study conducted between 
2015 and 2016 (ISRCTN57475376). 
The DASHER study (Describing And treating Severe HypERtension) was a 
single centre, non-blinded, cohort study of 54 patients in the South West of 
England. As described in chapter 1, hypertension is a significant healthcare 
burden and can lead to serious complications if not managed quickly and 
effectively. The DASHER study aimed to determine the proportion of patients 
with a new diagnosis of severe hypertension who reached the target blood 
pressure of <140/90 after 18 weeks of protocolised treatment. Participants 
underwent 24-hour ambulatory blood pressure monitoring and urinalysis at 
week 1 and week 18. Therefore, the DASHER study provides a useful data set 
to observe the relationship between 24-hour blood pressure patterns and urine 
albumin in hypertensive patients.    
Patients were screened to assess their suitability for the study. Patients were 
then examined and monitored over an 18 week period during which they were 
started on a nurse-led antihypertensive regime. 
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3.2 Aim 
 
The overall aim of this chapter is to examine the relationship between 24-hour 
ambulatory blood pressure parameters, particularly night time dipping patterns, 
and albuminuria into the normal albuminuric range and glycocalyx integrity in 
hypertensive patients, before and after protocolised treatment. 
 
3.3 Objectives 
 
1. Assess whether the protocolised hypertension treatment changes blood 
pressure parameters, albuminuria levels or glycocalyx integrity. 
2. Assess how albuminuria relates to the following different aspects of 24-
hour blood pressure and circadian blood pressure rhythms: 
- 24-hour, day and night parameters (systolic BP, diastolic BP, heart rate, 
pulse pressure, mean arterial pressure (MAP), double product, pulse 
pressure product) 
- Blood pressure and heart rate variability  
- Circadian rhythms (day to night blood pressure ratio and morning 
surge) 
3. Assess whether the different aspects of 24-hour blood pressure relate to 
glycocalyx integrity. 
4. Assess whether glycocalyx integrity is associated with albuminuria levels. 
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3.4 Methods 
 
3.4.1 Participants: 
 
Patients with newly diagnosed, untreated hypertension were referred from 
either primary care or secondary care (including the emergency department) 
following a single clinic systolic blood pressure reading of ≥170mmHg. The 
study team then performed screening to determine whether patients met the 
inclusion and exclusion criteria. 
3.4.1.1 Inclusion criteria 
 
- New diagnosis of severe hypertension with systolic BP ≥170mmHg by 
their usual medical care provider and ambulatory blood pressure daytime 
average systolic BP ≥150mmHg when performed by the study team 
starting at the screening visit.  
- Aged 18 +  
3.4.1.1 Exclusion criteria 
 
- Known eGFR <60 ml/min/1.73m2 by Modification of Diet in Renal Disease 
Study (MDRD) formula. 
- Previous or current prescription of any medication used in the study 
protocol. 
- Previous renal artery intervention. 
- Bleeding diathesis. 
- Haemaglobin <10 g/dl. 
- Platelet count <100 x109/l. 
- Inability to provide informed consent. 
- Pregnancy or breast-feeding. 
- Hypertension-related event (including stroke or acute kidney injury) within 
the preceding 3 months. 
- Any condition, including hypertensive urgency, which requires more 
immediate BP lowering or tailored anti-hypertensive strategy at enrolment. 
 
76 
 
3.4.2 Study Protocol 
 
The DASHER study protocol was approved by the South West – Cornwall and 
Plymouth Research Ethics Committee (REC ref. 15/SW/0077) and fully 
conformed to the principles of the Declaration of Helsinki and the ICH 
Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996.  
Written, informed consent was taken for participation and for storage and 
retesting of samples. Patient anonymity was maintained throughout and 
documents stored securely.  
3.4.3 Study design 
 
For detailed methods of data collection techniques, see Chapter 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening visit 
Preliminary informed consent 
Clinic blood pressure measurements 
Simple blood tests 
24-hour blood pressure monitor reading. 
Visit 2 
Full informed consent                          Fasting blood tests 
Drug review                                         Overnight and spot urine 
Physical examination                           ECG 
Lifestyle questionnaire                         BMI      
Microvascular functions                   Epworth score                                      
 
The patient then received a clinical consultation and started on anti-
hypertensive medication protocol. 
Visits 3-9 
Review of treatment and drug titration. 
Visit 10 
Final 24-hour ambulatory blood pressure monitoring 
BMI, microvascular function tests, blood samples, overnight urine and 
spot urine. 
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3.4.4 Anti-hypertensive treatment protocol 
 
The patients were initially started on Amlodipine 5mg once daily and 
Candesartan 8mg once daily. Ingestion of the drugs was initially separated by 
12 hours but then patients were allowed to adjust the timings to suit their 
lifestyle.  Patient BP was then monitored every two weeks, if target BP was not 
achieved then treatment was titrated or altered as follows: 
Week 2: Candesartan increased to 16mg once daily. 
Week 4: Addition of drug 3 - Indapamide 2.5mg once daily. 
Week 6: Renal function check and secondary hypertension screen. 
Week 8: Add spironolactone 25mg once daily (if normal potassium) OR switch 
indapamide to bendroflumethiazide 10mg once daily (reviewed dependent on 
potassium level) 
Week 10: Directly observed therapy, renal check and renal denervation 
decision. 
Week 12: Renal denervation. 
Week 14: Add Doxazosin 4mg at night, increased to 8mg daily after 2 weeks. 
Week 18: End point follow up. 
 
3.4.5 Measurement 
 
24-hour ambulatory blood pressure monitoring was undertaken and analysed as 
described in chapter 2.1. GlycoCheck measurements were taken and analysed 
as described in chapter 2.2. Urine albumin was collected by timed overnight and 
spot urine samples and measured by both the Cobas and Fitzgerald assays as 
described in Chapter 2.3. 
 
3.4.6 Statistical analysis 
 
Statistical analysis was performed using STATA 15 as described in Chapter 2.4. 
A cohort of 54 patients allowed detection of detection of correlation coefficients 
≥0.40, where p ≤ 0.05 with a statistical power of 80%. 
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3.5 Results 
3.5.1 Patient demographics 
 
The table below shows the patient demographics before and after treatment. 
The cohort was made up of 54 individuals with an average age of 59 (±10) so 
represents the older population. There was a slight male predominance (59%). 
The vast majority of the cohort was of white-British ethnicity. All other 
parameters remained the same, statistically, between week 1 and week 18 with 
the exception of clinic BP and number of anti-hypertensive medications. 
 
Variable Week 1 (n=54) Week 18 (n=54) P value 
Age (years) 59.13 (±10.78) - - 
Sex - Female 22 (41%) - - 
Ethnicity 98% White British - - 
BMI (kg/m2 ) 29.17 (25.64 – 33.46) 
29.09 (25.6 – 
34.06) 0.9325 
Clinic SBP/DBP 
(mmHg) 
170/102 
(±15/12) 130/79 (±11/8) <0.0001/<0.0001 
Creatinine 
(mmol/l) 74.69 (±13.21) 77.48 (±14.12) 0.1956 
HbA1c 
(mmol/mol) 38.22 (±3.42) 38.29 (±3.65) 0.4745 
Alcohol 
(units/week) 10.98 (±14.28) 7.45 (±10.16) 0.1520 
Smoking status 
Present, past 
6 (11%), 
23(42%) - - 
Epworth score 5.69 (±3.42) - - 
Exercise 
(hours/week) 3.5  (1 - 7) 5 (2 - 8) 0.2998 
No of 
Antihypertensive 
medications 
0 2.75 (±0.77) <0.0001 
Antihypertensive treatment at week 18 
(n (%)) CCB/ARB/ Indapamide/ 
Spironolactone 
53(98%)/ 46(85%)/ 30 (56%) 
/10(19%) 
Table 3 Patient demographics at week 1 and week 18. Data are presented as 
either mean (± standard deviation) or median (Interquartile range), Number 
(percentage of cohort %). 
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3.5.2 Objective 1: Assess whether the protocolised 
hypertension treatment changes blood pressure parameters, 
albuminuria levels or glycocalyx integrity. 
 
3.5.2.1 Does the protocolised hypertension treatment alter blood 
pressure? 
 
The DASHER protocolised hypertension treatment significantly reduced many 
aspects of blood pressure as detailed in tables 4, 5 and 6. The treatment 
reduced average 24-hour blood pressure from 156 to 130 (p<0.0001) and 24-
hour diastolic blood pressure from 90 to 75 (p<0.0001). The treatment also 
significantly decreased clinic systolic and diastolic blood pressure (p<0.0001 
and p<0.0001 respectively). The treatment regime did not alter pulse rate, 
morning surge or any of the day to night ratios. The treatment regime reduced 
blood pressure variability but increased heart rate variability.  
 
Figure 12 The spread of the cohort’s average 24-hour systolic and diastolic 
blood pressures at week 1 (pre-treatment) and week 18 (post-treatment). 
 
P<0.0001 
P<0.0001 
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Variable Week 1 Week 18 P value 
24-hour SBP (mmHg) 156  (150-162) 129.78 (±9.48) p<0.0001 
Daytime SBP (mmHg) 163.74  (±11.37) 134.8 (±10.07) p<0.0001 
Night SBP (mmHg) 138.6 (±15.34) 112.94 (±12.35) p<0.0001 
24-hour DBP (mmHg) 89.61 (±9.02) 74.72 (±6.23)  p<0.0001 
Daytime DBP (mmHg) 92.74 (±9.46) 77.83 (±6.65) p<0.0001 
Night  DBP (mmHg) 78.23 (±10.18) 64.08 (±7.79)  p<0.0001 
24-hour PP (mmHg) 69.93 (±14.38) 55.06 (±7.05) p<0.0001 
Daytime PP (mmHg) 71 (±9.09) 56.96 (±7.29) p<0.0001 
Night PP (mmHg) 60.38 (±10.46) 48.87 (±9.34) p<0.0001 
24-hour MAP (mmHg) 112.73 (±9.84) 92.7 (±6.76) p<0.0001 
Daytime MAP (mmHg) 116.07 (±9.08) 96.58 (±7.21) p<0.0001 
Night MAP (mmHg) 98 (±11.07) 79.96 (±8.51) p<0.0001 
24-hour pulse (mmHg) 73.02 (±8.14) 73.37 (±7.72) p=0.5413 
Daytime pulse (mmHg) 75.55 (±8.14) 76.08 (±7.72) p=0.2281 
Night pulse (mmHg) 64.17 (±9.39) 63.6 (±8.18) p=0.9203 
24-hour DP (mmHg) 115.28 (±14.85) 95.35 (±13.21) p<0.0001 
Daytime DP (mmHg) 123.66 (±15.91) 102.98 (±14.08) p<0.0001 
Night DP (mmHg) 88.69 (±14.98) 71.93 (±12.77) p<0.0001 
24-hour PPP (mmHg) 50.84 (±11.05) 40.37 (±6.56) p<0.0001 
Daytime PPP (mmHg) 53.39 (±7.42) 43.49 (±7.06) p<0.0001 
Night PPP (mmHg) 38.37 (±6.98) 31 (±6.91) p<0.0001 
Morning surge (mmHg) 45.5 (31.5-54.3) 37.3 (28.1-48.75) p=0.0918 
Clinic Systolic BP (mmHg) 168 (160-178) 130 (123-137) p<0.0001 
Clinic Diastolic BP (mmHg) 102 (95-108) 79 (74-87) p<0.0001 
Table 4 showing the mean (±standard deviation) or median (interquartile range) 
for 24-hour, day and night average BP parameters at week 1 and week 18. P 
values from a student’s t test or Wilcoxon signed rank test are shown. Those 
parameters which showed a significant difference between week 1 and week 18 
are highlighted. 
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Variable Week 1 Week 18 P value 
Standard deviation 
of 24-hour SBP 22.59 (±4.51) 20.94 (17.71-23.76) p=0.0364 
Standard deviation 
of daytime SBP 19.95 (±4.47) 20 (±3.87) p=0.9685 
Standard deviation 
of night SBP 16.29 (±5.51) 14.28 (±5.46)  p=0.0075 
Standard deviation 
of 24-hour DBP 18.38 (±3.4) 17.68 (±4.02) p=0.2405 
Standard deviation 
of daytime DBP 17.95 (±3.65) 17.76 (±4.56) p=0.7906 
Standard deviation 
of night DBP 12.49 (±5.14) 10.55 (±5.24) p=0.0393 
Standard deviation 
of 24-hour pulse 10.87 (9.82-12.84) 13.07 (10.51-15.44) p=0.0175 
Standard deviation 
of daytime pulse 11.21 (±2.67) 13.17 (±4.19) p=0.0034 
Standard deviation 
of night pulse 6.01 (±2.88) 6.8 (±2.91) p=0.2148 
Table 5 Mean (±standard deviation) or median (interquartile range) for the 
standard deviation of individual patients’ 24-hour, day and night BP parameters 
at week 1 and week 18. P values from a paired t test or Wilcoxon signed rank 
test. Those parameters which showed a significant difference between week 1 
and week 18 are highlighted.  
Figure 13 The spread of the standard deviation of individual patient’s blood 
pressure parameters at week 1 and week 18. * denotes a significant difference 
with p value<0.05. 
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Variable Week 1 Week 18 P value 
Day to night 
SBP ratio 1.2 (±0.12) 1.21 (±0.12) p=0.4028 
Day to night 
DBP ratio 1.2 (±0.13) 1.23 (±0.12) p=0.0697 
Day to night 
HR ratio 1.19 (±0.11) 1.2 (±0.1) p=0.3723 
Day to night 
PP ratio 1.2 (1.08-1.29) 1.15 (1.07-1.3) p=0.6800 
Day to night 
PPP ratio 1.42 (±0.24) 1.44 (±0.29) p=0.4375 
Day to night 
DP ratio 1.42 (±0.19) 1.45 (±0.21)  p=0.1570 
Table 6 showing the mean (±standard deviation) or median (interquartile range) 
for the day to night BP ratio at week 1 and week 18. P values from a paired t-
test or Wilcoxon signed rank test.  
 
 
 
 
Figure 14 The spread of day to night ratios for different blood pressure 
parameters at week 1 and week 18. 
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3.5.2.2 Interpretation of urinary albumin excretion using assays with 
different ranges of detection 
 
First we must look at the difference between each assay’s quantification of 
albumin. As described in 2.3.2, two different assays were used to quantify 
albumin excretion. Cobas is a commonly used assay, in the clinical setting, to 
measure albumin but cannot detect concentrations below 3μg/ml and, as a 
result, often cannot quantify albumin excretion in the lower range. The 
Fitzgerald assay can detect concentrations down to 0.5μg/ml. In this cohort, the 
Cobas assay was able to detect 37% and 20% of urinary albumin 
concentrations at week 1 and week 18 respectively. The Fitzgerald assay was 
able to detect urinary albumin concentrations in the entire cohort.  
  (n) Min 
Lower 
quartile 
Median 
Upper 
quartile 
Max 
Cobas ON 
ACR  week 1  
20 (37% 
detectable) 
0.42 0.78 1.40 3.34 10.01 
Cobas ON 
ACR week 18 
11 (20% 
detectable) 
0.34 0.53 1.26 1.47 3.42 
Cobas ON 
AER week1 
20 (37% 
detectable) 
2.97 6.88 11.41 41.87 144.57 
Cobas ON 
AER week 18 
11 (20% 
detectable) 
3.71 4.83 7.13 16.97 32.70 
Fitz ON ACR 
week 1 
54 0.27 0.64 1.04 1.81 8.46 
Fitz ON ACR 
week 18 
53 0.33 0.60 0.78 1.29 4.81 
Fitz ON AER 
week 1 
54 1.81 6.2 8.57 13.56 122.60 
Fitz ON AER 
week 18 
53 2.60 5.5 7.5 11.11 32.56 
Fitz Spot ON 
ACR week 1 
54 0.20 0.93 1.32 2.64 28.75 
Fitz Spot ON 
ACR week 18 
54 0.02 0.70 0.91 1.3 6.79 
Table 7 showing the median, interquartile range, minimum and maximum 
values for patient Overnight (ON) ACR (µg/mg), ON AER (µg/minute) and Spot 
sample ACR using Cobas and Fitzgerald ELISA urine albumin measurements.  
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As demonstrated in the figure 15, a Mann-Whitney U test shows that the Cobas 
and Fitzgerald analysis of the same urine sample is not significantly different. The 
Cobas method is still able to identify albumin excretion rates into the normal 
albuminuric range as the Cobas method is able to detect lower AERs in more 
concentrated urine samples.   
For example, if one individual excreted 4µg of albumin in a 24-hour period but was 
hydrated and also excreted 1.5L of water they would have a urinary albumin 
concentration of 2.67μg/ml and the Cobas assay would fail to detect this. If the 
same individual excreted 4µg of albumin in 24-hours, but was dehydrated and only 
excreted 0.5L of water they would have a urinary albumin concentration of 8μg/ml 
which would be readily detected by the Cobas assay.  
Therefore, the Cobas assay is able to detect low albumin excretion rates, but only 
under certain circumstances. In this cohort, the Cobas assay was able to quantify 
AER in 100% of individuals with moderately increased albuminuria but only 28% 
and 14% of AERs in those with normal albuminuria at week 1 and week 18 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 The spread of albumin excretion rate values from both Cobas and 
Fitzgerald analysis of overnight urine samples.  
Albumin excretion rate (μg/min) 
p=0.1055 
p=0.6500 
Cobas overnight 
AER Week 1 
 n=20 
Fitzgerald 
overnight 
AER Week 1  
n=54 
Cobas overnight 
AER Week 18 
n=11 
Fitzgerald 
overnight 
AER Week 18 
n=53 
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Often, when using the Cobas assay, a value of 2.9μg/ml is substituted for 
undetectable values in order to calculate an albumin excretion rate. Caution 
should be exercised when using this means of approximating AERs for 
undetectable albumin values as it is significantly different to the Fitzgerald AER; 
Week1 (p=0.0006, n=54), Week 18 (p=<0.0001, n=53) (see figure 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 The spread of albumin excretion rate values from both Cobas and 
Fitzgerald analysis of overnight urine samples. Cobas undetectable albumin 
values were substituted with 2.9μg/ml to calculate AER for entire cohort. 
 
 
 
 
 
 
 
 
p=0.0006 
P<0.0001 
Cobas overnight 
AER Week 1 n=20 
Cobas overnight 
AER (2.9) Week 1 
n=54 
Cobas overnight 
AER (2.9) Week 
18 n=53 
Fitzgerald 
overnight 
AER Week 18  
n=53 
Fitzgerald 
overnight 
AER Week 1 n=54 
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Albumin creatinine ratio was also analysed. Mann-Whitney U test showed that 
Cobas ACR and Fitzgerald ACR of the same overnight sample at week 1 were 
not significantly different (p=0.1505). Cobas ACR and Fitzgerald ACR of the 
same overnight week 18 sample were also not significantly different (p=0.2162).  
The Cobas assay was able to quantify ACR in 80% and 100% of moderately 
increased albuminuria patients at week 1 and week 18 respectively. Cobas 
quantified ACR in 32% and 19% of individuals with normal albuminuria at week 
1 and 18 respectively. Use of the Fitzgerald assay allowed quantification of 
ACR for all patients at both weeks. 
 
 
 
 
Figure 17 The spread of albumin creatinine ratio values from both Cobas and 
Fitzgerald analysis of overnight urine. 
 
 
p=0.1505 
p=0.2162 
Albumin creatinine ratio (μg/mg) 
n=20 
n=54 
n=11
 
 n=20 
n=54 
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When Fitzgerald ACR is compared to Fitzgerald AER of the same sample 
(figure 18) AER generally shows a higher level of albuminuria based on the 
definition for moderately increased albuminuria when using ACR (3.5μg/mg) 
and AER (20μg/min).  
 
 
 
Figure 18 a scatter graph showing AER against ACR (Fitzgerald assay) of the 
same sample with a line of identity based on the point at which an individual 
would be classed as having moderately increased albuminuria (3.5y=20x), 
n=53. 
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Spot urine sample ACRs were compared to ACRs from the overnight samples 
at both week 1 and week 18. Spot urine samples showed significantly higher 
ACR values than the overnight samples (see figure 19). This may be due to the 
influence of urinary albumin excretion variability during the day. Overnight urine 
samples may be more representative of basal urinary albumin excretion but do 
not take daytime albumin excretion variability into consideration. 
 
 
Figure 19 The spread of albumin creatinine ratio values from both Cobas and 
Fitzgerald analysis of overnight urine and spot urine samples.  
 
Due to this analysis, for the purposes of this research, most emphasis will be 
placed on analysing Fitzgerald overnight AER urine samples as it gives 
accurate measurements for the whole cohort’s urine albumin excretion. As well 
as this, the overnight urine collection sample matches the overnight blood 
pressure measurement period and may be subject to less variability.  
 
P<0.0001 
P<0.0001 
n=54 n=54 n=53 n=54 
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3.5.2.3 Does the hypertension treatment protocol alter albuminuria? 
 
3.5.2.3.1 Change in the cohorts’ albumin excretion rate from week 1 to week 18 
 
Initially the standard Cobas turbidimetry assay was used to determine whether 
albumin levels changed between week 1 and week 18. There were 8 individuals 
on whom a Wilcoxon signed-rank test could be performed. Wilcoxon signed-
rank test of patients’ AER gave a borderline significant result with only 8 
matched observations (p=0.0499). 
When all urinary albumin levels were detectable using the Fitzgerald albumin 
assay, analysis showed a significant difference between overnight AER at week 
1 and week 18 (p=0.0275) (figure 20).  There was also a significant difference 
between ACR of the overnight sample at week 1 and week 18 (p=0.0027).  
There was a significant difference between week 1 and week 18 spot urine 
sample ACR (p=<0.0001) (figure 21). 
 
 
 
Figure 20 The spread of Fitzgerald AER results at week 1 and week 18. One 
patient’s overnight urine sample was missing at week 18. 
 
 
 
 
p=0.0275 
n=54 n=53 
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Figure 21 The spread of patient Spot urine ACR (Fitzgerald assay) results at 
week 1 (n=54) and week 18 (n=54).  
 
As all patients urinary albumin was detectable, the Fitzgerald assay allowed 
separation and analysis of the normal and moderately increased albuminuria 
groups. Wilcoxon test showed that AER was significantly lower after treatment 
amongst patients who had moderately increased albuminuria at baseline 
(p=0.0180). AER was not significantly lower after treatment in those who had 
normal albuminuria at baseline (p=0.4196). 
Previous work has shown that cardiovascular risk is associated with albumin 
excretion even within the normal range 134. This data was explored further to 
investigate whether the relationship between treatment and reduction in AER 
was exclusive to those with moderately increased albuminuria (>20µg/min) or 
whether there was some crossover into the normal albuminuria group. 
Comparison of absolute change in AER from week 1 to week 18 was compared 
to baseline AER in the whole cohort. There was significant correlation between 
reduction in albumin excretion with treatment and baseline albumin excretion 
rate (Rs=0.6714, p=<0.0001) (see figure 22).  
 
P<0.0001  
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Figure 22 A scatter graph of absolute change in Fitzgerald AER from week 1 to 
week 18 against baseline AER, n=54. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rs=0.6715 
P=<0.0001 
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When figure 22 is examined in more detail at the lower ranges of albumin 
excretion (see figure 23 for expanded figure), above 15µg/min all individuals 
reduced AER with treatment by 10μg/min or more. Below 15µg/min all 
individuals slightly increased or decreased their albumin levels a similar amount 
after treatment. This could be accounted for by inter-assay variation (coefficient 
of variation=18%)132 and natural variation of trace amounts of urinary albumin 
(see figure 23). This reference point of 15µg/min was included in further 
analysis as it seems to more accurately describe the group of individuals in 
whom urine albumin excretion was affected by BP level and treatment. 
 
 
 
Figure 23 A section of figure 22 – a scatter graph of absolute change in 
Fitzgerald AER from week 1 to week 18 against baseline AER in patients with a 
baseline AER<50. The shaded area accounts for inter-assay variability (18%). 
Horizontal reference line indicates 0 above which patients reduced AER, below 
which patients increased AER after treatment. Vertical reference line shows 
AER=15µg/min above which all patients reduced AER with treatment.  
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3.5.2.3.2 How does reduction of different components of blood pressure relate 
to reduction in urinary albumin excretion? 
 
To further explore the effect of BP treatment on AER, percentage reduction of 
different BP components and percentage reduction of albumin excretion were 
compared. These blood pressure components include 24-hour, day and night 
values for systolic, diastolic, mean arterial pressure, pulse pressure, double 
product and pulse pressure product. Reduction in albumin excretion is 
expressed as percentage change, [(week 18 AER – Week 1 AER) ÷ week 1 
AER] x 100. Within the entire cohort, there was significant correlation between 
percentage change in AER and percentage reduction of MAP but no other 
significant correlations.  
 
Figure 24 A scatter diagram showing percentage change in Fitzgerald AER  
against percentage reduction in mean arterial pressure (n=50). 
 
When the cohort was split into those who had moderately increased albuminuria 
(n=7) and normal albuminuria (n=47) at baseline there were no observable 
correlations between percentage reduction in AER and percentage reduction in 
different BP parameters. The cohort was split into those with a baseline AER 
above 15µg/min (n=12) and below 15µg/min (n= 42) for reasons as previously 
described. This analysis showed some borderline significant and significant 
relationships in the baseline AER>15µg/min group but no significant 
relationships in the baseline AER<15µg/min group (see figure 25 and 26). 
Rs: -0.3196 
p= 0.0237 
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Figure 25 scatter diagrams showing percentage change in Fitzgerald AER 
against percentage reduction in systolic BP, diastolic BP and mean arterial 
pressure in those with a baseline AER>15µg/min (A, B and C) and 
AER<15µg/min (D, E and F). Correlation coefficients and p values are shown by 
each graph. N values are lower than previously described groups due to 
missing AER values at week 18, hence reductions could not be calculated. 
 
 
 
 
Rs: -0.59 
p= 0.0556 
n=11 
Rs: -0.12 
p= 0.4644 
n=39 
Rs: -0.22 
p= 0.1779 
n=39 
Patients with baseline  
AER above 15µg/min 
Patients with baseline 
 AER below 15µg/min 
Rs: -0.59 
p= 0.0556 
n=11 
Rs: -0.04 
p= 0.7835 
n=39 
Rs: -0.59 
p= 0.0556 
n=11 
A 
B 
C 
D 
E 
F 
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Figure 26 scatter diagrams showing percentage change in Fitzgerald AER 
against percentage reduction in pulse pressure and pulse pressure product in 
those with a baseline AER>15µg/min (A and B) and AER<15µg/min (C and D). 
Correlation coefficient and p values are shown. N values are lower than 
previously described groups due to missing AER values at week 18, hence 
reductions could not be calculated. 
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3.5.2.4 Does the protocolised hypertension treatment alter glycocalyx 
integrity? 
 
Glycocalyx integrity, as determined by the GlycoCheck method, did not show a 
significant difference between week 1 and week 18 as outlined in table 8 and 
figure 27 below.  
Table 8 showing the mean (±standard deviation) or median (interquartile range) 
for glycocalyx integrity parameters at week 1 and week 18. P values shown are 
from paired t test or Wilcoxon signed rank test.  
 
 
Figure 27 The spread of patient PBR results at week 1 and week 18. 
 
Variable Week 1 Week 18 P value 
PBR 5-25 1.63 (±0.19) 1.65 (±0.17) p=0.3707 
PBR 5-9 0.99 (0.91-1.09) 0.99 (0.93-1.04) p=0.7498 
PBR 10-
19 
1.69 (±0.21) 1.69 (±0.19) p=0.5996 
 
p= 0.3707 
 
p= 0.7498 
n=46 n=46 n=46 n=42 n=42 
 
p= 0.5996 
n=42 
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We explored the relationship between percentage change of glycocalyx integrity 
and percentage change in different blood pressure parameters after treatment. 
Reduction in systolic BP, diastolic BP and MAP significantly correlated with an 
increase in PBR 5-25, 5-9 and 10-19 (increase in glycocalyx integrity) (see 
figure 28-30). 
 
 
 
 
 
Figure 28 Percentage change in glycocalyx integrity (PBR 5-25, PBR 5-9 and 
PBR 10-19) against percentage reduction in systolic BP from baseline to week 
18.  
(Rs: 0.32, p=0.0393) n=42 
(Rs: 0.33, p=0.0308) n=42 
(Rs: 0.36 p=0.0200) n=42 
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Figure 29 Percentage change in glycocalyx integrity (PBR 5-25, PBR 5-9 and 
PBR 10-19) against percentage reduction in diastolic BP from baseline to week 
18. 
Figure 30 Percentage change in glycocalyx integrity (PBR 5-25, PBR 5-9 and 
PBR 10-19) against percentage reduction in MAP from baseline to week 18.  
(Rs: 0.36, p=0.0211) n=42 
(Rs: 0.29, p=0.0613) n=42 
(Rs: 0.43 p=0.0055) n=42 
(Rs: 0.35, p=0.0237) n=42 
(Rs: 0.33, p=0.0324) n=42 
(Rs: 0.43 p=0.0040) n=42 
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3.5.3 Objective 2: Assess how albuminuria relates to different 
aspects of 24-hour blood pressure and circadian blood 
pressure rhythms 
 
3.5.3.1 Albumin excretion and 24-hour, day and night blood pressure 
parameters  
 
When the Cobas assay was used to assess the relationship between urine 
albumin excretion and 24-hour blood pressure many patients had undetectable 
albumin values. Therefore there were 20 observations at week 1 and 11 
observations at week 20. One patient did not provide sleep and wake times so 
their day and night BP could not be calculated. Comparison of Cobas AER and 
blood pressure parameters showed correlation with systolic BP, pulse pressure, 
mean arterial pressure and pulse pressure product. Results are detailed in   
table 9.  
 
 
 
Week 1 Week 18  
Rs/r p value n= Rs/r p value n= 
24-hour SBP 0.6712 0.0012 20 0.7091 0.0146 11 
day SBP 0.6658 0.0019 19 0.6256 0.0395 11 
night SBP 0.6509 0.0025 19 0.5786 0.0622 11 
24-hour DBP 0.4239 0.0625 20 0.2374 0.4820 11 
day DBP 0.4839 0.0358 19 0.2273 0.5015 11 
night DBP 0.4917 0.0325 19 0.3196 0.3380 11 
24-hour PP 0.6757 0.0011 20 0.6834 0.0204 11 
day PP 0.5973 0.0069 19 0.7260 0.0114 11 
night PP 0.4890 0.0336 19 0.1735 0.6099 11 
24-hour MAP 0.3892 0.0899 20 0.4806 0.1346 11 
day MAP 0.5777 0.0096 19 0.4404 0.1752 11 
night MAP 0.5880 0.0081 19 0.4155 0.2037 11 
24-hour PPP 0.4030 0.0781 20 0.7818 0.0045 11 
day PPP 0.3158 0.1878 19 0.5545 0.0767 11 
night PPP 0.3519 0.1395 19 0.5273 0.0956 11 
Table 9 Correlation coefficients (Rs/r), p values and observations of some blood 
pressure parameters against Cobas immunoturbidimetry albumin excretion rate 
at week 1 and week 18. Statistically significant results are highlighted.  
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To explore whether the loss of correlation at week 18 was due to the effect of 
treatment or reduction in sample size due to increased number of undetectable 
albumins, the relationships in the same 20 individuals as previously analysed 
with the Cobas assay, were compared using the Fitzgerald assay results. This 
analysis showed complete loss of correlations at week 18 and supports that the 
loss of correlations shown previously may be due to the effects of the anti-
hypertensive treatment. 
 
 
 
Week 1 Week 18  
Rs/r p value n= Rs/r p value n= 
24-hour SBP 0.5476 0.0124 20 0.2057 0.3842 20 
day SBP 0.5559 0.0135 19 0.1669 0.4947 19 
night SBP 0.5296 0.0197 19 0.3418 0.1520 19 
24-hour DBP 0.4187 0.0662 20 0.2318 0.3255 20 
day DBP 0.4831 0.0362 19 0.1056 0.6670 19 
night DBP 0.3854 0.1032 19 0.3203 0.1813 19 
24-hour PP 0.5288 0.0165 20 0.2151 0.3624 20 
day PP 0.5086 0.0262 19 0.1310 0.5930 19 
night PP 0.3210 0.1802 19 0.0941 0.7014 19 
24-hour MAP 0.4132 0.0701 20 0.2190 0.3535 20 
day MAP 0.5417 0.0166 19 0.1358 0.5793 19 
night MAP 0.4806 0.0372 19 0.3147 0.1894 19 
24-hour PPP 0.3684 0.1100 20 0.3474 0.1334 20 
day PPP 0.3158 0.1878 19 0.2509 0.3002 19 
night PPP 0.2606 0.2811 19 0.2982 0.2149 19 
Table 10 Correlation between blood pressure parameters and Fitzgerald 
albumin excretion rate at week 1 and week 18 of the group of 18 individuals 
previously analysed with the Cobas albumin assay. Statistically significant 
results are highlighted.  
 
 
 
 
 
 
 
101 
 
Comparison of the whole cohort using the more sensitive Fitzgerald albumin 
assay gave a higher number of observations. When correlating albumin and 
blood pressure using the entire cohort, many of the correlations observed at 
baseline in the Cobas analysis were weakened or lost, and all correlations were 
lost at week 18 see table 11. One participant did not give their sleep and wake 
times and so their day and night BP values were not included in analysis. 
 
 
 
 
Week 1 Week 18  
Rs/r p value n= Rs/r p value n= 
24-hour SBP 0.2780 0.0418 54 0.0716 0.6105 53 
day SBP 0.2653 0.0549 53 0.1438 0.3091 52 
night SBP 0.2708 0.0499 53 0.1149 0.4175 52 
24-hour DBP 0.3959 0.0030 54 0.0660 0.6388 53 
day DBP 0.3722 0.0061 53 0.0444 0.7545 52 
night DBP 0.2315 0.0954 53 0.1757 0.2129 52 
24-hour PP 0.0917 0.5097 54 0.0178 0.8995 53 
day PP 0.0860 0.5402 53 0.1132 0.4244 52 
night PP 0.1702 0.2230 53 -0.1330 0.3471 52 
24-hour MAP 0.4432 0.0008 54 0.0765 0.5859 53 
day MAP 0.3739 0.0058 53 0.1020 0.4716 52 
night MAP 0.2522 0.0685 53 0.1403 0.3213 52 
24-hour PPP 0.0240 0.8632 54 0.0906 0.5231 53 
day PPP 0.0153 0.9135 53 0.1108 0.4341 52 
night PPP 0.0163 0.9078 53 -0.0060 0.9665 52 
Table 11 showing correlation coefficients (Rs/r), p values and observations of 
some blood pressure parameters against Fitzgerald albumin excretion rate at 
week 1 and week 18. Statistically significant results are highlighted. 
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Figure 31 Scatter diagrams showing Fitzgerald albumin excretion rate against 
24-hour systolic BP at week 1 (A) and week 18 (B). Graphs are set to the same 
scale for comparison. 
 
Rs=0.0716 
P=0.6105 
n=53 
 
Rs=0.2780 
P=0.0418 
n=54 
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To further analyse the relationship between albumin excretion and blood 
pressure the cohort was split into those with moderately increased albuminuria 
and normal albuminuria at baseline. At week 1 there were no significant 
correlations between BP parameters and Fitzgerald AER in either the 
moderately increased albuminuria (n=7) or normal albuminuria (n=47) group. At 
week 18 there were also no significant correlations between BP parameters and 
Fitzgerald AER in either the moderately increased albuminuria (n=8) or normal 
albuminuria (n=45) group.  
The correlations in the moderately increased albuminuria group may have been 
influenced by the small sample size. These correlations were then observed 
within the previously described groups of patients with baseline AER above and 
below 15μg/min. Within the group of patients with baseline AER above 
15µg/min there were 12 observations at week 1. Observations showed a 
significant relationship with systolic BP (24-hour systolic BP (Rs: 0.7005, 
p=0.0112) see figure 32) and borderline significant relationships with pulse 
pressure (Rs: 0.54, p=0.0682) and mean arterial pressure (Rs: 0.56, 
p=0.0581).  At week 1 there were 39 observations within the group with a 
baseline AER below 15 µg/min and no significant correlations were observed 
between AER and any BP parameters. 
At week 18 there were 13 observations within the baseline AER>15 µg/min 
group and 39 observations within the group with a baseline AER<15µg/min. 
There were no significant correlations observed between AER and BP 
parameters in either group at week 18. 
When comparing BP parameters to the Spot urine ACR of the whole cohort 
there were also no significant correlations at week 1 or week 18. 
When comparing BP parameters to the Spot urine ACR of those with normal 
albuminuria at baseline (n=46) there were also no significant correlations at 
week 1 or week 18. In those with moderately increased albuminuria at baseline 
(n=8) the following correlations were observed. Twenty-four-hour systolic BP 
(Rs=0.8095, p=0.0149) (see figure 33), 24-hour diastolic BP (Rs=0.7785, 
p=0.0229), MAP (Rs=0.8333, p=0.0102). Borderline correlation with morning 
surge of systolic BP (Rs=0.7500, p=0.0522). All correlations were lost at week 
18.  
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Figure 32 Scatter diagrams showing Fitzgerald albumin excretion rate against 
24-hour systolic BP at week 1 (A) and week 18 (B) in individuals with a baseline 
AER>15μg/min. Graphs are set to the same scale for comparison. 
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Figure 33 scatter diagrams showing Fitzgerald albumin creatinine ratio against 
24-hour systolic BP at week 1 (A) and week 18 (B) in individuals with 
moderately increased albuminuria at baseline. Graphs are set to the same scale 
for comparison. 
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3.5.3.2 Albumin excretion and blood pressure and heart rate variability  
 
No correlation was observed amongst any of the blood pressure variability 
parameters (systolic, diastolic and heart rate standard deviation) and Fitzgerald 
albumin excretion rate or Fitzgerald Spot urine sample ACR at week 1 or week 
18. See figure 34 and 35. These are additional hypothesis generating analyses. 
 
Figure 34 Fitzgerald albumin excretion rate at week 1 against individual 
patient’s standard deviation of night time systolic BP at week 1. 
 
Figure 35 Fitzgerald spot urine sample ACR at week 1 against individual 
patient’s standard deviation of night time systolic BP at week 1.  
 
Rs=-0.2341 
p=0.0916 
n=53 
 
Rs=-0.1235 
p=0.3782 
n=53 
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3.5.3.3 Urinary albumin excretion and blood pressure circadian rhythms 
 
There was no association between day to night ratio of any of the BP variables 
and AER or ACR in the whole group at week 1 (day to night ratio of systolic BP 
(p=0.7196)). In the moderately increased albuminuria group there was also no 
association (day to night ratio of systolic BP (p=0.8192)), although it is worth 
noting that there was only 1 patient with extreme dipping of systolic BP and 1 
patient with non-dipping of systolic BP in the moderately increased albuminuria 
group. The scatter graph resembles a bell shaped curve rather than a U-shaped 
curve which would be expected should the extremes of day to night BP ratios 
relate to worsening albuminuria (see figure 36).  
 
 
Figure 36 Fitzgerald albumin excretion rate at week 1 against day to night ratio 
of systolic BP at week 1. Day to night ratio of 1.11 is equal to a night time BP of 
90% of daytime BP, 1.25 is a night time BP equal to 80% of daytime BP.  
 
Extreme dippers  
à  
Non-dippers 
ß   
Moderately 
increased  
albuminuria 
 Normal  
albuminuria 
 
à
 
à
 
108 
 
Table 12 Spearman correlation coefficients, p values and observations of day to 
night blood pressure ratios and morning surge against Fitzgerald albumin 
excretion rate at week 1 and week 18. Statistically significant results are 
highlighted. 
 
Morning surge of systolic BP showed a negative correlation with albumin 
excretion suggesting that the greater the morning surge the lesser the albumin 
excretion, (see figure 37). Here this significant finding could due to chance as a 
result of the multiple negative analyses. 
 
Figure 37 scatter diagram showing Fitzgerald albumin excretion rate at week 1 
against morning surge at week 1 (n=51). 
 
Week 1 Week 18  
Rs p value n= Rs p value n= 
SBP D:N -0.0498 0.7233 53 0.0166 0.9067 52 
DBP D:N 0.0394 0.7795 53 -0.1480 0.2950 52 
MAP D:N -0.0072 0.9591 53 -0.0990 0.4850 52 
PP D:N -0.1204 0.3907 53 0.1857 0.1857 52 
HR D:N 0.1463 0.2960 53 -0.1124 0.4277 52 
DP D:N 0.0846 0.5471 53 -0.0319 0.8222 52 
PPP D:N -0.0036 0.9794 53 0.1165 0.4107 52 
Morning 
surge -0.3201 0.0220 51 0.0410 0.7752 51 
Rs: -0.32 
p= 0.0220 
109 
 
The relationship between dipping patterns and urinary albumin excretion was 
also assessed by splitting the cohort into groups of non-dippers, normal-dippers 
and extreme-dippers. In the literature, normal-dipping of systolic BP is defined 
as 10-20% of daytime average based on circadian rhythm studies. It has since 
been found that individuals who lay outside this normal range have an 
increased cardiovascular risk 135. Studies that consider dipping of diastolic blood 
pressure and other BP parameters are rare. When diastolic BP dipping is 
considered, a normal range of 10-20% is often quoted. This is not likely to 
represent the true level of normal night time diastolic dipping. In healthy, 
normotensive individuals diastolic BP drops by a larger proportion than systolic 
BP overnight 136, 137. To calculate and define the normal range within this thesis, 
dipping of other BP parameters has been compared to systolic dipping. Figure 
38 and 39 show the calculation of dipping parameters for diastolic BP and mean 
arterial BP at week 1. 
 
Figure 38 a scatter graph demonstrating the method to calculate the range of 
normal night time dipping of diastolic BP (n=53).  
Normal range 
Line of 
identity 
Line of  
best fit 
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Figure 39 a scatter graph demonstrating the method to calculate the range of 
normal dipping within mean arterial pressure (n=53).  
 
Using this method I have defined the normal ranges of BP dipping for all day to 
night ratios of BP within this cohort. Diastolic BP normal dipping is 1.09-1.27 as 
shown in figure 38 and mean arterial pressure normal dipping is 1.10-1.25 as 
shown in figure 39.  
Using these definitions, no significant relationships were observed between 
albumin excretion and blood pressure dipping when the cohort was split into 
non-dippers, normal-dippers and extreme-dippers for any blood pressure 
parameter at week 1 or week 18. Figures 40-43 show some examples of this. 
This analysis focussed on Fitzgerald overnight AERs, but dipping was also 
analysed against Fitzgerald spot urine ACR which showed no significant 
relationships.  
 
 
 
Line of  
best fit 
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identity 
Normal range 
111 
 
 
Figure 40 The spread of Fitzgerald albumin excretion rates for non-dippers 
(<1.11), normal-dippers (1.11-1.25) and extreme-dippers (>1.25) of systolic BP 
at week 1.  
 
Figure 41 The spread of Fitzgerald albumin excretion rates for non-dippers 
(<1.09), normal-dippers (1.09-1.29) and extreme-dippers (>1.29) of diastolic BP 
at week 1.  
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Figure 42 The spread of Fitzgerald albumin excretion rates for non-dippers 
(<1.04), normal-dippers (1.04-1.29) and extreme-dippers (>1.29) of pulse 
pressure at week 1.  
 
 
Figure 43 The spread of Fitzgerald albumin excretion rates for non-dippers 
(<1.11), normal-dippers (1.11-1.25) and extreme-dippers (>1.25) of systolic BP 
at week 18. 
 
p= 0.8081 
 
p= 0.4793 
 
p= 0.5099 
 
p= 0.2746 
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At week 18 several individuals who presented as non-dippers and extreme 
dippers became normal dippers. As an additional hypothesis generating 
analysis, these individuals were examined to assess whether normalisation of 
these abnormal dipping patterns related to reduction in albumin excretion rate. 
This analysis showed no significant results although the group sizes were small. 
 
 
 
 
 
 
 
Figure 44 The spread of change in Fitzgerald AER from week 1 to week 18 in 
those individuals who showed non dipping patters at week 1 but normal dipping 
at week 18, and those who remained non-dippers at both week 1 and week 18. 
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3.5.4 Objective 3: Assess whether the different aspects of 24-
hour blood pressure relate to glycocalyx integrity 
 
In this cohort, glycocalyx integrity was associated with morning surge of systolic 
BP at week 1 (PBR 5-25 and PBR 10-19 Rs:=-0.4506, p=0.0028 and          
Rs:=-0.4291, p=0.0046 respectively). However, these correlations were not 
held at week 18. There were no other observed associations between 
glycocalyx and blood pressure parameters.  
 
Figure 45 (A) showing the significant correlation between glycocalyx integrity 
(PBR 5-25) and morning surge at week 1(n=42). (B) showing the insignificant 
correlation between glycocalyx integrity (PBR 5-25) and morning surge at week 
18 (n=39).  
 
Rs= -0.4506 
p= 0.0028 
 
Rs= -0.0158 
p= 0.9231 
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Systolic blood pressure reduction was the main outcome of the DASHER study. 
As shown in the graph below, 24-hour average systolic blood pressure and PBR 
5-25 show no significant correlation (Rs:= -0.0643, p=0.6710 at week 1 and 
Rs:= -0.1062, p=0.5088 at week 18). Day to night blood pressure ratios also 
show no correlation with PBR.  
 
 
 
Figure 46 A scatter diagram showing the insignificant correlation between 
glycocalyx integrity (PBR 5-25) and 24-hour average systolic blood pressure at 
week 18 (n=41). 
 
 
 
 
 
 
 
 
Rs= -0.0643 
p= 0.6710 
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3.5.5 Objective 4:  Assess whether glycocalyx integrity is 
associated with albuminuria levels 
 
Glycocalyx integrity was not observed to be related to any of the measures of 
urine albumin (table 13). There was no relationship within the moderately 
increased albuminuria, normal albuminuria, AER>15µg/min or AER<15µg/min 
groups. There was also no observed relationship between percentage change 
in AER and percentage change in PBR (see figure 48). 
 
 
 
 n= PBR 5-25 PBR 5-9  PBR 10-19 
Cobas ACR 
week 1 16 
Rs:=-0.0941 
p=0.7288 
Rs:=0.0752 
p=0.7819 
Rs:=-0.1104 
p=0.6841 
Cobas ACR 
week 18 6 
Rs:=0.4286 
P=0.3965 
Rs:=-0.4058 
p=0.4247 
Rs:=0.6000 
p=0.2080 
Cobas AER 
week 1 16 
Rs:=-0.1971 
p=0.4645 
Rs:=0.0708 
p=0.7944 
Rs:=-0.2046 
p=0.4473 
Cobas AER 
week 18 6 
Rs:=0.2571 
P=0.6228 
Rs:=-0.7247 
p=0.0.1032 
Rs:=0.6000 
p=0.2080 
Fitzgerald 
AER week 1 40 
Rs:=-0.1414 
p=0.3485 
Rs:=-0.0354 
p=0.8154 
Rs:=-0.1429 
p=0.3433 
Fitzgerald 
AER week 18 40 
Rs:=-0.0861 
p=0.5972 
Rs:=-0.1691 
p=0.2906 
Rs:=-0.1236 
p=0.4412 
Fitzgerald 
Spot week 1 46 
Rs:= -0.1457 
p=0.3339 
Rs:=-0.0472 
p=0.7554 
Rs:=-0.1613 
p=0.2841 
Fitzgerald 
Spot week 18 41 
Rs:=0.0226 
p=0.8882 
Rs;=-0.0766 
p=0.6298 
Rs:=0.0300 
p=0.8503 
Table 13 Correlation coefficients,  p values and observation numbers for Urine 
albumin measurements against PBR 5-25, 5-9 and 10-19.   
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Figure 47 A scatter graph showing the relationship between Fitzgerald albumin 
excretion rate and PBR 5-9 at week 1 (n=45). 
 
 
Figure 48 A scatter graph showing the relationship between percentage change 
in Fitzgerald albumin excretion rate and percentage change in PBR 5-9 with 
treatment (n=42). 
 
Rs= -0.0354 
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3.6 Discussion of the DASHER study 
 
 
3.6.1 Discussion 
 
This study showed that the anti-hypertensive treatment regime significantly 
reduced both blood pressure and albuminuria in a group of treatment naïve, 
grade II hypertensive patients within 18 weeks. However, there was no 
relationship between the change in BP from day to night (day to night ratio) and 
albumin excretion rate within this group. It is estimated that 30-40% of treated 
hypertensives’ blood pressure remains outside the target range 138. As such, the 
reduction of systolic blood pressure to target in 80% of the patients is an 
achievement in itself. The management of hypertension is not the main aim of 
this thesis and will not be discussed in further detail. 
 
 
3.6.1.1 Quantification of urinary albumin excretion 
 
There is ongoing debate on the best way to quantify an individual’s true urinary 
albumin excretion. Firstly, there is the decision of how best to collect a urine 
sample and secondly, which assay to analyse it with. This study used both 
overnight urine collections from which albumin excretion rates and albumin 
creatinine ratios were calculated, and also spot sample urines from which 
albumin creatinine ratios were calculated. This study used the Cobas assay 
which is a commonly used albumin assay, both clinically and in research, and 
the Fitzgerald assay which has a much lower limit of detection than the Cobas. 
The results of this study show that the mean urinary albumin excretion values of 
the same urine samples were not significantly different when analysed with the 
Cobas and the Fitzgerald assay. This held true for both AER and ACR 
measurements. Therefore, the Cobas assay remains a valid means of 
quantifying albumin, particularly clinically where the importance of albumin 
excretion measurements rests mainly within the moderately increased and 
severely increased albuminuric ranges.  
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However, this study has shown that the Cobas assay cannot measure all of the 
patient’s urinary albumin levels when they fall within the normal range. The 
Cobas assay was unable to detect albumin concentrations in 72% of normal 
albuminuric participants’ samples. The loss of these numbers is of the utmost 
importance within clinical research as demonstrated within this study. The 
inability to detect urine albumin values meant that, even with a sample size of 
54, there were only 8 matched observations to determine whether the blood 
pressure treatment protocol significantly reduced albumin excretion and this test 
only gave a borderline significant result. Using the Cobas assay within research 
leads to the need for very large sample sizes to detect profound changes in 
urinary albumin excretion. It also means the findings may not be truly 
generalisable to the healthy population as they are based on a biased 
population. This study also showed that the Cobas assay gave correlations 
between albumin and blood pressure at week 18 that were not present when 
examining the entire cohort which could have led to false interpretation and 
conclusions around the strength of relationships to AER in the healthy 
population.  
Considering further the implications of the inability to measure albumin in a 
complete cohort, I investigated one common approach to dealing with missing 
values; that is to assign a normal value at the detection limit of the assay in 
order to calculate an AER or ACR. When a value of 2.9μg/ml was substituted 
for the undetectable albumin concentrations in this analysis, Cobas AER and 
ACR results differed significantly from the Fitzgerald AER and ACR results. This 
shows that substitution of undetectable albumin values is not a valid means of 
approximating albumin excretion in research cohorts as it is significantly 
different from the Fitzgerald analysis which was able to detect all albumin levels 
in this cohort. Consequently, the Fitzgerald or other highly sensitive albumin 
assay should be used preferentially to Cobas within clinical research.  
The second question is whether timed urine samples (AERs) are preferable to 
spot sample ACRs. There has been much debate as to which is the best 
collection method 123, 124, 139, 140. Urinary albumin concentration is influenced by 
the dilution of urine. This is usually accounted for by calculating an albumin 
excretion rate (AER) or relating albumin excretion to another solute filtered by 
the kidneys such as creatinine. Twenty-four hour or overnight timed urine 
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collections are usually considered the gold standard as the accuracy of albumin 
creatinine ratios is subject to the considerable variability of creatinine excretion 
due to muscle mass, diet, activity and normal variation 122, 123, 140.  It is well know 
that timed urine collections also have their fall downs and are prone to collection 
errors 123. This thesis’ compared Fitzgerald AER to Fitzgerald ACR of the same 
overnight urine sample. As the two are not directly comparable, this comparison 
used a line of identity based on the point at which an individual is classed as 
having moderately increased albuminuria with ACR and AER calculations 
(3.5y=20x). This showed that AER gave what would be classed as consistently 
higher albumin excretion levels relative to ACR. The most common collection 
errors of an overnight urine sample (as used in this study) are likely to be as 
follows; Emptying the bladder into the collection bottle before bed rather than, 
correctly, into the toilet which would give a falsely high AER; Emptying the 
bladder into the toilet during the night which would give a falsely low AER; 
Incorrectly writing down sleep times, either shorter time interval which would 
give a higher AER or longer time interval giving a lower AER. It is impossible to 
know which of these errors occur more commonly. It is more likely that within a 
large group, the cumulative effect of these errors would balance each other out 
to some extent rather than give a consistently higher AER reading. The most 
likely reason for the difference between AER and ACR in this group is the 
variability of urinary creatinine excretion. More creatinine excreted relative to 
albumin will lead to a lower ACR. This could be relevant within this group as 
creatinine excretion strongly correlates with increased body mass 140 and 75% 
of individuals in this cohort were classed as overweight or obese. However, 
creatinine excretion correlates more with muscle mass than fat mass and there 
was no measure within this study to approximate body fat percentage. 
Therefore, it was not possible to accurately assess the effect of variation of 
muscle mass on creatinine variability in this study. 
The spot sample ACR may be less reliable than the overnight AER due to 
creatinine variation. As well as this, the spot samples at both week 1 and week 
18 show a significantly higher ACR than ACR of the overnight sample. This is 
may be due to the substantial daytime variation of urinary albumin excretion 
which is likely primarily related to activity 132, 141. This means that the overnight 
urine sample may not represent an individuals’ total 24-hour albumin excretion 
121 
 
and perhaps underestimates cardiovascular and renal risk in cohorts in whom 
overnight samples are used 141. The focus of this research is mainly on the 
effect of night time blood pressure patterns and correlations with blood pressure 
that could be weakened by excess variability. Overnight urine samples were 
therefore deemed more useful within this analysis as they remove most of the 
influence of activity related urinary albumin variability. 
 
 
3.6.1.2 Reduction of urinary albumin excretion with the anti-hypertensive 
treatment protocol 
 
This study showed that the 18 week anti-hypertensive treatment protocol 
significantly reduced albuminuria within the cohort. This result was examined in 
more detail as it is known that renal risk and cardiovascular risk differ with 
different levels of albuminuria 27, 134. Results in this thesis showed that 
albuminuria was significantly reduced by blood pressure treatment in those with 
moderately increased albuminuria at baseline but not in those who had normal 
albuminuria at baseline. The study also found that the correlation between 
reduction of albuminuria with treatment and baseline AER appears to continue 
into the normal albuminuric range, perhaps to the level of 15μg/min after which 
the correlation becomes less distinct (figure 22 and 23). This is interesting as 
15μg/min has been used in the past to mark the threshold between normal and 
moderately increased albuminuria 134, 142. A review of screening and monitoring 
albuminuria suggests that it could be wise to lower the threshold for abnormal 
albuminuria to 15μg/min rather than the currently used 20μg/min due to the 
continuation of cardiovascular risk into this range 143.  
Percentage reduction of systolic, diastolic, mean arterial pressure showed 
borderline significant correlations and pulse pressure showed significant 
correlation with percentage reduction in AER in the >15μg/min group but no 
significant correlations were observed in the moderately increased albuminuria 
group. However, this is likely due to the small sample size of the moderately 
increased albuminuria group. Within the >15μg/min group, reduction in pulse 
pressure showed a stronger correlation with reduction in AER than reduction of 
systolic BP, diastolic BP and MAP. While the influence of systolic BP on 
122 
 
albuminuria is well described, some studies have suggested that pulse pressure 
relates to albumin excretion as strongly, if not more than systolic BP 112, 144. In 
this cohort, the sample size is too small to comment on whether this is a true 
difference (n=11).  
This poses the question of why the anti-hypertensive treatment regime would 
only significantly affect those who already have increased albumin excretion at 
baseline. It could be that the effect is simply regression towards the mean, or 
that there is a difference in pathophysiology between the groups. There are two 
main ways in which the anti-hypertensive treatment would reduce urinary 
albumin excretion; through reduction of blood pressure and transmission of this 
to hydrostatic pressure within the glomerulus, and through the effect of the 
Angiotensin receptor blocker on the glomerular arterioles (relative dilation of the 
efferent glomerular arteriole). This data shows that not all individuals with 
severe hypertension have pathological albuminuria. It may be that individuals 
who presented with high end normal albuminuria or moderately increased 
albuminuria already had some dysfunction of their glomerular blood flow 
regulatory mechanisms as described in chapter 1. This dysfunction would make 
them prone to albuminuria through increased hydrostatic pressure that comes 
alongside severe hypertension. As a result when the treatment reduced 
hydrostatic pressure and dilated the efferent glomerular arteriole, in these 
individuals, there may have been a significant difference in glomerular pressure 
resulting in a decrease in urinary albumin excretion. In the lower normal 
albuminuria group whose regulatory mechanisms may have been working 
normally (maintaining glomerular pressure in spite of severe hypertension), the 
reduction in blood pressure may not have had a significant effect on urinary 
albumin excretion. In these individuals, variation from week 1 to week 18 may 
simply be due to natural activity related variation or variation of the assay. To 
my knowledge this theory has not been researched and may be complex to 
assess in vivo, in humans. 
Another theory for the relationship between increased albuminuria and 
hypertension at week one in this study involves the bi-directional relationship of 
albuminuria and cardiovascular disease. As described in chapter 1.3.1, 
albuminuria is an independent risk factor for cardiovascular disease. Others 
have also found that albuminuria can predict progression of hypertension, even 
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within the normal range of albuminuria 145-147. This could mean that the 
relationship observed in this study is not as simple as high blood pressure 
forcing more albumin through the glomerulus, but that those who begin to 
increase their urinary albumin, damage their kidneys and exacerbate their 
hypertension. The higher blood pressure then exacerbates the albuminuria and 
the vicious cycle continues. The treatment protocol would successfully halt this 
cycle by targeting both the systemic blood pressure and the intra-glomerular 
pressure.  
 
 
3.6.1.3 Which aspects of blood pressure are related to urinary albumin 
excretion? 
 
As hypertensive treatment led to reduction of many different components of 
blood pressure alongside urinary albumin (systolic, diastolic, mean arterial 
pressure, pulse pressure, BP variation, double product and pulse pressure 
product), these components were analysed to gain understanding of which 
aspects of blood pressure most strongly related to urinary albumin excretion. 
Although all correlations were lost between blood pressure and urinary albumin 
excretion at week 18, the results show that this may be as a result of a change 
in range of blood pressure values: At week 1 blood pressures primarily ranged 
from 140-190mmHg, whereas at week 18 80% of the cohorts’ blood pressures 
were between 120 and 140mmHg. The loss of correlation at week 18 may 
mean that blood pressure within the target range does not influence urinary 
albumin excretion or that the relationship within lower blood pressures is too 
weak to detect within this sample size. The higher levels of blood pressure 
show a much more striking relationship within which it is easier to detect a 
correlation within this group size.  
The blood pressure parameters that showed the strongest relationships with 
urinary albumin excretion in this cohort were systolic, diastolic and mean arterial 
pressure at week 1, although the correlations within the entire cohort were 
weak. This is likely due to the previously described discrepancy between the 
strength of relationships to blood pressure in the normal albuminuria and 
moderately increased albuminuria group. However, there were no significant 
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correlations observed between different blood pressure parameters and urinary 
albumin excretion within the separated normal albuminuria or moderately 
increased albuminuria groups. The lack of correlation within the moderately 
increased albuminuria group was likely influenced by the small sample size 
(n=7). When the AER >15µg/min group were analysed (n=12) there was a 
significant correlation between Fitzgerald AER and 24-hour systolic blood 
pressure (p=0.0112) and borderline relationships with pulse pressure 
(p=0.0682) and mean arterial pressure (p=0.0581). Significant relationships 
were also observed between the spot sample ACR and 24-hour systolic, 24-
hour diastolic and mean arterial pressure in those with moderately increased 
albuminuria at baseline (n=8). The sample sizes of these groups limit the 
conclusions that can be drawn from these data. However, the fact that systolic, 
diastolic, mean arterial pressure and pulse pressure related to urinary albumin 
excretion in several different forms of analysis within this cohort is in line with 
current literature on the topic 146, 148.  
In this cohort there were no associations between blood pressure variability and 
urinary albumin excretion which is contrary to emerging literature suggesting 
that short term variability of blood pressure is potentially the strongest predictor 
of moderately increased albuminuria in untreated hypertensives 149, 150. There 
are multiple factors which may explain these apparently discordant results. The 
nature of the present cohort’s severe hypertension at week 1 may have had 
such a large effect on albumin excretion that it masked the relationship between 
BP variability and AER. The effect of anti-hypertensive treatment, particularly 
CCBs which have been shown to reduce BP variability 151, may have also 
influenced the relationship between BP variability and AER at week 18.  
In terms of variability of blood pressure, the morning surge in systolic BP also 
showed some borderline correlation with the spot sample ACR (p=0.0522). 
While not significant, this could suggest that the spot sample (usually taken in 
the morning) is influenced by the magnitude of a person’s systolic morning 
surge. These readings could lead to false impressions of an individual’s overall 
daily albumin excretion. However, due to the concurrent multiple analyses 
which were all negative, this finding could be due to chance and should be 
investigated further. 
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3.6.1.4 Urinary albumin excretion and day to night blood pressure ratios 
 
The main aim of this thesis was to examine the relationship between day to 
night blood pressure ratios and urinary albumin excretion and to compare this 
relationship with the relationship of AER to other standardly measured BP 
parameters as previously discussed in 3.6.1.3. In this cohort there were no 
significant relationships between day to night ratios and urinary albumin 
excretion. 
Day to night ratios were not altered by the anti-hypertensive treatment protocol. 
Previous research has attempted to enhance the night time blood pressure dip, 
as discussed in 1.5.2.3, by bedtime administration of anti-hypertensive 
medication 118, 121.  Within the DASHER study time of medication ingestion was 
not controlled or noted. However, there were 5 non-dipper individuals who 
became normal dippers with treatment and these individuals seemed to have a 
larger reduction in AER than the non-dippers who remained non-dippers. This 
result was not statistically significant although with a sample size of 5 a type 2 
error cannot be ruled out. As discussed in 1.5.2.3, evidence for targeting night 
time dipping patterns to reduce albuminuria is inconclusive and warrants further 
investigation.  
It could be argued that the effect of the severe hypertension on urinary albumin 
excretion could be masking a more subtle relationship between day to night BP 
ratios and AER. If this was the case, a relationship may have become 
observable at week 18 when the vast majority of patients’ blood pressures were 
controlled to target. As no relationship was observed at week 18 this is less 
likely to be true, although at week 18 the cohorts AER was also significantly 
lower making it less likely that a relationship would be observed. 
If the theory of both non-dipping and extreme dipping contributing to 
albuminuria is correct, one would expect to see a U-shaped relationship 
between day to night ratios and AER. In this cohort, the relationship resembled 
a bell shaped curve. Contrary to evidence discussed in 1.5.2, the likely 
conclusion from these results is that within this cohort, day to night BP ratio has 
no observable effect on urinary albumin excretion. Day to night ratio is likely not 
independently associated with level of albuminuria and is as such would not be 
a suitable target for reno-protective strategies directed at reducing albuminuria. 
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3.6.1.5 Relationship of glycocalyx integrity to urinary albumin excretion 
and blood pressure 
 
Analysis of relationships to glycocalyx integrity showed no observable 
relationship between PBR values and AER. This is contrary to earlier work 
discussed in 1.3.2.3 26, 36, 41, 42 It may be that glycocalyx integrity is less 
influential in the pathophysiology of albuminuria in hypertension as it is in 
diabetes as the vast majority of glycocalyx related albuminuria research focus 
on diabetes. 
PBR also showed no correlation with BP parameters. However, a reduction with 
treatment in diastolic, systolic and mean arterial pressure all consistently 
correlated with an increase in PBR. This is surprising as a higher PBR implies 
worse glycocalyx integrity. As well as this, results showed that a greater 
morning surge resulted in a lower PBR value. It should follow that higher blood 
pressure values increase shear stress on the glycocalyx, damage the integrity 
and increase the PBR. These results suggest the opposite is true. These results 
may mean that the glycocalyx does not respond to changes in blood pressure in 
the way we would expect. Acutely, the integrity of the glycocalyx may be 
damaged by increased blood pressure but the long-term response of the 
glycocalyx to high blood pressure may not be so simple. There is some 
research to further understanding of glycocalyx function under shear stress 152 
but this does not shed light on the long term response and so the subject 
requires further research.  
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3.6.2 Limitations of the research 
 
This is a post hoc analysis of the DASHER study. As such, the study was not 
purposefully designed to answer the present question. Firstly, the sample size 
was not calculated for the purpose of this research but to enable the detection 
of clinically significant change in BP with treatment. Although the cohort size 
was initially adequate to detect correlations above 0.40 to 80% power, when the 
cohort was split into separate groups of non-dippers, extreme-dippers and 
different levels of albuminuria there was inadequate power to detect 
correlations. Therefore, correlations found in these smaller groups are only 
suggestive of a relationship, not definitive. Spot urines were random samples 
not first morning voids which may have influenced albumin excretion variability. 
The timings of drug ingestion were not noted; ideally we would have known 
which patients took the drugs in the evening as this could affect night time 
dipping and morning surge. The ethnicity of the cohort reflects the population of 
Devon from which it is drawn. Consequently, there is substantially less variation 
in ethnicity compared with the UK population as a whole which does reduce the 
wider generalisability of these findings. There were no measures of cardiac 
autonomic neuropathy which would have added to the critical analysis.  
Statistical analysis often involved multiple analyses and so one off significant 
findings such as the association of morning surge with spot urine albumin 
should be interpreted with caution. 
It is also worth noting that the duration of which each participant had been 
experiencing high blood pressure prior to treatment is likely to have varied. This 
duration could have had an effect on markers such as albuminuria and 
glycocalyx integrity, an even longer follow up period may have shed light on this 
effect.  
Inter-arm difference in BP, which has been shown to be related to 
cardiovascular risk153, was not taken into account when deciding on placement 
of the ABPM cuff. This may have had an effect on the analysis of overall BP 
measurements between patients, but there is little evidence to suggest whether 
lack of consideration of inter-arm difference would have altered the observed 
night-time dipping of blood pressure. 
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3.6.3 Implications for future work 
 
Future work should strongly consider the use of a highly sensitive albumin 
assay for research concerning urinary albumin excretion in order to truly assess 
relationships to albumin excretion in the population. Substitutions for 
undetectable values are not a valid means of approximating low AERs and 
could cause incorrect interpretation of population data. Judgement should be 
used, considering the relative merits of AER or ACR and the aims of the 
research in question, when deciding which type of measurement to use. There 
is still no perfect method of quantifying albuminuria and future work should 
focus on reducing the effect of variability and collection error in urine sampling. 
This research also supports other findings that the threshold for moderately 
increased albuminuria should perhaps be lowered into the normal albuminuric 
range to 15μg/min 143.   
In terms of blood pressure, future work should focus on larger studies of 
hypertensive patients with adequate power when split into groups of non-
dippers, normal-dippers and extreme dippers to observe relationships. Future 
work should also aim to determine whether short term blood pressure variability 
really is a strong marker of albuminuria, particularly within the hypertensive 
population, and if so could this be a worthwhile treatment target.  
Future work on the glycocalyx must focus on the normal acute and long term 
physiological changes in response to different stimuli such as high blood 
pressure to determine how treatment of blood pressure may or may not 
adversely affect glycocalyx. Other work could aim to validate the GlycoCheck 
method of glycocalyx analysis with a sufficient sample size and validation using 
biological markers of glycocalyx health to further our understanding of these 
results.  
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3.7 Conclusion 
 
Overall, this study demonstrated no relationship between day to night blood 
pressure ratios and urine albumin excretion in hypertensive patients before and 
after treatment. Relationships of similar strength were observed between urine 
albumin excretion and systolic, diastolic, mean arterial pressure and pulse 
pressure. However, these relationships were only present at week 1 and in 
those with AER above 15μg/min. This suggests that blood pressure most 
strongly influences albuminuria at higher blood pressure values within those 
who already have some underlying damage to their glomerular regulatory 
mechanisms. It could also support the theory that albuminuria itself exacerbates 
hypertension.  
The results support earlier work by others suggesting that the threshold for 
moderately increased albuminuria could be lowered as the relationship between 
cardiovascular risk and morbidity continues into the current normal albuminuric 
range 143.  
The study showed no significant relationship between albuminuria and 
glycocalyx integrity and so the GlycoCheck measure of glycocalyx was not 
informative of albuminuria. Glycocalyx integrity showed an interesting response 
to blood pressure treatment and the physiology of glycocalyx response to long 
term changes in blood pressure needs further research.  
This research also recommends that for future clinical research involving 
albuminuria, a highly sensitive assay should be used, rather than the Cobas 
assay as it cannot describe the entire normal albuminuric population and 
substitution for undetectable values is not a valid method to approximate AER 
or ACR. However, the best method of correcting for urine dilution is still unclear 
and further work should be put into perfecting AER, ACR or a new method 
entirely.  
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Chapter 4: The BEAT-DKD Study 
 
 
 
4.1 BEAT-DKD Study Overview 
 
BEAT-DKD is an EU IMI funded study of 31 European partner institutions. The 
imaging work package uses MRI, renal ultrasound, Pet-CT, urine and blood 
testing. Additionally, in Exeter, 24-hour ambulatory blood pressure monitoring 
and microvascular imaging are being undertaken.  
The data used in the present chapter are derived from the BEAT-DKD study. I 
have been responsible for the collection, quality control, data entry and analysis 
of the ambulatory blood pressure monitoring within this study. 
As described in Chapter 1, diabetic kidney disease is a significant and ever 
increasing healthcare burden. The BEAT-DKD work package, undertaken in 
Exeter, has the primary aim of identifying novel microvascular imaging 
biomarkers of early disease in patients with diabetes and an 
eGFR>30ml/min/1.73m2. This aims to increase understanding of the early 
stages of DKD development and enable early identification of those with risk 
factors of faster disease progression. Further understanding of the 
pathogenesis and epidemiology of DKD may lead to better prevention of end 
stage renal disease in this patient group. 
 
 
 
 
 
 
 
 
131 
 
4.2 Aim 
 
The overall aim of this chapter is to examine the relationship between 24-hour 
ambulatory blood pressure parameters, urinary albumin excretion into the 
normal albuminuric range and glycocalyx integrity in people with type 2 
diabetes. 
 
4.3 Objectives 
 
1. Assess how urinary albumin excretion relates to the following different 
aspects of 24-hour blood pressure and circadian blood pressure rhythms: 
- 24-hour, day and night parameters (systolic BP, diastolic BP, heart rate, 
pulse pressure, mean arterial pressure, double product, pulse pressure 
product) 
- Blood pressure and heart rate variability  
- Circadian rhythms (day to night blood pressure ratio and morning surge). 
2. Assess whether the different measures of 24-hour blood pressure, day and 
night parameters relate to glycocalyx integrity. 
 
3. Assess whether glycocalyx integrity is associated with albuminuria. 
 
4.  Assess how day to night blood pressure ratios relate to different markers of 
diabetes: 
- HbA1c, Fasting blood glucose 
- Duration of diabetes 
- Peripheral neuropathy 
- BMI and body fat percentage 
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4.4 Methods 
 
4.4.1 Participants: 
 
Participants were identified and recruited into BEAT-DKD from several sources. 
This includes databases of patients in Exeter who were interested in 
participating in research studies such as the Exeter 10,000 and DARE cohorts. 
Patients were also identified and recruited from clinics. Patients will be followed 
up for 4 years. 
4.4.1.1 Inclusion criteria 
 
- Aged 18-80 years inclusive. 
- Unchanged anti-diabetic and anti-hypertensive medication in the last 3 
months.  
Patients were divided into 3 different groups: 
Group 1: Control, non-diabetic individuals with normal albuminuria and 
eGFR>60ml/min. 
Group 2: Diabetic individuals with normal albuminuria and an eGFR ≥30ml/min. 
Group 3: Diabetic individuals with moderately increased albuminuria with an 
eGFR ≥30ml/min. 
4.4.1.1 Exclusion criteria: 
Group 1 (Control) 
 
Albuminuria; eGFR ≤ 60ml/min; presence of diabetes (HbA1c >48mmol/mol); 
known cardiovascular, cerebrovascular or peripheral artery disease.  
Group 1- 3 
 
 eGFR < 30 ml/min; Significant comorbidities with life expectancy of < 1 year; 
Use of investigational drug within 1 month prior to screening; Renal or hepatic 
pathology; Metastatic malignancy; Malignancy with expected survival <4 years; 
Any other significant disease or disorder which, through participation, may 
either adversely affect the patient or the study. 
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Group 3 
 
In addition to exclusion criteria above, if participants in group 3 were not 
receiving ACE inhibitors or ARBs at screening, they were referred to their GP 
with recommendations by a physician on the Exeter BEAT-DKD research team. 
These participants were invited back to be re-consented and screened for the 
study > 3 months after their original screening visit.  
 
4.4.2 Study Protocol 
 
The BEAT-DKD study protocol was approved by the NHS Research Ethics 
Committee, Health Authority and local R&D, Royal Devon and Exeter NHS 
Foundation Trust. (REC ref. 18/SW/0061).   
Written, informed consent was obtain from all patients prior to entering the study 
including for the storage and retesting of urine samples. Patient anonymity was 
maintained throughout and documents stored securely. The study was carried 
out according to the declaration of Helsinki. 
 
 
4.4.3 Study Design 
 
For detailed methods of data collection see Chapter 2. 
 
 
 
 
 
 
 
 
 
Baseline assessments (2-3 visits) 
Microvascular assessments including:  GlycoCheck, Overnight urine 
collection, Spot urine, 24-hour ambulatory blood pressure monitoring. 
Screening visit 
Standard clinical examination (BMI)                 Sudoscan assessment 
HbA1c and Fasting glucose                               Medical history                                                    
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4.4.4 Measurements 
 
24-hour ambulatory blood pressure monitoring was undertaken and analysed as 
described in chapter 2.1. GlycoCheck measurements were taken and analysed 
as described in chapter 2.2. Urine albumin was collected by timed overnight and 
spot urine samples and measured by both the Cobas and Fitzgerald assays as 
described in Chapter 2.3. Sudoscan, HbA1c, Fasting glucose, BMI and body fat 
percentage measurement methods are described in detail in 2.4-2.8. 
 
4.4.5 Statistical analysis 
 
Statistical analysis was performed using STATA 15 as described in Chapter 2.4. 
A cohort of 34 patients allowed detection of correlation coefficients ≥0.50, where 
p ≤ 0.05 with a statistical power of 80%. 
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4.5 Results 
4.5.1 Patient demographics 
 
During my research period, BEAT-DKD was recruiting the first baseline cohort 
of patients. According to projected recruitment it was expected that 80 patients 
would be recruited. The study was however delayed in starting so the number of 
patients recruited was smaller than originally anticipated (n=34). 
This patient cohort showed an average age of 69 (±6.8) so represents the older 
population. The cohort was predominantly male (65%). The patients had an 
above average body fat percentage and the average BMI was within the ‘obese’ 
BMI bracket. Fifty-nine percent of patients were diagnosed hypertensive and on 
varying antihypertensive treatment. The characteristics of the 34 individuals 
recruited are shown in table 14. 
Table 14 Patient demographics for the T2DM cohort in BEAT-DKD expressed 
as mean (±standard deviation) or median (lower quartile-upper quartile) or 
number (percentage of total. Percentage of patients receiving different types of 
anti-hypertensive treatment is also shown. 
Variable Week 1 (n=34) 
Age (years) 69.0 (±6.8) 
Sex – Female 12 (35%) 
BMI (kg/m2 ) 31.3 (±5.4) 
Waist: hip ratio 0.98 (±0.1) 
Body fat (%) 33.5 (29.3-40.5) 
Clinic systolic BP/diastolic BP (mmHg) 148/76 (136/70-156/82) 
HbA1c (mmol/mol) 60.8 (±11.9) 
Diabetes duration (years) 13.33 (±8.5) 
Fasting glucose (mmol/L) 8.86 (±2.74)  
Peripheral neuropathy history 4 (12%) 
eGFR ( mL/min per 1.73 m2 ) 80.0 (64.5-90.0) 
Diagnosed Hypertensive (n(%)) 20 (59%) 
Moderately increased albuminuria (n 
(%)) 19 (55%) 
Anti-hypertensive treatment (n(%)) 
None/ACE/ARB/CCB/β-blocker/ diuretic 
11(32%)/ 21(62%)/ 5(15%)/ 8(24%)/ 
11(32%)/ 15(44%) 
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4.5.2 Objective 1: Assess how urinary albumin relates to 
different aspects of 24-hour blood pressure and circadian 
blood pressure rhythms 
 
4.5.2.1 Interpretation of urinary albumin excretion using assays with 
different ranges of detection 
 
When using the Cobas albumin assay, only 20 (59%) of the patients had 
detectable urinary albumin values. In contrast, when urinary albumin was 
measured using the Fitzgerald assay, all patients had detectable urinary 
albumin levels (n=34). The following table 15 and figure 49 and 50 show the 
spread of results from each assay and urine sample. There was no observable 
significant difference between any of the different measures of urinary albumin 
in the urine samples collected as shown in figures 49 and 50. 
 
 
Detectable 
albumins 
(n(%)) 
Min 
Lower 
quartile 
Median 
Upper 
quartile 
Max 
Cobas ON 
ACR 
(μg/mg) 
20 (59%) 0.72 1.47 3.68 14.53 27.04 
Cobas ON 
AER 
(μg/min) 
20 (59%) 2.78 11.02 27.55 98.97 360.61 
Fitz ON ACR 
(μg/mg) 
34 0.55 1.46 4.07 17.08 41.6 
Fitz ON AER 
(μg/min)  
34 2.99 10.02 25.47 99.74 554.67 
Fitz Spot 
ACR 
(μg/mg) 
34 0.72 1.65 3.70 19.71 47.40 
Table 15 Cobas and Fitzgerald assay results of overnight urine sample and a 
spot urine sample (AER and ACR values). 
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Figure 49 The spread of Cobas overnight (n=20), Fitzgerald overnight (n=34) 
and Fitzgerald spot urine sample (n=34) albumin creatinine ratios. 
 
Figure 50 The spread of Cobas overnight (n=20) and Fitzgerald overnight 
(n=34) albumin excretion rates. 
 
 
 
 
p=0.7648 
p=0.9429 
p=0.9286 
138 
 
4.5.2.2 Urinary albumin excretion and 24-hour, day and night blood 
pressure parameters 
 
Firstly, blood pressure parameters were compared to urinary albumin using the 
Cobas albumin excretion rate (see table 16). Only 20 (59%) patients had 
detectable albumin levels using the Cobas assay. This analysis showed no 
evidence of a significant relationship between blood pressure and urinary 
albumin level. The Cobas assay was only able to quantify urine albumin 
concentration in 2 of 15 patients with normal albuminuria (13%). 
 
Cobas albumin excretion rate (µg/min)  
Rs p value n= 
24-hour SBP (mmHg) 0.1054 0.6582 20 
day SBP (mmHg) 0.1036 0.6730 19 
night SBP (mmHg) -0.0360 0.8836 19 
24-hour DBP (mmHg) -0.0603 0.8006 20 
day DBP (mmHg) 0.0088 0.9715 19 
night DBP (mmHg) 0.0492 0.8414 19 
24-hour PP (mmHg) 0.0196 0.9346 20 
day PP (mmHg) 0.0079 0.9743 19 
night PP (mmHg) -0.0694 0.7777 19 
24-hour MAP (mmHg) 0.0256 0.9146 20 
day MAP (mmHg) 0.0880 0.7202 19 
night MAP (mmHg) 0.1097 0.6547 19 
24-hour PPP  
(mmHg*bpm) -0.0120 0.9599 20 
day PPP (mmHg*bpm) 0.0070 0.9773 19 
night PPP (mmHg*bpm) -0.0702 0.7753 19 
Table 16 Spearman correlation coefficients (Rs), p values and number of blood 
pressure parameters against Cobas albumin excretion rate in patients with type 
2 diabetes. Units for PPP are mmHg times by beats per minute (bpm). 
 
Figure 51 A scatter graph showing the distribution of Cobas AER values by 24-
hour systolic blood pressure in patients with type 2 diabetes n=20. 
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When all patients’ urinary albumin levels were detectable using the Fitzgerald 
assay, no correlations were observed between different BP parameters and 
albumin excretion rate or spot urine samples with the exception of 24 hour pulse 
pressure product (see table 17 and figure 52). 
 
Fitzgerald AER Fitzgerald Spot urine ACR  
Rs p value n= Rs p value n= 
24-hour SBP (mmHg) 0.2072 0.2397 34 0.0869 0.6250 34 
day SBP (mmHg) 0.1755 0.3286 33 0.0246 0.8919 33 
night SBP(mmHg) 0.1720 0.3384 33 0.1272 0.4806 33 
24-hour DBP(mmHg) 0.0346 0.8458 34 -0.1277 0.4717 34 
day DBP(mmHg) 0.0040 0.9823 33 -0.1536 0.3933 33 
night DBP(mmHg) 0.0909 0.6149 33 -0.0082 0.9639 33 
24-hour PP(mmHg) 0.2398 0.1719 34 0.1861 0.2920 34 
day PP(mmHg) 0.2916 0.0997 33 0.2082 0.2449 33 
night PP(mmHg) 0.1966 0.2728 33 0.1896 0.2906 33 
24-hour MAP(mmHg) 0.1184 0.5049 34 -0.0303 0.8648 34 
day MAP(mmHg) 0.0773 0.6688 33 -0.0862 0.6334 33 
night MAP(mmHg) 0.1981 0.2692 33 0.1490 0.4078 33 
24-hour PPP 
(mmHg*bpm) 0.2905 0.0956 34 0.3665 0.0330 34 
day PPP (mmHg*bpm) 0.2717 0.1261 33 0.3189 0.0705 33 
night PPP (mmHg*bpm) 0.2066 0.2488 33 0.2689 0.1302 33 
Table 17 Spearman correlation coefficients (Rs), p values and number of blood 
pressure parameters versus Fitzgerald albumin excretion rate and Fitzgerald 
Spot urine ACR in patients with type 2 diabetes.  
 
Figure 52 A scatter graph showing the distribution of Fitzgerald AER values by 
24-hour systolic blood pressure in patients with type 2 diabetes, n=34. 
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As cardiovascular risk differs with level of albuminuria, to further analyse these 
relationships the cohort was split into groups of normal albuminuria and 
moderately increased albuminuria. This analysis showed no significant 
relationships (see table 18). 
 
Normal albuminuria Moderately increased albuminuria  
Rs/r p value n= Rs/r p value n= 
24-hour SBP (mmHg) 0.1201 0.6699 15 -0.0228 0.9260 19 
day SBP (mmHg) 0.0877 0.7559 15 0.0145 0.9546 18 
night SBP (mmHg) 0.0877 0.7561 15 -0.1302 0.6067 18 
24-hour DBP (mmHg) 0.2617 03462 15 -0.1319 0.5903 19 
day DBP (mmHg) 0.2417 0.3855 15 0.0010 0.9967 18 
night DBP (mmHg) 0.1614 0.5654 15 -0.1539 0.5420 18 
24-hour PP (mmHg) 0.0734 0.7949 15 -0.0079 0.9743 19 
day PP (mmHg) 0.0750 0.7905 15 -0.0559 0.8256 18 
night PP (mmHg) 0.0682 0.8093 15 -0.0589 0.8165 18 
24-hour MAP (mmHg) 0.1930 0.4908 15 -0.0896 0.7152 19 
day MAP (mmHg) 0.1614 0.5654 15 0.0031 0.9903 18 
night MAP (mmHg) 0.1199 0.6705 15 -0.1094 0.6655 18 
24-hour PPP  
(mmHg*bpm) -0.1964 0.4829 15 -0.1088 0.6576 19 
day PPP  (mmHg*bpm) -0.0964 0.7325 15 -0.0898 0.7231 18 
night PPP 
(mmHg*bpm) -0.2964 0.2834 15 -0.1249 0.6215 18 
Table 18 Correlation coefficients (Rs/r), p values and number of blood pressure 
parameters against Fitzgerald albumin excretion in patients with type 2 diabetes 
with normal albuminuria (<20µg/min) and moderately increased albuminuria 
(>20µg/min).  
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4.5.2.3 Urinary albumin excretion and blood pressure variability 
 
Blood pressure variability (as assessed by standard deviation of BP) showed 
some relationship with the T2DM group. Night time diastolic BP variability was 
also associated with Cobas ACR (p=0.0458) (figure 53). Blood pressure 
variability was not significantly associated with Fitzgerald albumin excretion rate 
in the entire cohort (figure 54 and 56). Blood pressure variability was 
significantly associated with Fitzgerald AER for both night time systolic and 
diastolic blood pressure in those with an AER above 20 µg/min (moderately 
increased albuminuria) (figure 55 and 57). There was no relationship within the 
normal albuminuria group. There was no evidence of correlation between other 
BP variability parameters and Cobas ACR or AER. 
Figure 53 The relationship between Cobas ACR and night time diastolic 
variability in patients with type 2 diabetes (n=19). Red line represents the 
threshold for moderately increased albuminuria (>3.5μg/mg). 
 
Rs=0.4632 
p=0.0458 
n=19 
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Figure 54 Scatter diagram showing the standard deviation of night time systolic 
BP against Fitzgerald albumin excretion rate in patients with type 2 diabetes 
(n=33). Red line represents the threshold between normal albuminuria and 
moderately increased albuminuria (20μg/min). 
 
 
Figure 55 The relationship between Fitzgerald AER and night time systolic 
variability in patients with type 2 diabetes with moderately increased 
albuminuria (>20μg/min) (n=18). 
Rs: 0.5686 
p= 0.0138 
n=18 
Rs=0.0755 
p=0.6761 
n=33 
Entire cohort 
Moderately increased 
albuminuric patients 
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Figure 56 Standard deviation of night time diastolic BP against Fitzgerald 
albumin excretion rate in patients with type 2 diabetes (n=33). Red line 
represents the threshold between normal albuminuria and moderately increased 
albuminuria (20μg/min).  
 
 
Figure 57 The relationship between Fitzgerald AER and night time diastolic 
variability in patients with type 2 diabetes with MIA (>20μg/min) (n=18). 
Rs: 0.6553 
p= 0.0032 
n=18 
Rs=0.0968 
p=0.5922 
n=33 
 
Moderately increased 
albuminuric patients 
Entire cohort 
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4.5.2.4 Urinary albumin excretion and blood pressure circadian rhythms 
 
No significant correlation was observed with either Cobas or Fitzgerald 
measures of albumin and non-dipping of different BP parameters (see table 19). 
An example relationship of Fitzgerald albumin excretion rate and day to night 
ratio of systolic BP is shown below in figure 58. 
 
Figure 58 The relationship between day to night ratio of systolic BP and 
Fitzgerald AER in patients with type 2 diabetes (n=34). 
 
Table 19 Spearman correlation coefficients of Fitzgerald AER and Spot urine 
Fitzgerald ACR and day to night ratios of blood pressure in patients with type 2 
diabetes. 
 
 
Fitzgerald AER Spot urine Fitzgerald ACR  
Rs p value n= Rs p value n= 
SBP D:N -0.0320 0.8575 34 -0.0751 0.6729 34 
DBP D:N -0.1351 0.4462 34 -0.1409 0.4267 34 
MAP D:N -0.0946 0.6006 34 -0.1213 0.5012 34 
PP D:N 0.0699 0.6991 34 0.0381 0.8332 34 
HR D:N -0.1407 0.4348 34 -0.0702 0.6979 34 
DP D:N -0.1223 0.4977 34 -0.1237 0.4929 34 
PPP D:N -0.0187 0.9177 34 -0.0003 0.9985 34 
Morning 
surge (mmHg) -0.1629 0.3812 31 -0.1222 0.5126 31 
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The relationships were also analysed by splitting the cohort into groups of non-
dippers, normal dippers and extreme dippers. As also described in Chapter 
3.5.3.3 normal dipping values for diastolic BP and other BP parameters were 
calculated by comparison to systolic BP day to night ratio (see figure 59 below). 
When split into non-dipper, normal dipper and extreme dipper categories, the 
pathological non-dipper and extreme dipper categories showed no statistically 
significant differences (see figure 60 and 61). Statistical analysis was only 
performed to assess the difference between normal dippers and the abnormal 
non-dippers and extreme dippers. The non-dipper and extreme dipper groups 
were not statistically compared as this was not a component of the original 
research question. 
 
 
Figure 59 The method of calculating the normal range for diastolic night time 
dipping (1.14-1.32) through comparison to systolic day to night ratio (normal 
range 1.11-1.25) in the type 2 diabetic cohort. Red line represents the linear 
regression of each variable, the blue line represents the line of identity) 
 
 
Line of identity 
146 
 
Day to night ratio of systolic BP  
 
 
 
Figure 60 The spread of Fitzgerald AER values of patients who displayed non-
dipping (median: 33.9, IQR: 13-102.5μg/min), normal dipping (median: 17.3, 
IQR 13.5-56.2μg/min) and extreme dipping (median:75.1, IQR:9.2-99.7μg/min) 
of systolic BP.  
 
 
 
 
 
 
 
 
p=0.3841 p=0.3329 
n=9 n=13 n=12 
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Day to night ratio of diastolic BP 
 
 
 
Figure 61 The spread of Fitzgerald AER values of patients who displayed non-
dipping (median: 74.3, IQR: 24.2-223μg/min), normal dipping (median: 17.7, 
IQR: 9.2-56.2μg/min) and extreme dipping (median: 75.1, IQR: 16.2-
332.7μg/min) of diastolic BP. 
 
 
 
 
 
 
 
p=0.1924 p=0.5246 
n=9 n=19 n=6 
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Morning surge of systolic BP also showed no relationship with AER (p=0.3812) 
as shown in the graph below (figure 62).   
 
Figure 62 A scatter graph of the relationship between morning surge and 
Fitzgerald albumin excretion rate in patients with type 2 diabetes (n=31). 
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4.5.3 Objective 2: Assess whether the different aspects of 24-
hour blood pressure relate to glycocalyx integrity. 
 
There were no statistically significant correlations with different aspects of 24-
hour blood pressure and glycocalyx integrity. The T2DM group had an average 
PBR 5-25 of 1.91 (±0.17) and an average PBR 5-9 of 1.05 (±0.05). Glycocalyx 
integrity was also compared to clinic BP measurements taken the same 
morning as the GlycoCheck measurement. Clinic BP showed a borderline 
significant relationship between PBR 5-25 and diastolic BP (see figure 63), 
however when only the smallest vessels were examined the relationship was 
lost (see figure 64). Clinic systolic and mean arterial pressure did not relate to 
PBR 5-25 (see table 20). 
 PBR 5-25 n= PBR 5-9 n= 
24-hour systolic BP 
(mmHg) r=-0.209, p=0.9161 29 r=0.0620, p=0.7540 29 
Day systolic BP  
(mmHg) r=-0.0358, p=0.8563 28 r=0.0593, p=0.7643 28 
Night systolic BP 
(mmHg) r=-0.0441, p=0.8238 28 r=0.0591, p=0.7651 28 
24-hour diastolic BP 
(mmHg) r=0.2049, p=0.2956 29 r=0.0398, p=0.8407 29 
Day diastolic BP 
(mmHg) r=0.1562, p=0.4274 28 r=0.0597, p=0.7629 28 
Night diastolic BP 
(mmHg) r=0.2085, p=0.2869 28 r=-0.0241, p=0.9032 28 
24-hour pulse pressure 
(mmHg) r=-0.1797, p=0.3601 29 r=0.0617, p=0.7552 29 
Day pulse pressure 
(mmHg) r=-0.1803, p=0.3586 28 r=0.0439, p=0.8246 28 
Night pulse pressure 
(mmHg) r=-0.1912, p=0.3297 28 r=0.0957, p=0.6281 28 
Night systolic BP 
variability  (mmHg) r=-0.3316, p=0.0847 28 r=0.0146, p=0.9413 28 
Night diastolic BP 
variability  (mmHg) r=-0.2157, p=0.2702 28 r=0.0807, p=0.6830 28 
Systolic BP Day:Night 
ratio r=0.0635, p=0.7484 28 r=0.0177, p=0.9287 28 
Diastolic BP Day:night 
ratio r=-0.0821, p=0.6777 28 r=0.0913, p=0.6440 28 
Clinic systolic BP 
(mmHg) r=0.0737, p=0.7039 29 r=0.0035, p=0.9857 29 
Clinic diastolic BP 
(mmHg) r=0.3524, p=0.0608 29 r=0.0193, p=0.9209 29 
Clinic mean arterial 
pressure  (mmHg) r=0.2767, p=0.1462 29 r=0.0148, p=0.9392 29 
Table 20 Pearson correlation coefficients between blood pressure parameters 
and PBR 5-25 and PBR 5-9. 
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Figure 63 Scatter graph showing clinic diastolic blood pressure against PBR 5-
25. 
 
Figure 64 Scatter graph showing clinic diastolic blood pressure against PBR 5-
9. 
r= 0.3524 
p= 0.0608 
n=29 
r=0.0193 
p= 0.9209 
n=29 
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In terms of the variability of blood pressure, negative associations, which just 
failed to reach significance, were present for diastolic and systolic BP variability 
within the larger blood vessels (PBR 5-25) (see figures 65 and 66). 
 
Figure 65 Scatter graph showing standard deviation of night time diastolic 
blood pressure against PBR 5-25, n=28. 
 
Figure 66 Scatter graphs showing standard deviation of night time systolic 
blood pressure against PBR 5-25, n=28. 
r= -0.3016 
p= 0.1188 
r= -0.3667 
p= 0.0549 
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4.5.4 Objective 3: Assess whether glycocalyx integrity is 
associated with albuminuria 
 
Glycocalyx integrity showed no statistically significant correlation with any 
measure of urinary albumin excretion (see table 21, figure 67 and figure 68). 
 PBR 5-25 n= PBR 5-9 n= 
Cobas ON ACR Rs= -0.1767, p=0.5126 15 Rs=-0.0074 p=0.9782 15 
Cobas ON AER Rs= -0.2809, p=0.3106 15 Rs=-0.1209, p=0.6677 15 
Fitzgerald Spot 
ACR Rs=-0.2799, p=0.1491 28 Rs=-0.1320, p=0.5033 28 
Fitzgerald ON ACR Rs=-0.3369, p=0.0796 28 Rs=-0.3018, p=0.1186 28 
Fitzgerald ON AER Rs=-0.2996, p=0.1214 28 Rs=-0.3111, p=0.1071 28 
Table 21 showing correlation coefficients and p values for different urine 
albumin measures against PBR 5-25 and PBR 5-9.  
 
Figure 67 Scatter graphs showing Cobas albumin excretion rate against PBR 
5-9 (A, n=15) and PBR 5-25 (B, n=15).  
 
Figure 68 Scatter graphs showing Fitzgerald albumin excretion rate against 
PBR 5-9 (A, n=28) and PBR 5-25 (B, n=28). 
Rs= -0.2809 
p= 0.3106 
Rs= -0.1209 
p= 0.6677 
Rs= -0.2996 
p= 0.1214 
Rs= -0.3111 
p= 0.1071 
A B 
A B 
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 4.5.5 Objective 4: Assess how day to night blood pressure 
ratios relate to characteristics of diabetes 
 
No relationships were observed between non-dipping BP patterns and diabetic 
markers with the exception of a borderline significant relationship between day 
to night ratio of heart rate and diabetes duration as shown in table 22 and figure 
69. This was an additional hypothesis generating analysis and it is likely that 
this finding is chance due to multiple analyses. 
 BMI 
(n=34) 
HbA1c 
(n=32) 
Diabetes 
duration 
(n=30) 
Fasting 
glucose 
(n=30) 
Body fat 
(%) 
(n=34) 
Sudoscan 
(n=32) 
DN systolic BP Rs=0.1832 p=0.2996 
Rs=-0.0402 
p=0.8269 
Rs=-0.1737 
P=0.3586 
Rs=-0.0211 
p=0.9120 
Rs=-0.0631 
p=0.7229  
Rs=0.1781 
p=0.3295 
DN diastolic 
BP 
Rs=0.0455 
p=0.7982 
Rs=-0.0034 
p=0.9853 
Rs=-0.1129 
p=0.5524 
Rs=-0.0664 
p=0.7273 
Rs=-0.0654 
p=-0.7132 
Rs=0.0836
p=0.6492 
DN heart rate Rs=0.0772 p=0.6644 
Rs=-0.2046 
p=0.2614 
Rs=0.3513 
P=0.0570 
Rs=-0.2152 
p=0.2535 
Rs=-0.0999 
p=0.5739 
Rs=-0.0959 
p=0.6015 
DN pulse 
pressure 
Rs=0.2214 
p=0.2082 
Rs=0.0138 
p=0.9404 
Rs=-0.0412 
p=0.8288 
Rs=0.0102 
p=0.9572 
Rs=-0.0612 
p=0.7312 
Rs=0.1658 
p=0.3645 
DN double 
product 
Rs=0.1779 
p=0.3142 
Rs=-0.1552 
p=0.3963 
Rs=0.1199 
p=0.5279 
Rs=-0.1869 
p=0.3226 
Rs=-0.0698 
p=0.6947 
Rs=0.0398 
p=0.8288 
DN pulse 
pressure 
product 
Rs=0.2210 
p=0.2091 
Rs=-0.1383 
p=0.4502 
Rs=0.1208 
p=0.5248 
Rs=-0.1411 
p=0.4571 
Rs=-0.0533 
p=0.7645 
Rs=0.0820 
p=0.6555 
Morning surge 
(mmHg) 
Rs=0.0863 
p=0.6443 
Rs=-0.2002 
p=0.2977 
Rs=-0.0478 
p=0.8127 
Rs=-0.2748 
p=0.1654 
Rs=-0.0520 
p=0.7811 
Rs=0.1333 
p=0.4905 
Table 22 Correlation coefficients and p values for day to night blood pressure 
and heart rate ratios and morning surge of systolic blood pressure against 
diabetic markers.  
 
Figure 69 A scatter graph showing day to night ratio of heart rate against 
duration of diabetes, n=30. 
Rs= 0.3513 
p= 0.0570 
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4.6 Discussion of the BEAT-DKD Study 
 
4.6.1 Discussion 
 
4.6.1.1 Quantification of urinary albumin excretion 
 
The analysis of different collection methods and assays used to measure 
urinary albumin excretion in this cohort showed similar results to the DASHER 
cohort of patients, the results of which are discussed in detail in chapter 3.6.1. 
The Cobas assay results did not differ significantly from the Fitzgerald assay 
results in this cohort but again, the Cobas assay was unable to quantify urinary 
albumin in a large proportion of patients with normal albuminuria (87%) and so 
cannot be used to meaningfully investigate albuminuria in this group of patients 
or the general healthy population. In this cohort, the spot urine sample results 
were not statistically different from the overnight sample. This may be as the 
spot sample was a first morning void. First morning void is likely to be similar to 
the overnight urine samples as it is produced during the asleep period and will 
be subject to much of the same conditions as the overnight urine sample. The 
first morning void is also less subject to activity related variation of albumin 
excretion. For these reasons and as demonstrated by these results and other 
studies, first morning voids are preferable to random spot samples unless the 
question one is seeking to address requires the effect of activity on urinary 
albumin to be taken into account 154, 155.  
 
 
4.6.1.2 Urinary albumin excretion and 24-hour blood pressure parameters 
 
Before examining the relationship between circadian blood pressure rhythms 
and albuminuria, this report will consider how standard blood pressure 
parameters affected albumin excretion. This cohort showed no correlation 
between urinary albumin excretion and systolic or diastolic blood pressure, 
mean arterial pressure or pulse pressure which is contrary to the literature. It 
may be that blood pressure is not the largest factor influencing albuminuria 
within this cohort and so the relationship is masked due to other diabetic 
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pathophysiology. For example, a relationship between blood pressure and AER 
in this cohort may be unobservable due to the small sample size (n=34) and a 
lower range of blood pressure values (100-165mmHg). Another factor which 
could be affecting this relationship in this cohort is that 23 (68%) patients, were 
receiving anti-hypertensive treatment. Of these individuals receiving anti-
hypertensive treatment, the vast majority of patients were receiving either ACE 
inhibitors or ARBs as part of their treatment. This treatment is likely to affect the 
relationship between blood pressure and albumin excretion due to their 
mechanism of action on the glomerulus, as described in chapter 1. This 
relationship of blood pressure parameters to AER in this cohort will be 
discussed further in chapter 5, in comparison to the DASHER study results.  
Night time variability of blood pressure did show correlation with albumin 
excretion in the diabetic cohort, but only within those with moderately increased 
albuminuria. This relationship may only be observable during the night time 
period due to the lack of external influencers which are usually present during 
waking hours. Night time BP variability may therefore be more representative of 
an individual’s basal BP variation and allow easier visualisation of relationships 
to variability in smaller sample sizes. This finding is supported by several other 
studies which have shown the importance of blood pressure variability in 
albumin excretion and renal damage 149, 156.  
It is likely that the pathophysiology of increased blood pressure variability may 
involve increased fasting blood glucose, cardiac autonomic neuropathy and 
arterial stiffness and that some night time sympathetic arousal may be 
increased in diabetic patients with increased BP variability 156. BP variability has 
also been shown in other studies to be informative of renal disease progression, 
independent of average BP 149. However, it is uncertain whether BP variability 
directly leads to increased albumin excretion or whether BP variability and 
albuminuria are both concomitant signs of a worsening disease progression.  
Higher night time BP variability has also been shown to indicate risk of 
cardiovascular events 156 and increasing renal atherosclerotic damage 157. 
Interestingly, in this cohort, glycocalyx integrity (a marker of vessel endothelium 
health) showed a trend of negative correlation with night time diastolic BP 
variability and 24-hour systolic variability. This could suggest that as night time 
variability increases, glycocalyx integrity improves. This could indicate an 
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interesting relationship between blood pressure variability and glycocalyx 
regeneration. It may be that there is a physiological compensation in glycocalyx 
regeneration in response to increased blood pressure variability and hence 
shear stress on the glycocalyx. However these results did not reach statistical 
significance and the correlation may well be due to chance, this is supported by 
there being no observable relationship between glycocalyx integrity and other 
BP variability parameters. The relationship was also only observable within the 
entire range of blood vessels including larger blood vessels (PBR 5-25).  
 
4.6.1.3 Day to night blood pressure ratios and urinary albumin excretion 
 
When considering day to night variation of blood pressure (dipping, non-dipping 
and extreme-dipping) the data showed no linear correlations. When day to night 
ratio was split into the three groups there were also no statistically significant 
differences between groups. Non-dippers and extreme dippers seemed to have 
higher average albumin excretion than ‘normal’ dippers across all parameters, 
demonstrating the U-shaped curve which you would expect to see should non-
dipping and extreme dipping relate to worsening albuminuria. Again, these 
results did not reach statistical significance and do not provide strong support 
for the theory that non-dipping and extreme dipping demonstrate relationships 
with increased albumin excretion in type 2 diabetes. The lack of statistical 
significance could be due to under powering as a result of splitting the cohort in 
three.  
In an attempt to gain insight into the why these BP patterns may develop in type 
2 diabetes, day to night ratios were compared to different markers of diabetes. If 
loss of normal day to night ratios are a complication of type 2 diabetes such as 
autonomic neuropathy it is likely to be more prevalent in those who have been 
subjected to hyperglycaemia for a longer period or with evidence of other 
diabetic complications. In this cohort, day to night ratios showed no relationship 
with Sudoscan results (a measure of small peripheral nerve damage). It would 
be expected that if patients had cardiac autonomic neuropathy manifesting as 
an abnormal day to night BP ratio, they may also show signs of peripheral 
neuropathy 71.  
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4.6.1.4 Glycocalyx integrity, blood pressure and urinary albumin excretion 
 
Beyond the previously discussed relationship with BP variability, glycocalyx 
integrity showed no significant relationship with albumin excretion or any blood 
pressure parameter including day to night blood pressure ratios. This suggests 
that the glycocalyx integrity is not involved in the mechanism behind the 
relationship between increased albumin excretion and blood pressure. One 
study which focussed on mathematically modelling the glycocalyx suggested 
that the porosity of the glycocalyx, rather than thickness, exerted more of an 
effect on the vessel wall permeability and therefore albumin leakage 158. This 
could be an explanation for the lack of relationship shown in this study. The lack 
of correlation between ambulatory blood pressure and glycocalyx integrity may 
be influenced by the different time courses of the two measurements. This is 
supported by the borderline significant relationship between glycocalyx integrity 
and clinic diastolic blood pressure measurement of the same morning. As the 
glycocalyx is constantly degraded and reformed as it is sheared by blood flow, 
to properly assess the relationship between glycocalyx and blood pressure, the 
two would need to be measured simultaneously. Simultaneous measurement of 
markers of glycocalyx shedding would provide further insight.  
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4.6.2 Limitations 
 
This study had several limitations. Firstly, this cohort is representative of older 
diabetic patients and so the results may not be relevant to younger people with 
diabetes. The cohort also had a male predominance so may not represent the 
general population. Due to time constraints of this project only 34 patients were 
recruited into this study which meant more modest correlations may not have 
been identified. This was particularly relevant when the cohort was split into 
groups as became necessary through analysis. This project used data from the 
BEAT-DKD study and so was not specifically designed for the purpose of this 
research. The overnight urine samples used to calculate AER with the highly 
sensitive albumin assay were taken on a different day to the overnight 
ambulatory monitoring potentially weakening the association between the two 
measures. Simultaneous urine and blood pressure measurements would have 
been a more robust design. No tests were undertaken as a measure of cardiac 
autonomic neuropathy. In addition to this there was no control group to compare 
this data to as the control group recruitment to BEAT-DKD had only 4 subjects 
at the deadline for data analysis within this thesis.   
Due to the multiple statistical analyses performed, one off significant findings 
should be interpreted with caution, such as the relationship between duration of 
diabetes and day to night heart rate ratio are likely due to chance 
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4.6.3 Implications for future work 
 
These results suggest the need for a larger study of people with diabetes to 
increase the power across each dipping group. Although several studies have 
looked at BP dipping in diabetes, they have not used a highly sensitive albumin 
assay and so can only make assumptions about the normal albuminuria group 
of patients. These assumptions are confounded by assigning a common 
“undetectable” value to values which cannot be measured, which I have shown 
to give a significantly different data set to the Fitzgerald assay where all values 
are detectable. These data were inconclusive as to whether non-dipping 
patterns relate to increased urine albumin levels in the diabetic population. The 
main area for future work should be to further understand the mechanism 
behind the development of non-dipping patterns. This would involve detailed 
analysis of diabetic markers and autonomic function alongside several 
ambulatory blood pressure measurements. If there is a relationship between 
abnormal dipping and increased AER but it is due to both being concomitant 
signs of diabetic pathology and not a direct causal relationship, then BP dipping 
may not be a beneficial treatment target. This may explain why studies aiming 
to reverse abnormal dipping have not yet found substantial effects on AER. 
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4.7 Conclusion 
 
This type 2 diabetic cohort showed no statistically significant relationship 
between albumin excretion and systolic, diastolic or other standard components 
of BP. This is contrary to the literature and could be influenced by the narrow 
range of blood pressure values and ACE or ARB treatment of the majority of 
patients in the cohort. Night time BP variability in those with moderately 
increased albuminuria showed the strongest relationship with AER. This cohort 
showed no statistically significant relationship between dipping patterns and 
AER. However, this could be due to limited statistical power of each group when 
the cohort is split into three. Abnormal dipping patterns showed little relationship 
with diabetic markers apart from diabetes duration and so little can be drawn 
from these results about the pathophysiology of loss of normal dipping. 
Glycocalyx integrity was not related to average BP, dipping patterns or AER and 
is unlikely to be involved in the pathophysiology behind abnormal dipping or 
increased AER in this group. Further research is needed to understand the 
mechanism behind abnormal dipping and whether it is a relevant treatment 
target. 
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Chapter 5: Comparison of results from the 
DASHER and BEAT-DKD studies 
 
 
5.1 Discussion 
 
This chapter will discuss the similarities and differences between the results 
from both the hypertensive cohort and the T2DM cohort to explore the 
relationships between albuminuria, blood pressure and glycocalyx in these 
closely linked conditions.  
 
5.1.1 Comparison of 24-hour blood pressure and AER in the 
T2DM and hypertensive cohorts 
 
The two cohorts showed striking differences in how aspects of the patients’ 
blood pressure related to albuminuria. Untreated hypertensives showed a 
correlation between urine albumin excretion and average systolic, diastolic, 
mean arterial blood pressure and pulse pressure but no other correlations and 
most strongly in those with higher levels of urine albumin. However all of these 
correlations were lost when the hypertensive patients were treated. The diabetic 
group (68% of whom were already receiving anti-hypertensive treatment) 
showed no relationship with any of these parameters, even within the 
moderately increased albuminuria group. These results were examined further 
to determine whether there are true differences in these relationships within the 
hypertensive and diabetic groups or whether the differences observed are due 
to sample size, range of albumin values, range of blood pressure values or anti- 
hypertensive treatment.  
Firstly we will consider the spread of data within the untreated hypertensive, 
treated hypertensive and the T2DM groups. As illustrated by figures 70-72, 
which are taken from chapter 3 and 4, the range of average systolic blood 
pressure values of the diabetic group (100-165mmHg) spans the entire range of 
the treated hypertensives but does not quite reach the highest value of the 
untreated hypertensives (190mmHg).  
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It could be argued that the lack of relationship between urine albumin and blood 
pressure in the T2DM group is as a result of a narrower and lower range of 
blood pressure values. Fesler et al also showed that urine albumin excretion is 
unchanged by blood pressures below 140mmHg 159. In this case, the T2DM 
cohort might have shown a similar spread of data to the treated hypertensive 
group. The treated hypertensive and T2DM groups have similar demographics. 
As well as this, 68% of the diabetic group were receiving anti-hypertensive 
treatment, the vast majority of which included an ACE inhibitor or ARB. Eighty-
five percent of the treated hypertensive group were also taking an ARB. Despite 
the similar demographics, similar range of blood pressures and lack of 
correlation between AER and blood pressure, these two groups showed very 
different ranges of urine albumin. The highest urine AER observed in the 
treated hypertensive group was 32μg/min, whereas 56% of the T2DM group 
had an AER higher than 32μg/min the highest of which being 554μg/min. There 
was also no difference in AER between those receiving anti-hypertensive 
medication and those not receiving anti-hypertensive medication in the T2DM 
group (p=0.3643). Despite 50% of patients achieving target blood pressure, the 
T2DM group still exhibited very high levels of urinary albumin, this suggests that 
there are different factors contributing to albuminuria within the T2DM group 
that are not present within the treated hypertensive group.  
The mechanism behind these high levels of urinary albumin in the T2DM group 
are likely to involve aspects of diabetic pathophysiology as described in chapter 
1.3.  Glomerular hyperfiltration was targeted by the use of ACE inhibitors and 
ARBs in many of the T2DM patients, therefore pathology of the glomerular 
filtration barrier may play a larger role in the increased albuminuria in this group. 
The measurement of glycocalyx showed no relationship to urine albumin 
excretion, suggesting that damage to the glycocalyx is not involved in the 
mechanism despite other studies suggesting its importance 36, 41, 160, 161. This 
could mean that damage to other aspects of the glomerular filtration barrier 
such as the basement membrane, podocytes and slit diaphragm have a larger 
role in development of albuminuria in this group.  
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Hypertensive group pre-treatment 
Hypertensive group post-treatment 
Type 2 diabetes group 
 
Figure 70 The spread of 
Fitzgerald albumin 
excretion rates compared 
to 24-hour average 
systolic BP in the 
hypertensive group 
before treatment. 
Figure 71 The spread of 
Fitzgerald albumin 
excretion rates compared 
to 24-hour average 
systolic BP in the 
hypertensive group after 
treatment. 
 
Figure 72 The spread 
of Fitzgerald albumin 
excretion rates 
compared to 24-hour 
systolic BP in the 
T2DM group. The red 
line indicates 
120μg/min, the upper 
limit of the y axis of 
figure 70 and 71, for 
comparison of albumin 
excretion rates across 
the 3 groups. 
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5.1.2 Comparison of day to night ratio of blood pressure and 
AER in the T2DM and hypertensive cohorts 
 
Neither the T2DM group nor the hypertensive group showed a relationship 
between urinary albumin and day to night blood pressure ratios. There were 
also no observable significant relationships when the cohorts were split into 
normal dippers, non-dippers and extreme dippers. The lack of relationship in 
both groups may indicate that dipping status has no effect on urinary albumin. If 
dipping status does affect urine albumin, it is likely that the sample sizes of 
these studies would have been too small to detect these relationships. 
It is worth noting that the relationship between AER and day to night ratio 
showed slightly different distributions in the hypertensive group and T2DM 
group. In the hypertensive group the relationship resembled a bell shaped curve 
whereas in the T2DM group the relationship resembled a U shaped curve. This 
is particularly evident within the day to night ratio of diastolic blood pressure, 
which, interestingly, several others found to have a stronger relationship with 
AER than day to night ratio of systolic BP 103, 109, 110. However, as illustrated in 
figure 73, this U shaped relationship is dependent on the 6 individuals in the 
T2DM group with an AER above the range of the untreated hypertensives. 
Below 200μg/min, both groups display a similar distribution.  
Figure 73 The relationship between day to night ratio of diastolic blood 
pressure and Fitzgerald albumin excretion rate in (A) the type 2 diabetic group, 
n=34 and (B) the hypertensive group before treatment, n=54. 
 
A B 
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While it is possible that this finding is due to chance, it could suggest that those 
with advanced diabetic pathology, in this case high AER, are also likely to 
display abnormal blood pressure dipping patterns. This could support the theory 
that the mechanism behind non-dipping patterns, while linked to cardiovascular 
risk, is not directly related to urinary albumin excretion but often goes hand in 
hand with certain disease states as has been observed in the diabetic and 
hypertensive population. This theory is further supported by the previously 
discussed reports that extreme dipping of blood pressure does not give rise to 
increased cardiovascular risk when induced by anti-hypertensive treatment 89, 
suggesting that the abnormal day to night ratio itself is not the determinant of 
increased cardiovascular risk. It may be that the underlying mechanism of the 
extreme dipping, which may involve cardiac autonomic neuropathy is 
associated with increased cardiovascular risk. 
Following this, one limitation of these studies was that there was no control 
over, or notation of anti-hypertensive medication ingestion time. Therefore, it is 
not possible to know whether medication administration time influenced dipping 
status in either group.  
It is also worth considering that there is some debate on the reproducibility of 
blood pressure dipping162-164 and it seems likely that sleep quality may impact 
night-time dipping. For this reason with only one 24-hour BP measurement 
individuals may be misclassified as dippers or non-dippers. Future research 
should aim to identify and observe individuals with true loss of night time 
dipping rather than those in whom dipping is merely observed to be absent on 
occasion, perhaps with repeated ABPM measurements and monitoring of sleep 
quality. 
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5.1.3 Comparison of short-term blood pressure variability and 
AER in the T2DM and hypertensive cohorts 
 
Short-term blood pressure variability, as assessed in this work by the standard 
deviation of blood pressure, is often discussed in the same category as day to 
night ratios of blood pressure. In this thesis, the T2DM and hypertensive groups 
showed a difference in the relationship of blood pressure variability (standard 
deviation of blood pressure) to urinary albumin. In the hypertensive group there 
was no observed relationship between blood pressure variability and AER. 
Individuals with moderately increased albuminuria or above within the T2DM 
group showed a stronger relationship between AER and night time BP 
variability than with any other aspect of 24-hour ambulatory blood pressure. 
Some studies and meta-analyses have shown a link between blood pressure 
variability and increased cardiovascular risk and mortality in both diabetes and 
hypertension 165-168 These studies vary greatly in their size, cohort demographic 
and protocol, so direct comparison between them and this research is difficult. 
However the core conclusions drawn from this research are useful to consider. 
In a meta-analysis by Stevens et al.166 the results are comparable to this 
research as the cohort of patients were older adult of European decent, and 
people with diabetes were included. Another strength of this study is that it 
included three measurements of blood pressure variability independent of the 
mean. Additionally ABPM measurements were over 24 hours with at least 14 
day time readings. This meta-analysis showed that blood pressure variability of 
all kinds was linked to mortality. Their blood pressure variability measurement 
was independent of the mean similar to the work of Rothwell et al.168, which 
shows that visit to visit and short-term blood pressure variability, independently 
of the mean blood pressure, predicts vascular outcomes such as stroke. These 
studies are of considerable size increasing the robustness of their conclusions, 
and the demographics are comparable to this study. The weaknesses of these 
pieces of research are that due to their size the exact method of blood pressure 
measurement may have been variable and difficult to standardise. These 
studies while different in their approach to this study, provide good evidence 
that BP variability is a significant component of blood pressure and likely 
contributes to mortality independently of average systolic BP, which is often the 
sole focus of BP measurement. Other work has found associations between 
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short-term blood pressure variability and urinary albumin excretion 149, 169-171. 
However the difficulty in separating blood pressure variability from the mean 
systolic blood pressure hinders this work and should be assessed in more 
detail. If a true link exists between short term blood pressure variability and 
albumin excretion, the mechanism is unclear. It could be that dramatic 
fluctuations in blood pressure over a short period of time damage vessel health 
and influence cardiovascular risk and urinary albumin filtration. However, 
sympathetic drive is likely one of the major determinants of blood pressure 
variability 156. It could be that the relationship between blood pressure variability 
and increased urine albumin excretion as seen within the individuals with 
moderately increased albuminuria in the T2DM group of this research, is similar 
to the relationship proposed between day to night ratio BP and AER. That is 
that increased blood pressure variability, including day to night ratio, is a sign of 
underlying pathophysiology that is also related to increased albumin excretion 
and cardiovascular risk, such as diabetic pathophysiology leading to cardiac 
autonomic neuropathy and diabetic kidney disease.  
These relationships need further exploration as standard deviation of blood 
pressure may not be the most robust method of determining blood pressure 
variability 172. Standard deviation of blood pressure may be related to mean 
blood pressure, however within this thesis there was no observed relationship 
between blood pressure variability and mean blood pressure in either cohort. 
Despite this, average real variability may be a more reliable measure of blood 
pressure variability and should be used in future analysis 172.  
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5.1.4 Use of GlycoCheck as a measure of glycocalyx integrity 
 
The GlycoCheck measure of glycocalyx integrity showed no relationship with 
blood pressure or albuminuria with the exception of the previously discussed 
percentage change in blood pressure and change in PBR before and after 
treatment in the hypertensive group.  
The average measurements of PBR 5-25 in healthy individuals as stated by the 
GlycoCheck reproducibility studies (described in 2.2.4) suggests a healthy 
range of PBR 5-25 is 1.86 (±0.16). The hypertensive group both pre and post 
treatment showed an average PBR 5-25 of 1.63 (±0.19) and 1.65 (±0.17), 
indicating a similar PBR or in fact, healthier PBR than healthy individuals. The 
T2DM cohort had an average PBR 5-25 of 1.91 (±0.17) which is again, not 
dissimilar from the healthy individuals of GlycoCheck reproducibility studies.  
While the external reproducibility of GlycoCheck conducted in this thesis 
showed that the measurement technique gives reproducible results for 
individuals from visit to visit (coefficient of variation between 6.17 and 6.73), the 
relevance of this technique to determine actual differences between individuals 
seems questionable.  
The results of this thesis show the need for extensive validation of the 
GlycoCheck method of measuring glycocalyx integrity and its relevance in 
research and clinical practice.  
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5.1.5 Measurement of urinary albumin excretion 
 
The measurement of urinary albumin within this thesis has already been 
discussed extensively within chapters 3 and 4, but will be discussed again 
briefly here. Measurement of urinary albumin within both the DASHER and 
BEAT studies showed the Cobas albumin assay was able to detect albumin in 
less than 28% of normal albuminuric urine samples. With the ever increasing 
interest in the continuation of cardiovascular risk into the normal range of 
albuminuria, it is vital that an assay with a lower limit of detection such as the 
Fitzgerald assay be used in future research. The Cobas assay may give false 
conclusions when used to examine relationships into the normal albuminuric 
range.  
This thesis has also shown that substitution of a normal albumin value in place 
of those that are undetectable with the Cobas assay is not an accurate measure 
of approximating these missing values and should not be used in future 
research. 
Urinary albumin creatinine ratio of first morning void spot samples did not differ 
significantly from overnight urine samples, whereas the random spot ACR were 
significantly different from the overnight samples. This shows two things: 
random spot samples may be influenced by activity related variability of albumin 
excretion in the daytime and also overnight urine samples may not be 
representative of an individual’s total 24-hour urinary albumin excretion. These 
results emphasise the need for consideration of research aims when choosing a 
method of urine collection. For example, for a study aiming to explore the effect 
of albumin toxicity on the kidneys, a 24-hour urine collection may be more 
suitable than overnight or spot sample.  
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5.1.6 Is reduction of albuminuria truly associated with reduction 
of cardiovascular risk? 
 
Interesting work is emerging debating whether the reduction of albuminuria can 
be used as a surrogate for decreased cardiovascular mortality. The effect of 
increased urine albumin levels on the increased risk of cardiovascular mortality 
is well described and discussed throughout this thesis. Although, the 
significance of whether decreasing albuminuria through treatment truly lowers 
cardiovascular risk, independent of other factors is still under scrutiny. Two 
studies in 2011 and 2016 retrospectively analysed data and concluded that 
reduction of albumin did indeed lower cardiovascular risk independent of 
systolic blood pressure173, 174. In 2019 Harrison et al conducted a meta-analysis 
of randomised controlled trials concluding that reduction of albumin shows 
inconsistent effects on cardiovascular mortality175, however a response to this 
article by Panahi et al questioned the robustness of Harrison et al’s complex 
statistical analysis and suggested that this may have influenced the results of 
the analysis176. A randomised controlled trial of 8494 participants using blood 
pressure treatment, blood glucose treatment and placebos analysed whether 
changes in urine albumin predicted changes in mortality risk177. They found that 
reduction in urine albumin did significantly predict reduction in mortality, 
particularly macrovascular mortality, but only when regression to the mean was 
accounted for which they claim no other study has done previously.  
In light of this evidence it seems that the questionable strength of the 
relationship between reduction of albuminuria and cardiovascular risk could be 
due to lack of consideration of regression to the mean in previous work which 
may have skewed the data in both directions. Future work should consider the 
true strength of this association and consequently whether urine albumin 
excretion is an appropriate treatment target. 
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5.3 Implications for future work 
 
Future research should use a highly sensitive albumin assay such as the 
Fitzgerald, where possible, and take care when choosing a urine collection 
method in relation to the aims of the study.  
Future work should also aim to determine whether the relationship between BP 
variability and target organ damage is due to correlation or causation and 
should use a robust method of determining short-term BP variability.  
The GlycoCheck method of measuring glycocalyx integrity requires further 
validation to determine if it has a role in the clinical setting. 
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5.4 Conclusion 
 
In conclusion, this work has shown that a highly sensitive albumin assay should 
be used within clinical research but that the Cobas assay may still be relevant in 
clinical practice. This work has also shown that there is need for research into a 
better method of adjusting for urine dilution when quantifying albumin as both 
AER and ACR have limitations. When conducting research care should be 
taken to choose an appropriate method of urine collection, considering their 
benefits and limitations.  
This research also supports the lowering of the threshold of moderately 
increased albuminuria from 20μg/min to 15μg/min as relationships between 
blood pressure and AER continue to this level. 
This work has also shown no relationship between day to night ratio of blood 
pressure and urine albumin excretion and speculates that any previous 
observed relationship is due to concomitant signs of underlying 
pathophysiology.  
The T2DM group show different relationships between AER and aspects of 24-
hour blood pressure than untreated hypertensives, perhaps due to a lower 
range of blood pressures and other factors more strongly influencing AER. 
In the untreated hypertensives there were strong correlations with systolic, 
diastolic, mean arterial pressure and pulse pressure but only in those with an 
AER above 15μg/min. This may mean that higher levels of albuminuria 
contribute to hypertension or that hypertension mainly exacerbates albuminuria 
in those with underlying glomerular damage. 
In the diabetic group the strongest association was between AER and night time 
blood pressure variability in those with moderately increased AER. More 
research is needed into the relevance of BP variability on target organ damage 
to determine whether there is a causal relationship or if it is a correlation due to 
underlying pathophysiology. 
The GlycoCheck measure of glycocalyx integrity showed no statistically 
significant relationships to AER or BP. GlycoCheck shows visit to visit 
reproducibility in individuals but requires further validation to show its relevance 
in determining differences between individuals.  
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